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NOTA PRÉVIA 
 
A dissertação que agora apresento segue as linhas de investigação em Biomedicina e Saúde Pública 
inseridas no Grupo de Estudos Biomédicos do Laboratório de Feixe de Iões do Instituto Tecnológico e 
Nuclear (ITN) e no Centro de Biologia Ambiental (CBA) da Universidade de Lisboa.  
A excelente colaboração entre as duas instituições acima referidas tem permitido a realização de 
diversos projectos com elevado valor científico. Entre estes destaco o projecto intitulado “Markers 
of the pro-oxidant/antioxidant balance and characterization of the allelic profile of apo E in 
inhabitants of Lisbon and Ponta Delgada” (POCTI/ESP/4108/2001), no qual participei como bolseira 
de investigação científica. Este projecto pretendia, entre outros objectivos, caracterizar possíveis 
alterações no balanço antioxidante/oxidante associadas à aterosclerose. Os resultados obtidos 
permitiram que a equipa, inclusive eu própria, focalizasse os seus interesses na doença 
aterosclerótica. É nesta perspectiva que surge a presente tese de doutoramento, onde a 
necessidade do estudo mais aprofundado e incisivo da aterosclerose e de uma excelente 
caracterização dos doentes, conduziram à abordagem da doença coronária e à colaboração com o 
Serviço de Cardiologia do Hospital de Santa Marta (Lisboa).  
Este trabalho foi financeiramente suportado por uma Bolsa de Doutoramento da Fundação para a 
Ciência e Tecnologia (SFRHI/BD/18822/2004) e pela Liga dos Amigos do Hospital de Santa Marta 
através de diversos projectos institucionais. 
A presente dissertação divide-se em 6 capítulos, alguns dos quais correspondem a um 
aproveitamento parcial de trabalhos já publicados, submetidos ou a submeter para publicação, nos 
termos do nº 1 do Artigo 41º, Capítulo V, do Regulamento de Estudos Pós-Graduados da Universidade 
de Lisboa, publicado no Diário da República – II Série Nº 209 de 30 de Outubro de 2006. Neste 
contexto, esclareço que participei de forma integral em todos os trabalhos, tanto na recolha das 
amostras, obtenção dos resultados laboratoriais, sua análise estatística e interpretação, como na 
elaboração dos manuscritos resultantes.  
O Capítulo 1, designado de “General Introduction”, introduz a problemática de investigação e 
apresenta os objectivos da presente tese de doutoramento. 
Os Capítulos 2 a 5 correspondem a um aproveitamento parcial de artigos aceites (1), submetidos 
(3) ou a submeter (1) a revistas de prestígio internacional. A ordenação dos capítulos pretende 
recriar a importância faseada que cada parâmetro desempenha na doença coronária, e em 
particular no enfarte agudo do miocárdio.  
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Desta forma, no Capítulo 2 (“Serial Changes of Oxidized Low-density Lipoproteins”), são 
apresentadas as variações longitudinais das lipoproteínas de baixa densidade oxidadas (ox-LDL), 
cuja formação é um processo de fundamental importância na iniciação do processo aterosclerótico 
bem como no enfarte agudo do miocárdio. Este capítulo corresponde ao aproveitamento parcial de 
um trabalho aceite para publicação na Revista Portuguesa de Cardiologia (“Serial changes of 
oxidized low-density lipoprotein associated with culprit vessel in ST-elevation myocardial 
infarction – a promising marker?”) em 27 de Novembro de 2008.  
Numa abordagem que se debruça um pouco mais sobre os mecanismos de acção, tanto quanto um 
estudo in vivo o permite, o Capítulo 3 (“Oxidized Low-density Lipoproteins and Immune Response”) 
pretende avaliar a relação entre as ox-LDL e a resposta imunitária através da avaliação de linfócitos 
T e de citocinas pró-inflamatórias como o TNF-α. O trabalho correspondente a este capítulo foi 
submetido à revista Heart (“Oxidized low-density lipoproteins associated to immune response in 
acute myocardial infarction”) em 5 Agosto de 2008. 
No Capítulo 4 (“Inflammatory Responsiveness”) pretende-se esclarecer o importante papel da 
inflamação tanto na fase aguda do enfarte agudo do miocárdio como durante o período de 
recuperação, evidenciando a relação entre os diversos marcadores de inflamação estudados. Este 
capítulo corresponde a um trabalho em preparação (“Differential inflammatory responsiveness in 
acute myocardial infarction evolution”).  
No Capítulo 5 (“Serial Changes of CD40L – Relationships to Endothelial Dysfunction and 
Thrombosis”) são apresentadas as variações longitudinais de CD40L (tanto a nível solúvel como 
expresso nas plaquetas e linfócitos T) e a sua relação com marcadores de activação plaquetária e de 
disfunção endotelial, como é o caso do óxido nítrico. Neste capítulo são ainda apresentados 
resultados inovadores de caracterização de micropartículas tanto de origem plaquetária como 
endotelial. Os resultados apresentados nesta secção correspondem à integração de 2 artigos (“High 
soluble CD40 ligand is associated to low NT-proBNP in ST-elevation myocardial infarction patients” 
submetido à Clínica Chimica Acta a 17 de Janeiro de 2009, e “CD40L relationship to platelet 
activation and endothelial dysfunction” em preparação). 
Por fim no Capítulo 6, designado por “Conclusions and Implications”, são apresentados os 
principais resultados e conclusões de cada um dos capítulos anteriores, os quais são discutidos de 
forma integrada de modo a responder aos objectivos gerais desta tese. São ainda discutidas algumas 
limitações do estudo e apontadas as principais implicações dos resultados e conclusões obtidos, que 
permitem delinear novas perspectivas de investigação no âmbito da doença coronária. 
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ABSTRACT 
 
The aim of this study was to investigate the association between different processes implicated in 
acute myocardial infarction (AMI), such as inflammation, thrombosis, immune response and 
endothelial dysfunction, at different phases of the disease. Thus, a follow-up of 50 AMI patients was 
evaluated at 3 time points: at admission before the administration of IIb/IIIa inhibitors and 
angioplasty, 2 days and 40 days after. A group of 25 healthy volunteers was used as reference (REF). 
The higher concentrations of ox-LDL at AMI onset were suggested to be related to plaque instability. 
Furthermore, the serial changes of ox-LDL were associated with CAD severity and eventually to 
lesion characteristics depending on the infarct-related artery. The results also highlight the great 
magnitude of the thrombotic process associated to plaque disruption at AMI onset that conceals 
possible variations of platelet-related thrombosis markers, mainly expressed by CD40L. Additionally, 
the results emphasize the importance of the inflammatory response that remains after clinical 
stabilization as given by the interplay of TNF-α, sICAM-1, sP-selectin, CD40L, leukocytes, NO and 
EMPs. Importantly, the results of sCD40L longitudinal variations allowed the differentiation of two 
groups of AMI patients, which also differed in NT-proBNP concentrations but did not shown 
variations in terms of risk factors and co-morbidities, nor influence of drug intake. This is the first 
study evaluating the inter-relationships between markers of inflammation, thrombosis, immune 
response and endothelial damage using multi-parameter longitudinal approach. The results revealed 
the interplay between those mechanisms and their relative importance in each phase of the 
disease. In conclusion, the work allowed a better understanding of the complex relationships 
between the studied markers involved in the different phases of AMI evolution, decisively 
contributing to a better understand of the pathology and mechanisms of AMI. 
 
Keywords: Oxidized LDL (ox-LDL); T lymphocytes; TNF-α; CD40 ligand; Longitudinal study. 
 
  
RESUMO 
 
A doença coronária é a principal causa de morte em todo o mundo, sendo responsável, segundo dados da 
Organização Mundial de Saúde, por quase 13% do número total de óbitos.  
Do ponto de vista patofisiológico, a doença coronária pode ser considerada uma manifestação clínica 
grave da aterosclerose. Aliás, sabe-se actualmente que a ruptura de uma placa aterosclerótica com 
subsequente formação de trombo é a principal causa dos síndromes coronários agudos, entre os quais se 
inclui o enfarte agudo do miocárdio. 
A progressão de uma placa aterosclerótica ocorre durante toda a vida de um indivíduo, podendo ser 
amplificada pelos clássicos factores de risco como a hipertensão, diabetes mellitus e dislipidémia, entre 
outros. Tal progressão é assintomática, mas pode ser seguida de uma fase de desenvolvimento até atingir 
um grau de estenose que comprometa o fluxo sanguíneo, e/ou sofrer ruptura com consequente formação 
do trombo e oclusão da artéria. Dependendo do grau de oclusão, do tempo de isquemia, e da existência ou 
não de fluxo sanguíneo colateral, o tecido a jusante pode sofrer danos consideráveis, incluindo morte 
celular e perda das suas funções. No caso de a oclusão ocorrer numa artéria coronária, o resultado é um 
enfarte do miocárdio, cuja importância é sem dúvida ampliada pelo facto de afectar um órgão vital como o 
coração. 
Nas últimas duas décadas têm sido alcançados consideráveis avanços na área da Cardiologia, o que 
permitiu progressos significativos no conhecimento dos mecanismos que iniciam a formação de lesões 
ateroscleróricas e que conduzem ao seu desenvolvimento. Permitiram também uma mudança em relação à 
visão tradicional da aterosclerose como uma simples deposição de lípidos na parede arterial. Actualmente 
o papel desempenhado pela inflamação, stress oxidativo e resposta imunitária já não é controverso no 
desenvolvimento da patologia. No entanto, e apesar de um número considerável de eventos inflamatórios, 
imunológicos e de stress oxidativo terem sido identificados na placa vulnerável, o conhecimento acerca dos 
mecanismos celulares e moleculares que conduzem à ruptura da placa aterosclerótica é ainda escasso e um 
pouco especulativo. Algumas das moléculas identificadas reflectem simplesmente o desenvolvimento da 
lesão, enquanto que outras podem estar envolvidas nos mecanismos que conduzem à sua ruptura e 
formação do trombo (i.e., à aterotrombose). Assim, a melhor estratégia para compreender as relações 
intrincadas entre os processos envolvidos na aterotrombose é através da avaliação de diversos marcadores 
que reconhecidamente (através de investigação básica e/ou clínica) reflictam cada um desses processos. 
A ideia-chave na génese desta tese de doutoramento foi o estudo das relações complexas entre os 
múltiplos processos envolvidos na evolução do enfarte agudo do miocárdio, como a disfunção endotelial e a 
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aterotrombose, o stress oxidativo, a inflamação e a resposta imunitária. Para atingir este objectivo foi 
adoptada uma abordagem multi-paramétrica e longitudinal inovadora. 
O estudo incidiu sobre um grupo de 50 indivíduos com enfarte agudo do miocárdio caracterizados pela 
elevação do segmento ST registada no respectivo electrocardiograma. Os doentes foram avaliados em 3 
fases sucessivas: na admissão ao hospital antes da administração de inibidores da glicoproteína IIb/IIIa e da 
angioplastia; 2 e 40 dias após a intervenção inicial. Um grupo de 25 voluntários saudáveis e não fumadores 
foi também constituído de modo a estabelecer valores de referência para cada parâmetro estudado. Em 
ambos os grupos foram medidas as concentrações no sangue de lipoproteínas de baixa densidade oxidadas 
(ox-LDL), marcadores inflamatórios como as citocinas TNF-α e CD40L, moléculas de adesão P-selectina e 
ICAM-1, e ainda o marcador da função endotelial, óxido nítrico (NO). Para além destes marcadores, foi 
estimada a percentagem de linfócitos T (CD3+, CD4+ e CD8+), bem como a expressão de CD40L nestas 
células. A expressão de CD40L e de CD62P como marcadores de activação plaquetária e a libertação de 
micropartículas (MPs) resultantes de activação tanto de plaquetas (PMPs) como de células endoteliais 
(EMPs) foram também avaliadas ao longo do período de estudo. 
O design escolhido para a amostragem permitiu identificar através dos parâmetros estudados dois 
processos distintos nos doentes com enfarte agudo do miocárdio: a ruptura de placa e o consequente 
processo trombótico que conduzem à patogénese do enfarte do miocárdio na fase aguda; e o processo de 
inflamação pós-enfarte, resultante de uma situação de isquemia/reperfusão, que conduz à remodelação 
vascular.  
As elevadas concentrações de ox-LDL observadas na fase aguda do enfarte do miocárdio poderão reflectir 
a instabilidade da placa. Esta destabilização pode aumentar os processos inflamatório e trombótico e 
estimular a resposta imunitária. A activação do sistema imunitário pelas ox-LDL manifesta-se pela sua 
associação com os linfócitos T (CD3+), podendo resultar num aumento da produção de TNF-α por estas 
células. De facto, observa-se um aumento significativo de TNF-α nos pacientes em fase aguda, 
relativamente aos níveis de referência. 
Por outro lado, os níveis mais baixos de linfócitos T observados na fase aguda do enfarte do miocárdio 
podem ser indicadores de um mecanismo de “feedback” para proteger o organismo de um choque 
inflamatório de maior amplitude. 
Aquando da admissão hospitalar dos doentes, não foram observadas diferenças consideráveis nos níveis 
séricos de sCD40L, na expressão de CD40L e de CD62P em linfócitos T e plaquetas, nem na libertação de 
PMPs, os quais são considerados marcadores de activação plaquetária. Nesta fase, o processo trombótico 
está maximizado, pelo que, tais resultados apontam para a retenção no trombo destes marcadores. Aliás, 
os resultados apresentados neste estudo parecem evidenciar a utilização de CD40L por diversas células 
circulaantes e plaquetas activadas a fim de manter o processo trombótico e eventualmente perpetuar o 
estímulo inflamatório.  
À medida que os doentes estabilizam e a magnitude do processo trombótico e da activação celular vão 
sendo controlados, o CD40L deixa de ser retido nas múltiplas interacções das células que mantêm o 
trombo, e o vasculatura cardíaca pode tornar-se um alvo importante da sua actividade biológica. De facto, 
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verificou-se que as variações ao longo do tempo para a concentração sérica de CD40L e a sua expressão 
membranar estavam relacionadas com os marcadores da função endotelial NO e EMPs, mas não com a 
activação plaquetária (CD62P e PMPs). 
A resposta inflamatória do miocárdio resultante da isquemia/reperfusão traduz-se no presente estudo 
pelos valores progressivamente aumentados de TNF-α, de sICAM-1 e pelo aumento da percentagem de 
linfócitos T. Este resultado é reforçado pelas associações encontradas entre os agentes do sistema 
imunitário e indicadores fisiológicos: linfócitos T CD8+ e NT-proBNP; sICAM-1 e linfócitos, monócitos e 
plaquetas; sP-selectina e troponina T. Assim, os resultados parecem apontar para uma acção temporal de 
acontecimentos orquestrada pelos linfócitos T, monócitos e plaquetas, e por marcadores de inflamação, 
tais como o TNF-α, sICAM-1, sP-selectina e CD40L, a qual parece ser crucial no desencadear da resposta 
inflamatória após danos por isquemia/reperfusão.  
De um modo geral, os resultados sugerem a existência de um aumento da resposta inflamatória no 
enfarte agudo do miocárdio até pelo menos 40 dias depois do evento agudo, suportando a hipótese da 
persistência da inflamação mesmo após a estabilização clínica dos doentes. A inexistência das associações 
acima descritas para o grupo de referência vem confirmar esta hipótese.  
Surpreendentemente, os resultados das variações longitudinais de sCD40L permitiram a diferenciação dos 
pacientes em dois grupos: um grupo caracterizado por um notável aumento das concentrações de sCD40L 
no dia 40, apresentando valores semelhantes aos dos indivíduos saudáveis; e um segundo grupo de doentes 
que mantém níveis baixos de sCD40L até ao dia 40. Estes dois grupos apresentaram diferenças nas 
concentrações de NT-proBNP (indicador de disfunção ventricular) inversas às de sCD40L, mas não 
mostraram quaisquer outras variações quer em termos de factores de risco, outros dados bioquímicos ou 
influência da medicação. Assim, esta diferenciação dos doentes baseada nos valores de sCD40L medidos no 
dia 40 pode ter importantes implicações clínicas, nomeadamente no possível valor de prognóstico na 
evolução do enfarte agudo do miocárdio, o qual advém da combinação dos dois marcadores. Para além 
disso, pode também ter uma implicação directa na prática clínica, especialmente no delineamento do 
plano terapêutico individual. 
Relacionando os marcadores estudados com os indicadores morfológicos e fisiológicos, verificou-se as 
concentrações de sP-selectina e ox-LDL se associavam à severidade e extensão da doença coronária, 
nomeadamente ao comprometimento de múltiplos vasos e à artéria culpada pelo enfarte agudo do 
miocárdio. 
Em conclusão, a presente tese permitiu identificar algumas das interacções entre os mecanismos 
inflamatório, trombótico, imunitário e da função endotelial e sua importância relativa em cada fase da 
doença. Nesta perspectiva, este estudo contribui para melhorar o conhecimento da patologia e dos 
mecanismos associados ao enfarte agudo do miocárdio.  
 
Palavras-chave: LDL oxidadas (ox-LDL); Linfócitos T; TNF-α; CD40 ligando; Estudo longitudinal. 
 
 
  
 
1 GENERAL INTRODUCTION 
 
 
1. 1. INTRODUCTION 
Coronary artery disease (CAD) is the world leading cause of illness and death. In 2005, 
approximately 7.6 millions deaths were attributed to CAD, accounting almost 13% of the total 
deaths.(1) From a pathophysiological point of view the disease could be considered as a severe 
clinical manifestation of atherosclerosis.(2) The disruption of an atherosclerotic plaque with 
superimposed thrombosis had been identified as the main cause of acute coronary syndromes (ACS), 
including myocardial infarction (MI), unstable angina and sudden death.(3,4) The importance is 
magnified because the disease affects a vital organ, i.e. the heart. 
The process of developing thrombosis on an atherosclerotic plaque could lead to the concept of 
atherothrombosis.(3,5) The initially silent progression of arterial plaque, prompted by classic risk 
factors (including hypertension, diabetes mellitus, dyslipidemia, age, stress, physical inactivity, 
dietary habits and cigarette smoking), is followed by a phase of acute or chronic progression toward 
an increasing degree of stenosis that eventually cause thrombosis.  
Plaque disruption and/or endothelial activation represent the main trigger event for ACS, through 
exposure of plaque thrombogenic components to platelets and to clotting components of flowing 
blood. In this phase, hemostasis related risk factors and platelet status play a crucial role.  
 
1.1.1. Pathophysiology of atherosclerosis 
The simplistic view of atherosclerosis as a disorder of pathological lipid deposition and platelet 
aggregation have been redefined by the more complex concept of an ongoing immunoinflammatory 
response.(6-8) Atherosclerosis is extremely complex and involves all the structural elements of the 
arterial wall, circulating cells, such as platelets, and a number of inflammatory cells particularly 
monocytes/macrophages and T lymphocytes.(9) The pathology of the disease, which develops during 
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the lifetime of an individual, can be simplistically summarized into three distinct phases: formation 
of fatty streaks; development of a complex lesion; and plaque disruption (Fig. 1.1).  
Nowadays, it is generally accepted that atherosclerosis is initiated by damage to the endothelial 
lining of the vascular wall.(10) The endothelial damage is increasingly believed to be mediated by 
oxidative stress, which could result from either (or both) diminished antioxidants and oxidative 
defence or increased production of free radicals, as reactive oxygen species (ROS).(11)
A primary initiating event is the accumulation of LDL in the subendothelial matrix, which is 
enhanced when the serum LDL levels are raised and the arterial wall permeability is higher.(11) LDL 
diffuses passively through endothelial cells (ECs), and its retention in the arterial wall seems to 
involve interactions between the LDL and matrix proteoglycans. Particularly when associated with 
such extracellular matrix macromolecules, LDL can undergo modification, including oxidation as a 
result of exposure to the ROS and oxidative enzymes.(12) Oxidized LDL (ox-LDL) acts both as an 
inflammatory mediator itself, capable of stimulating the recruitment of immune cells, and by 
inducing an inflammatory response in the overlying ECs.(9,13) Oxidized LDL can also incite the 
production of pro-inflammatory cytokines that alter the functions of intrinsic vascular cells and 
participate in the recruitment of inflammatory leukocytes to the atheromatous lesion(14) and inhibit 
the production of nitric oxide (NO).(15)
NO is the major factor in the normal activity of endothelium.(16) The anti-atherosclerotic effects 
rely upon sufficient amounts of NO to regulate platelet function (inhibits platelet adhesion), 
leukocyte adhesion and extravasation (block stimulation of endothelial adhesion molecule 
expression), inhibit LDL oxidation (by scavenging free radicals) and prevent smooth muscle cells 
(SMCs) proliferation.(9,17) In addition, NO could also contribute to lipoprotein oxidation by several 
mechanisms including the formation of the highly oxidant peroxynitrite, which could promote or 
accelerate lipid peroxidation.(18) A decreased formation of NO or a reduced bioavailability could 
lead to endothelial dysfunction,(9,16) altering the normal homeostatic properties of the 
endothelium.(19)
The injured endothelium release several pro-inflammatory cytokines (tumor necrosis factor-α - 
TNF-α and interferon-γ - IFN-γ) and chemokines, and produce adhesion molecules (e.g. P-selectin 
and intracellular adhesion molecule-1 - ICAM-1) and growth factors.(15) The expression of the cell 
adhesion molecules recruits immune and inflammatory cells, including monocytes and T 
lymphocytes.(20-22) In addition, adhered activated platelets could also interact with circulating 
leukocytes and facilitate platelet-leukocyte-endothelial cell adhesion.(23) Leukocytes attachment to 
adhesion molecules causes them to move out of the blood stream and roll along the surface of 
ECs,(20) in a process mediated by selectins (such as P- and E-selectin). Once in the intima, some 
inflammatory mediators stimulate the proliferation and differentiation of monocytes into 
macrophages, and augment the expression of macrophage scavenger receptors, leading to uptake of 
modified lipoprotein particles and formation of lipid-laden macrophages or “foam cells”.(15)  
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Macrophages signal the recruitment and activation of T lymphocytes that also join the intima 
during lesion evolution.(24) The pro-inflammatory TNF-α also elicits the expression of the several 
cytokine, such as IL-6,(25) which, in turn, induces expression of hepatic acute-phase reactants, such 
as C-reactive protein (CRP),(26) as well as the production of other effector molecules in the 
inflammatory response, as cellular adhesion molecules.(25-26) As a downstream biomarker, CRP 
provides functional integration of overall upstream cytokine activation.(27) 
 
Figure 1.1 – Progressive cellular and molecular mechanisms of the atherothrombotic process. (1) LDL enters 
the arterial wall and undergoes oxidative modification. (2) ox-LDL stimulates a cascade of cellular responses 
that culminate in endothelial dysfunction. (3) The production of inflammatory cytokines and the expression of 
adhesion molecules attract circulating immune cells, such as macrophages and T lymphocytes. (4) Macrophages 
in the arterial wall uptake ox-LDL becoming foam cells. (5 and 6) Many of these stimuli induce migration and 
proliferation of SMCs, leading to the degradation of the arterial extracellular matrix and to the growth of the 
plaque. (7) Plaque disruption exposes the necrotic core to the blood components, initiating a coagulation 
cascade and the subsequent thrombus formation. 
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All those processes contribute to a state of chronic inflammation. The leukocytes and activated 
ECs secrete cytokines and growth factors that trigger proliferation and migration of SMCs into the 
intima,(26) contributing to the degradation of the arterial extracellular matrix.(22,28) The necrotic 
lipid core results of the accumulation of lipids in extracellular matrix and the death of lipid-laden 
macrophages. Furthermore, oxygen radicals, generated from many sources, oxidize LDL, 
contributing to necrosis of cells.(29) The combination and interaction of all these processes leads to 
the growth of an advanced fibrous plaque (Fig. 1.1). 
 
1.1.2. Plaque disruption and thrombotic events 
Pathological studies suggest that the development of thrombus-mediated acute coronary events 
depends principally on the composition and vulnerability of a plaque rather than the severity of 
stenosis.(15) A thin fibrous cap, a large lipid core and a high density of macrophages contribute to 
the structural instability of plaques and thus to their rupture.(29)  
The major mechanism that cause the physical disruption of the vulnerable plaque responsible for 
the thrombotic complication, include the rupture of the plaque’s fibrous cap or superficial erosion 
of the endothelium.(30) Several researchers have been hypothesized that depletion of matrix 
components (specifically, collagens) from the fibrous cap caused by an imbalance between synthesis 
and breakdown, leads to cap thinning.(4) The cap is a dynamic structure within which the connective 
tissue matrix is constantly being replaced and maintained by SMCs. The synthesis of collagen by 
SMCs is stimulated by growth factors (e.g. transforming growth factor-β - TGF-β). However, when 
inflammation prevails in the intima, T cells can signal SMCs through IFN-γ, restricting new collagen 
synthesis. Furthermore, the T lymphocytes can also send signals to the macrophages trapped in the 
intima, enhancing the production of metalloproteinases (e.g. matrix metalloproteinases – MMPs) and 
cathepsins, which digest collagen and elastin.(29,31) Increased MMP production can be further induced 
by ox-LDL, CD40 ligand (CD40L) and inflammatory cytokines, among other stimuli.(4,31)  
CD40L (CD154) is a 33kDa trans-membrane glycoprotein structurally related to TNF-α. Was 
originally identified in stimulated CD4+ T cells,(32-33) mast cells and basophils.(34) Subsequent studies 
demonstrated its expression on platelets, which carry pre-formed CD40L that can be rapidly 
translocated onto the cell surface following activation.(35) The receptor for CD40L, CD40, is 
constitutively expressed on monocyte/macrophages, ECs, SMCs and platelets.(36-37) The interaction 
CD40L/CD40 is thought to be involved in both thrombosis and inflammation.(38)  
The primary mechanism that leads to both mural and occlusive thrombosis is represented by the 
adhesion and aggregation of platelets in disrupted plaques and by fibrin formation, with consequent 
strengthening of platelet thrombi (Fig. 1.2).(3) Fracture of the plaque’s fibrous cap allows blood to 
come in contact with the highly thrombogenic lipid-necrotic core, which contain tissue factor (TF)  
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Figure 1.2 – Lesion in a coronary artery totally occluded by a thrombus due to plaque rupture. The fibrous cap 
of the plaque rupture and thrombus within the lipid core extends into the lumen occluding it. This is the 
typical lesion of acute myocardial infarction. (Adapted from Davies(30)) 
 
 
and fragments of collagen. Such exposure results in thrombin generation and subsequent conversion 
of fibrinogen to fibrin. Simultaneously, activation of platelets occurs both by thrombin and by 
exposure to collagen and others sub-endothelial platelet-activating factors.(39) Therefore, the 
clotting cascade is activated promoting thrombus formation,(30) and the platelet-initiated thrombus 
enlarges with the incorporation of red blood cell, others circulating cells and fibrin. The binding of 
TF, thrombin and other activated coagulation proteases to specific receptor on inflammatory cells 
may affect inflammation inducing release of pro-inflammatory cytokines, which subsequently 
further modulate coagulation and fibrinolysis.(39) The TF expression on macrophages is regulated by 
inflammatory mediators found in the plaque, such as CD40L,(31) and can also be enhanced by 
expression of P-selectin on platelets.(39) 
In cases of plaque rupture, at first the thrombus forms in the plaque itself, and is predominantly 
formed of platelets, which are activated through the liberation of collagen and thrombin. Platelets 
can also exteriorize CD40L upon activation, providing a potential amplification loop in 
thrombosis.(31,40) As the thrombus begins to stick out into the lumen the fibrin components increases 
and any surface exposed to the blood in the lumen will be covered by activated platelets. Thrombus 
may grow to occlude the artery (Fig. 1.2), leading to a final stage in which there is a loose network 
of fibrin containing large numbers of entrapped red cells, having a structure very sensible to either 
natural or therapeutic lysis.(30)
In cases of superficial erosion, the thrombosis is triggered by an enhanced systemic thrombogenic 
state: enhanced platelet aggregability, increased circulating TF levels and depressed fibrinolytic 
state.(4,30) Platelets in contact with the subendothelial extracellular matrix and other constituents of 
the basement membrane are activated and become adherent. The CD40L expressed by platelets in 
this circumstance could activate TF on neighbouring ECs and propagate local formation of the 
thrombus. Furthermore, thrombin stimulation prompts the secretion of platelet, ECs and SMCs 
factors that trigger macrophages to produce TF, pro-inflammatory cytokines, lipid mediators of 
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inflammation and ROS. Via these mechanisms, thrombin initiates vascular inflammation, which 
promotes additional thrombin production through amplification loops that perpetuate atherogenic 
and thrombogenic signals.(31)  
Recently, novel findings suggest that inflammatory and vascular cells when activated by several 
stimuli release vesicles shed from plasma membrane, called microparticles (MPs). These MPs can be 
an additional factor that could contribute to the pathogenesis of cardiovascular disease by acting as 
pro-inflammatory agents, promoting coagulation and influencing endothelial function.(41-43) MPs are 
small vesicles (0.05 - 1 µm) that contain surface proteins and cytoplasmatic components of the 
original cell, so their composition reflects the state of the membrane of the originating cell.(44) MPs 
participate in mechanisms by which they mediate signalling, having differential consequences in the 
cell types that are activated. Thus, MPs can be viewed as a new pathway that can be used by cells 
to exchange information in addition to the signal transduction linked to the activation of receptors 
or transporters. Moreover, recent data provide evidence that the MPs, independent of their origin, 
can transfer biological information between cells, acting as vectors of signal molecules.(42)
 
1.1.3. Myocardial infarction 
Coronary occlusion by thrombosis due to plaque disruption critically reduces blood flow to the 
portion of the myocardium downstream, markedly impairing the energy metabolism. Total occlusion 
produces ischemia and could progress to necrosis if the occlusion is maintained and there where 
inadequate or no collateral blood supply (Fig. 1.3).(45)  
Myocardial necrosis begins approximately 30 minutes after coronary occlusion. Classic acute 
myocardial infraction (AMI) with extensive damage occurs when the perfusion of the myocardium is 
reduced severely below its needs for an extended period of time (usually at least 2 to 4 hours), 
causing profound, prolonged ischemia and resulting in cell death. The predominant mechanism of 
cell death is necrosis; apoptosis may also be important, but this is yet uncertain.(46) The regions 
were cell death occurs will permanently loss their function. The most effective way to save 
ischemic myocardium threatened by infarction is to restore tissue perfusion as rapidly as possible. In 
most of the cases this is accomplished through the restoration of coronary flow by angioplasty.(46)
The sequential phases that follow plaque disruption and thrombosis are ischemia, infarction and 
repair/remodelling.(45) The irreversible injured myocardial cells release, through their damaged cell 
membranes, several macromolecules, including troponin T (which is a protein component of the 
tropomyosin-actin complex that regulates muscle contraction).(45-46) Myocardial necrosis induces the 
generation of free radicals, which trigger a cytokine cascade initiated by TNF-α release, resulting in 
a inflammatory response.(47) This inflammatory response could be accelerated and augmented by 
reperfusion.  
Activation of several pro-inflammatory cytokines and complements has a crucial role in recruiting 
neutrophils to the ischemic and reperfused myocardium. Neutrophils infiltration is regulated  
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Figure 1.3 - Schematic representation of the progression of myocardial infarction after coronary artery 
occlusion. Necrosis begins in a small zone of the myocardium beneath the endocardial surface in the center of 
the ischemic zone. This entire region of myocardium (shaded) depends on the occluded vessel for perfusion and 
is the area at risk. The end result of the obstruction to blood flow is necrosis of the muscle that was dependent 
on perfusion from the coronary artery obstructed. (Reprinted with the permission of Elsevier(46)) 
 
 
through a complex sequence of molecular steps involving selectins and integrins, which mediate 
leukocytes adhesion to the endothelium. Neutrophils exert potent cytotoxic effects through the 
release of proteolytic enzymes and the adhesion with cardiomyocytes that express ICAM-1.(47) 
Despite this potential injury, substantial evidence suggests that reperfusion enhances cardiac 
repair; an effect that may be in part related to the inflammatory response. Macrophages and mast 
cells may produce cytokines and growth factors necessary for fibroblasts proliferation and 
neovascularization, leading to effective vascular remodelling.(47) Furthermore, when thrombus 
resorbs products associated with thrombosis such as thrombin and mediators released from 
degranulating platelets, can cause healing response, leading to increased collagen accumulation and 
SMCs growth.(48)
Cardiac remodelling is characterized by a structural rearrangement of the cardiac chamber wall 
that involves cardiomyocyte hypertrophy, fibroblasts proliferation and increased deposition of 
extracellular matrix proteins. The proliferation of interstitial fibroblast and increased deposition of 
extracellular matrix components results in myocardial stiffness and diastolic dysfunction, which 
ultimately leads to heart failure.(49) Several neurohumural or growth factors are implicated in the 
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development of cardiac fibrosis, including angiotensin II, endothelin-1, platelets-derived growth 
factor and TGF-β, and can cause direct cardiac damage and have proatherogenic, mitogenic and 
inflammatory properties.(50) A set of compensatory mechanisms exists including those based on 
hormone peptides B-type natriuretic peptides (BNP) and also N-terminus pro-BNP (NT-proBNP).(51) 
These hormones can inhibit fibrotic responses, preventing cardiac remodelling in pathological 
conditions.(49) BNP is a cardiac neurohormone released from ventricular myocardium in response to 
increased wall stress and myocardial tension. 
 
1. 2. RESEARCH PROBLEM 
The review presented above summarizes the current understanding of cellular and molecular 
mechanisms regulating the inflammatory and immune responses in atherothrombosis and 
subsequent myocardial ischemia and necrosis associated to AMI. The findings included in this review 
were achieved by clinical and pathophysiological studies and also in basic science work. 
In the past two decades exciting discoveries in the field of Cardiology and significant advances on 
the knowledge of mechanism underlying the initiation and growth of plaques were accomplished. 
However, it is important to emphasize that the understanding of the cellular biology of the unstable 
plaque remains speculative and consequently poorly known. Therefore, the crucial question is still 
the identification of the factor or factors that play a significant role in plaque disruption.  
The key-idea behind the present PhD thesis was to assess the complex relationships between the 
multiple processes involved in atherothrombosis, e.g. atherosclerosis, thrombosis, inflammation and 
immune response, which may contribute to answer the question of their relative importance in 
plaque disruption. 
Hence, the choice of AMI as a study-case come out naturally, since the processes of 
atherosclerosis, thrombosis, inflammation and cardiac repair are determinant in that clinical 
condition, which remains a major medical problem in spite of the advances lately achieved in 
Cardiology.  
Several clinical and basic studies have identified a considerable number of inflammatory, immune 
and oxidative stress events within the vulnerable plaque. Some markers may reflect the 
atherosclerotic plaque growth, while others may be more mechanistically linked to 
atherothrombosis and associated complications.(52-53) Therefore, the best outcomes in terms of 
understanding the intricate interplay between those different and complex processes may be 
achieved by evaluating longitudinal variations of a panel of markers that capture some of the 
processes involved in AMI evolution. The markers studied in this work were selected because of 
their well established relation (through basic science work) to atherothrombosis. Their role and 
relevance has been recognized by the scientific community, as attested by the increasing number of 
publications in high impact journals in the last five years.  
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This multi-parameter longitudinal approach, established in the approved PhD programme in 2004, 
has provided novel results, still relevant and interesting nowadays in this area of research.(31,53)  
As mentioned before, important information about the pathophysiology and mechanisms of 
atherosclerosis had been achieved using experimental animal models and/or cell cultures assays. 
However, both methodologies had great disadvantages in AMI study. There are many different types 
of animal models to study atherosclerosis, yet there are no good models of plaque 
destabilization.(29,54) Nonetheless, the most commonly used are rabbits and mice, in which the 
atherosclerosis has to be induced. On the other hand, cell culture experiments are almost-
universally used to examine metabolic pathways and to elucidate mechanisms involved in a variety 
of processes including CAD. However, it is important to recognize that cells that survive and grow in 
culture are not always representative of cells in vivo and may indeed behave differently from cells 
in vivo in many ways.(55) When extrapolating data obtained in cell culture assays and in animal 
models to human in vivo studies caution must be taken due to the different complexity of each 
system. For the above reasons, assessing circulating markers in samples taken from patients 
continues to be the most accurate approach in terms of clinical practice benefits. 
 
1. 3. OBJECTIVES 
The present thesis was designed as a clinical registry of several markers related to different 
processes implicated in AMI, such as inflammation, thrombosis, immune response and endothelial 
dysfunction.  
The main objective of the study was to understand the interactions between inflammation, 
thrombosis, immune response and endothelial dysfunction during AMI evolution, and to contribute 
to advances in the knowledge about the pathophysiology of the disease.  
To achieve this goal, systemic mediators of the immune and inflammatory response, thrombosis 
and endothelial dysfunction/damage were determined in AMI patients, at infarct onset and during 
the recovery period (a 40 days follow-up), by measuring: 
? the concentration of ox-LDL in plasma; 
? the serum concentrations of soluble inflammatory markers, such as the cytokines TNF-α, 
and CD40L (sCD40L), and the adhesion molecules P-selectin (sP-selectin) and ICAM-1 
(sICAM-1); 
? the percentages of T lymphocytes subpopulations and the expression of CD40L on those 
cells; 
? the expression of platelet activation markers CD40L and CD62P; 
? the serum concentrations of NO; 
? and the release of MPs resulting from endothelial cells and platelet activation. 
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The inter-relationship between these markers at the infarct onset and during recovery period, and 
their relation with the morpho-physiological data of the disease was performed. The integrative 
analysis of the relationship between the studied markers and the disease data, the interactions 
between markers and the influence of confounders could help revealing their relative importance in 
different phases of the disease, contributing to a better comprehension of the mechanisms involved 
in AMI. Finally, a better understanding of the pathophysiology of AMI may have important 
implications in the identification of prognostic and/or novel diagnostic markers to assess the risk of 
cardiovascular events, and in the development of new therapies. 
 
 
 
  
2 SERIAL CHANGES OF  
OXIDIZED LOW-DENSITY LIPOPROTEINS  
 
 
2. 1. INTRODUCTION 
The oxidative hypothesis of atherosclerosis recognizes the oxidative stress and subsequent 
modification of LDL as a central paradigm of atherosclerosis.(56) The transport of LDL across the 
endothelium into the artery wall and their oxidative modification are therefore important initiating 
events.(57)
Human studies have confirmed that ox-LDL and oxidized lipid by-products are present within 
atherosclerotic plaques.(58) The oxidation of LDL has been associated with atherothrombosis as it 
promotes apoptosis of ECs and macrophages and impairs the anti-coagulant balance in endothelium 
that in turn stimulates TF production and promotes platelet adhesion, facilitating the plaque 
destabilization and erosion.(58-59) Therefore, ox-LDL plays an important role in initiating and 
maintaining the inflammatory process in atherosclerotic lesions,(58) and the levels of ox-LDL in blood 
seem to associate with that process.  
Although it is widely accepted that ox-LDL exists in blood, the mechanism of oxidative 
modification of LDL in circulation remain unclear,(60) especially the place of such modification.(61-62) 
In fact, several authors proposed that the oxidation of LDL may not preferentially occur in blood.(60-
61,63) The plasma levels of ox-LDL associated with CAD may derive from the arterial wall by back-
diffusion(61,63) or oxidative modification of LDL by leukocytes at sites of plaque rupture.(57,62)
Several studies have shown a correlation between plasma levels of ox-LDL and the presence 
and/or severity of CAD.(60-61,63-68) However, it remains to be established the clinical importance of 
this marker in CAD both at the onset of acute episodes and at different stages of the disease 
evolution, and therefore to appraise its possible prognostic value. 
The objective of this study was to investigate the serial changes of ox-LDL in the plasma of 
patients immediately after AMI and during the recovery period, and to explore the relation of this 
marker with coronary disease severity and extension. 
 
12 Chapter 2 
 
2. 2. MATERIALS AND METHODS 
2.2.1. Study groups 
A total of 75 subjects (16 women and 59 men) were recruited at the Cardiology Service of Santa 
Marta Hospital, Lisbon. Among them, 50 patients with acute myocardial infarction constituted the 
myocardial infarction (AMI) group. 
A reference group (REF) of 25 healthy non-smokers volunteers with no previous history of coronary 
disease or chest discomfort was established to help on data baseline interpretation. Those 
volunteers were not submitted to coronary angiography, and had not taken aspirin or any other 
drugs known to affect platelet function within the previous week. 
 
2.2.2. Patients’ inclusion and exclusion criteria and characterization 
The subjects of AMI group all had ST-elevation myocardial infarction in the first 24 hours of 
evolution and underwent primary percutaneous transluminal coronary angioplasty (PTCA) as 
reperfusion therapy. The average time period from the onset of chest pain to the intervention less 
than 6 hours, and stents and glycoprotein IIb/IIIa blockers were used at the discretion of the 
handling physician. 
Subjects aged above 90 years or with significant co-morbidities as peripheral artery disease or 
carotid artery disease, known antecedents of malignance or infectious diseases, chronic renal 
insufficiency and previous MI in the last 5 years, were excluded. 
Clinical characteristics of the AMI patients at hospital admission such as, age, sex, smoking habits, 
diabetes mellitus, hypertension, hyperlipidemia, personal and family history of CAD were 
registered. The infarct-related artery (IRA) and the culprit lesion were identified by the 
combination of electrocardiogram (ECG) findings, left ventricle wall motion abnormalities, and 
angiographic lesion morphology. A coronary stenosis was considered clinically significant if it was 
>70% in diameter. Multivessel disease was defined when >1 major epicardial coronary arteries 
presented a significant stenosis. Blood tests included blood cells count, levels of C-reactive protein 
(hsCRP) and NT-proBNP, among other parameters. Current, in-hospital and after angioplasty 
medication was also recorded: insulin or other anti-diabetic drugs; platelet inhibitors agents, such 
as aspirin, clopidogrel or glycoprotein IIb/IIIa receptor antagonists; β-blockers; angiotensin-
converting enzyme (ACE) inhibitors and statins.  
Patients enrolled who received medication for hypertension or those with a systolic blood 
pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg were classified as having 
hypertension. Subjects who smoked within the previous 1 year were defined as smokers. Patients 
receiving cholesterol-lowering drugs or with total serum cholesterol level ≥190 mg/dl or serum 
triglycerides ≥180 mg/dl were classified as having hyperlipidemia. Abdominal obesity was 
considered when the waist perimeter was higher than 102 cm in men and 88 cm in women.  
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Informed consent was obtained for all subjects enrolled, and the study was approved by the local 
Ethical Committee. 
 
2.2.3. Study protocol and sampling 
A longitudinal follow-up of all patients in AMI group was carried out at three different occasions. For 
AMI patients blood samples were obtained from the right femoral artery before the administration 
of IIb/IIIa inhibitors and angioplasty (day 0 – baseline measure). Additionally, blood samples were 
obtained by venous puncture two (day 2) and 40 (day 40) days after the initial PTCA. 
Blood samples were drawn into blood collection tubes with EDTA and immediately centrifuged at 
2500 rpm for 10 minutes. The plasma-EDTA was collected after centrifugation and placed on ice. 
Aliquots were stored in liquid nitrogen until analysis (no longer than 6 months).  
The assays were performed in EDTA-plasma according to the manufacturer’s recommendations. 
Concentrations of ox-LDL were determined using a commercial (Mercodia, Sweden) enzyme-linked 
immunosorbent assay (ELISA). This capture ELISA kit uses a specific murine monoclonal antibody, 
mAB-4E6 m, which is the same used by Holvoet et al.(63-64). Two control plasmas with known ox-LDL 
concentrations supplied in the commercial kit were used as internal controls in the assay. Each 
sample was assayed in duplicate; the intra-assay variation among the duplicates for all samples was 
<10%. The concentrations of ox-LDL were expressed in U/l. 
 
2.2.4. Statistical analysis 
Data was summarized as mean and standard deviation (sd) for continuous variables and as 
proportions for categorical variables. Non-continuous variables were analyzed using a 2x2 table and 
Fisher’s exact test. Differences between healthy subjects and AMI patients in each time point were 
tested with Bonferroni correction. 
A longitudinal study was conducted in AMI group. The defining characteristic of any longitudinal 
study is that measures within the same individual through time can present serial correlation. So, 
special statistical methods are required to take into account this inter-correlation. The plasma 
concentrations of ox-LDL were studied in AMI patients by modelling it as a response variable over 
time. A logarithmic transformation of ox-LDL values was applied. The time variable was categorized 
as 1, 2 and 3 for the three samplings (days 0, 2 and 40), and hence, changes of log(ox-LDL) per time 
unit should be interpreted as changes between these samplings. A linear mixed effects model with 
random intercept and slope was fitted to the longitudinal variations of each patients’ log(ox-LDL). 
The model intercept gives the average level of ox-LDL at the acute event and estimates the 
differences in average slopes between baseline and the other two time points. 
In addition, coronary disease extension and severity indexes were included to the above model to 
evaluate their association with the log(ox-LDL) variation through time. Likely, biochemical data, 
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number of disease vessels, culprit vessel, number and type of stents used and ongoing therapy were 
also included as co-variables.  
Values of p<0.05 were considered statistical significant. The calculations were performed using 
SPSS (version 10.0) and R (version 2.5) software.  
 
2.3. RESULTS 
2.3.1. Characteristics of the study groups  
The demographic characteristics and baseline clinical data are listed in Table 2.1. Since coronary 
disease risk factors and co-morbidities were exclusion criteria in REF group, subjects enrolled were 
inevitably different from AMI patients.  
Previously to the myocardial infarction only 17 patients did not take any kind of medication. After 
admission, in-hospital medication included aspirin (91%), β-blockers (14%), ACE-inhibitors (77%), 
 
Table 2.1 – Baseline clinical characteristics of the subjects enrolled. 
 
 
REF 
(n=25) 
AMI 
(n=50) 
 
 Sex (f/m) 7/18 9/41  
 Age (y) 44±10 60±14 a  
 BMI (kg/m2) 25±2 27±4  
 Waist perimeter (cm) 88±8 97±12 a  
 Systolic BP (mm Hg) 124±12 122±20  
 Diastolic BP (mm Hg) 72±10 72±12  
 Ejection fraction (%) – 51±12  
 Risk factors and co-morbidity    
 Hypertension (n (%)) 0 (0) 29 (57) a  
 Smoking (n (%)) 0 (0) 25 (49) a  
 Hyperlipidemia (n (%)) 9 (36) 28 (55)  
 Diabetes (n (%)) 0 (0) 13 (26) a  
 Abdominal obesity (n (%)) 1 (4) 14 (28) a  
 Family history of CAD (n (%)) 0 (0) 8 (18)  
 Previous-event medication    
 Aspirin (n (%)) 0 (0) 10 (20)  
 ACE-inhibitor (n (%)) 0 (0) 19 (20)  
 β-blockers (n (%)) 0 (0) 9 (18)  
Statins (n (%)) 0 (0) 11 (22)  
Values are expressed as mean±sd, except otherwise indicated; a p<0.05 vs REF group. 
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statins (26%) and platelet inhibitors agents (86%). During follow-up all patients took platelet 
inhibitors (clopidogrel, 93%; aspirin, 93%) in addition to the medication referred above.  
Forty seven percent of AMI patients had multi-vessel disease. The culprit vessel was left anterior 
descending coronary artery (LAD) in 25 patients, right coronary artery (RCA) in 17, and left 
circumflex artery (LCX) in only 8 patients. IRA flow was classified as TIMI (thrombolysis in 
myocardial infarction) grade 0 to 1 (occlusion) in 79% of patients, TIMI grade 2 in 11% and TIMI grade 
3 (normal) in 11%. In the course of the angioplasty, stents were implanted in 96% of the patients, 
being 57% drug-eluting stents. 
Patients’ lost was registered for 14 subjects. However, patients who died (n=3) or were lost to 
follow-up (n=11) were not significantly different from the other AMI patients in terms of 
demographic and clinical characteristics (see Table A.1) or biochemical parameters at baseline (see 
Table A.2).  
 
Table 2.2 – Biochemical data and inflammatory markers in the two study groups. 
  AMI  
  
REF 
Day 0 Day 2 Day 40  
 Lipid profile      
 TC (mg/dl) 192±28 199±48 b 169±36 b 152±35 b  
 LDL-C (mg/dl) 123±31 133±42 b 103±26 b 89±28 b  
 HDL-C (mg/dl) 54±12 40±13 b 37±12 b 37±10 b  
 TG (mg/dl) 74±27 112±60 b 104±24 b 131±79 b  
 ox-LDL (U/l) 57±27 92±39 a 81±38 a 57±27  
 Blood cell count      
 Total WBCs (x103/µl) 5.6±0.9 12±4 a 9.2±3.5 a 6.7±1.7  
 Neutrophils (x103/µl) 3.0±0.7 9.6±4.0 a 6.4±3.5 a 4.1±1.4 a  
 Lymphocytes (x103/µl) 2.0±0.4 1.9±1.2 1.9±0.8 2.1±1.1  
 Monocytes (x103/µl) 0.40±0.15 0.63±0.38 0.75±0.23 a 0.50±0.2  
 Platelets (x103/µl) 229±62 224±67 199±78 231±68  
 Inflammatory marker      
 hsCRP (mg/dl) 0.37±0.17 0.71±0.50 a 3.9±3.4 a 0.43±0.28  
Other physiological markers     
Glucose (mg/dl) 90±9 177±69 b 137±48 b 118±43 b  
Albumin (g/dl) 3.9±0.4 3.4±0.4a 3.2±0.4 a 3.9±0.3  
Troponin T (ng/ml) <0.01 c 2.25±4.94 a 4.15±4.47 a 0.05±0.17  
NT-proBNP (pg/ml) 38±27 663±840 a 1843±1594 a 781±583 a  
Values are expressed as mean±sd. a p<0.05 vs REF group; b not compared (see text); c values below 
detection limit. 
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Lipid and glucose data obtained for the two studied groups could not be directly compared as 
fasting-blood tests were only performed for REF individuals (Table 2.2). Maximum values of hsCRP 
(an acute phase inflammatory indicator), of NT-proBNP and troponin T (markers of ventricle failure 
and myocardial damage) were observed at day 2. 
 
2.3.2. Longitudinal variations of ox-LDL 
At the onset of myocardial infarction plasma ox-LDL concentrations were markedly increased when 
compared to the values obtained for the REF group (Table 2.2). The ox-LDL levels decreased 
through time. In fact, the estimate log(oxLDL) time-variations, using a linear mixed effect model, 
were significant (p<0.001). The decrease in log(oxLDL) values from day 0 to day 40 was significant 
(Fig. 2.1). Furthermore, forty days after PTCA, AMI patients reach values of ox-LDL similar to REF 
group (Table 2.2).  
To evaluate the possible influence of drug-intake in ox-LDL concentrations, the 12 AMI patients 
that did not take any kind of pre-event medication were compared to the remaining patients. The 
levels of ox-LDL were not statistically different (p=0.138) between both sub-groups. To further 
evaluate the possible influence of drug therapy in serial changes of log(ox-LDL), the pre-event, in-
hospital and follow-up medication data were categorized and added to the linear mixed effects 
models as co-variables. With the exception of aspirin, none of the other drugs administered to the 
patients before admission significantly influence the changes of log(ox-LDL) through time (see Table 
A.3). However, the administration of in-hospital ACE-inhibitor and of follow-up β-blockers and 
statins further decrease log(ox-LDL) levels (see Table A.3). 
 
Figure 2.1 – Results of the linear mixed effects models evaluating changes of log(ox-LDL) over 40 days follow-
up. The estimated average values at each time point and the respective variances (95% confidence interval) 
are plotted. *p<0.05 vs AMI day 0. 
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Figure 2.2 – Influence of the culprit vessel (LAD – squares; RCA – circles; and LCX – triangles) in ox-LDL 
concentrations (mean) from the myocardial infarction onset (day 0) until day 40.  
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2.3.3. Association to coronary artery disease severity 
The linear mixed effect model used to describe log(ox-LDL) average decrease over time was also 
tested including the number of diseased vessels, culprit vessel and biochemical indicators such as 
hsCRP, troponin T and NT-proBNP as co-variables. No associations were verified between serial 
changes of log(ox-LDL) and the biochemical markers studied (p=0.204, p=0.092 and p=0.114, 
respectively; see Table A.3) nor the number of diseased vessel (p=0.973; see Table A.3).  
However, examining the longitudinal variations of ox-LDL according to the 3 culprit vessel was 
verified that patients with LCX as culprit had the lowest ox-LDL levels (Fig. 2.2). Although a general 
decreasing trend of ox-LDL was observed in all situations, low levels of log(ox-LDL) were 
consistently associated with patients having LCX as culprit vessel (p=0.046; see Table A.3) relative 
to those with LAD and RCA. The model significance was especially correlated to ox-LDL 
concentrations at day 0.  
 
2.4. DISCUSSION 
The present study demonstrates that the plasma levels of ox-LDL were remarkably elevated at MI 
onset before therapeutic intervention and decreased shortly after (day 2), continuing to fall 40 days 
later. The decline in ox-LDL concentrations with time was significant. 
There are few studies reporting ox-LDL measurements at the onset of MI or a few days after.(68-70) 
Longitudinal data for ox-LDL in MI is rather limited,(71) but in the overall a good agreement was 
found between data sets at discrete time points obtained in this work with similar disease 
conditions reported by other authors. In fact, enhanced ox-LDL levels were reported in patients 
18 Chapter 2 
 
with CAD, at different clinical conditions such as myocardial infarction, stable and unstable angina, 
or transplanted.(58,632-65,68,72)  
The high levels of ox-LDL at AMI onset (day 0) verified in the present study emphasize the concept 
that an increase in ox-LDL levels are associated with plaque instability, as previously 
suggested.(58,65,69-70,73) In fact, the inflammatory process associated to plaque rupture and 
ischemia/reperfusion injury favour the generation of excessive pro-oxidants, disrupting the balance 
between antioxidants and pro-oxidants in blood.(70) The gradual reduction of ox-LDL concentrations 
with clinical stabilization observed in this study could be partially due to changes in the redox 
balance, either through an increase of the antioxidant systems activity or a reduction of the 
oxidants, as proposed by Nakuro et al.(70).  
As AMI patients stabilize, the decrease of ox-LDL levels also reflect the effect of therapy. The 
benefits of medication, such as aspirin, ACE-inhibitors, β-blockers and statins in cardiovascular 
diseases were object of various studies. Statins could reduce ox-LDL levels by their well know lipid-
lowering effect: through the reduction of the circulating LDL-cholesterol pool the amount of LDL 
available for oxidation is decreased.(74) Furthermore, statins(75-78) and ACE-inhibitors(79-80) potentially 
reduce oxidative stress and endothelial dysfunction, therefore decreasing ROS and peroxynitrite 
generation which could result in a reduced ox-LDL formation. The effect can be fostered by β-
blockers. The reduction of lipid oxidation and ox-LDL back-diffusion into the circulation could also 
be accomplished by limiting the inflammatory process in the lesion and enhancing endothelial 
function. In this matter, the anti-inflammatory capacity of aspirin is well documented.(81-82) An 
interfering effect of aspirin with LDL oxidation and to the initiation of ROS has also been 
described.(83)
The above described serial changes were influenced by the culprit lesion location. The AMI 
patients with LCX artery as culprit vessel had the lowest concentrations of ox-LDL, especially at MI 
onset, opposite to patients where the cause of infarction originated in LAD or RCA. Thus, these 
results suggest that the increase of ox-LDL concentration is related with CAD severity as conditions 
such as LCX lesions are usually associated with a favourable prognosis, contrasting with LAD-
associated conditions that can impair large areas of myocardium (see Fig. 1.3).  
This seems to be the first study reporting an association between circulating ox-LDL decreases and 
the LCX culprit vessel in AMI patients. The very high levels of ox-LDL in patients with LAD or RCA as 
culprit vessel and the low levels of ox-LDL in LCX patients, suggest that ox-LDL may be associated 
with CAD severity and eventually to lesion characteristics depending on the infarct-related artery 
involved. The above findings are consistent with the concept of ox-LDL hold an important role in the 
atherosclerotic process, both as an inflammatory mediator and as a product of pro- and antioxidant 
system imbalance. Plaque composition and activity has been associated with enhanced 
inflammatory indices and different lesion characteristics in the 3 coronary arteries.(84) Therefore, 
supplementary studies, using advanced imaging techniques for lesion assessment, and plaque 
Serial changes of ox-LDL 19 
 
biological characterization, such as ultrasound and tomography based techniques, will be mandatory 
to verify this hypothesis.  
In conclusion, the serial changes in ox-LDL values in AMI patients suggest that this marker may be 
useful to broaden the understanding on plaque instability and to improve the evaluation of coronary 
artery disease severity.  
 
  
3 OXIDIZED LOW-DENSITY LIPOPROTEINS  
AND IMMUNE RESPONSE 
 
 
3. 1. INTRODUCTION 
Atherosclerosis has traditionally been viewed to simply reflect the deposition of lipids within the 
vessel wall of medium-sized and large arteries. This concept has evolved, and inflammation,(27) 
oxidative stress(56) or immune processes(85) are no longer controversial issues. Research focus have 
been directed on investigating how inflammation is regulated, ROS and others oxidant compounds 
interfere and promote oxidation of lipoproteins, or combinations of these and other factors leads to 
inflammatory response, induce endothelial dysfunction and plaque stability.  
Endothelial dysfunction favours the entry of circulating lipoproteins in the vessel wall where they 
can be oxidatively modified. In vascular cells, increased ROS can activate intracellular signalling 
molecules involved in gene expression. Oxidized LDL induces chemoattraction of monocytes and 
lymphocytes. In the intima, macrophages uptaking ox-LDL, become foam cells and eventually die. 
Infiltrating T cells and macrophages locally interact in a synergistic manner. Vascular wall 
infiltration of T lymphocytes respond to macrophage-derived interleukin increasing circulating 
levels of pro-inflammatory cytokines such as IFN-γ and TNF-α.(56-57) These cytokines together with 
the release of proteases by activated macrophages promote endothelial cell dysfunction, further 
immune cell activation, and degradation of extracellular matrix, contributing to the plaque rupture 
triggering the extrinsic coagulation pathway.  
The role of inflammation in plaque destabilization should provide a link between cell infiltration 
and thrombosis developing on the vessel wall. Oxidized LDL proved to impair anti-coagulant balance 
in endothelium that in turn stimulates TF production and promotes platelet adhesion, facilitating 
the plaque destabilization.(58) As referred before (see Chapter 2) the mechanisms of oxidative 
modification of LDL and their place of occurrence remain unclear. Holvoet et al.(61,63) hypothesized 
that plasma levels of ox-LDL may derive from the arterial wall by back-diffusion, where, as 
demonstrated by several in vitro studies, lymphocytes, neutrophils and macrophages can oxidatively 
modify LDL.(57,65) These cells are known to accumulate at sites of plaque rupture or erosion, and 
could therefore contribute to an increase in the ox-LDL levels in the blood.(65)
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Atherosclerotic plaques are heavily infiltrated by T cells that secrete mediators influencing plaque 
development, and T cells activity depends on the triggering of specific antigens that are found 
within the disease site, such as those of ox-LDL. Taken together these findings point out for a 
functional role of ox-LDL, T cells and pro-inflammatory cytokines in lesion evolution and plaque 
rupture, calling the attention for their particular interest in AMI.  
Therefore, this study was designed to investigate the concomitant serial changes of circulating ox-
LDL and TNF-α, together with the proportion of T lymphocytes sub-sets at the AMI. Patients with 
myocardial infarction were studied from the acute event onset to the recovery period, and the 
interrelationships between the above parameters were assessed. 
 
3. 2. MATERIALS AND METHODS 
3.2.1. Study groups 
The study groups consisted of 50 patients with acute myocardial infarction (AMI group) and 25 
healthy non-smokers volunteers (REF group), as previously described (see Section 2.2). A 
longitudinal follow-up of all AMI patients was carried out at three different times: 1) at day 0 before 
the administration of IIb/IIIa inhibitor and PTCA intervention; 2) 2 days after PTCA (day 2); and 3) at 
day 40, during the recovery phase (see Section 2.2). 
 
3.2.2. Determination of ox-LDL and TNF-α  
Blood samples were drawn into blood collection tubes and immediately centrifuged (2500 rpm for 
10 minutes). Aliquots were stored in liquid nitrogen or at -80ºC, accordingly to the assay, until 
analysis (no longer than 6 months).  
Plasma-EDTA ox-LDL concentrations were assessed by ELISA (Mercodia, Sweden). TNF-α 
concentrations were measured in serum, according to the manufacturer’s recommendations, using a 
commercial available high sensitivity ELISA (R&D Systems, USA). Each sample was assayed in 
duplicate; the intra-assay variation among the duplicates for all samples was <10%. The 
concentrations of ox-LDL and TNF-α were expressed in U/l and pg/ml, respectively.  
 
3.2.3. Lymphocyte profile  
Blood, from all healthy volunteers and 28 AMI patients, was drawn into EDTA blood collection tubes. 
A direct immunofluorescence staining of whole blood using a lyse/wash procedure was applied for 
the T lymphocytes assessment. Briefly, 100 µl aliquots of whole blood were mixture with 
fluorochrome-labeled antibodies (BD, USA) and incubated at room temperature in the dark for 20 
minutes. A PE-Cy7-CD45 was used as marker of leukocytes and a FITC-conjugate anti-CD3 identify 
the T lymphocyte class (see Fig. A.1). T-lymphocyte CD4 and CD8 sub-sets were identified using 
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APC-CD8 and APC-Cy7-CD4. After incubation, 2 ml FACS lysing solution (BD, USA) was added and 
samples were incubated for 10 minutes. Samples were centrifuged twice (500 g for 5 minutes) and 
the supernatant removed each time. After centrifugation, PBS buffer (500 µl) was added and 
samples were promptly analysed by flow cytometry.  
Flow cytometry was performed on a FACSCanto (BD, USA) and data processed with FlowJo 7.2.4 
software package. All samples were analysed using the same voltage setting. A threshold was 
defined for FITC fluorescence, below which 95% of all lymphocytes events from unstained samples 
stained with FITC-CD3 (see Fig A.1C). A similar threshold was also defined for APC and APC-Cy7 
fluorescence’s (see Fig A.1D). After that correction of non-specific binding, data was expressed as 
percentage of CD3, CD4 and CD8 positive lymphocytes. 
 
3.2.4. Statistical analysis 
Data was summarized as mean and standard deviation (sd) for continuous variables and as 
proportions for categorical variables. The statistical differences between groups for the categorical 
variables were evaluated using Fisher’s exact test, while for the continuous variables were tested 
with Bonferroni correction.
Concentrations of ox-LDL, TNF-α and percentage of T lymphocytes in AMI patients were studied by 
modelling these variables as a response variable over time. A logarithm transformation was applied 
to ox-LDL data and a square root transformation to TNF-α. A linear mixed effects model, with 
intercept and slope as random effects, was formulated. To assess ox-LDL, TNF-α and percentage of 
T lymphocytes interrelationships through time, these parameters were added to the above linear 
mixed effects model as co-variables. 
Values of p<0.05 were considered statistical significant. The calculations were performed using 
SPSS (version 10.0) and R (version 2.7.0) software. 
 
3. 3. RESULTS 
3.3.1. Characteristics of the study groups 
The demographic and baseline clinical characteristics of the study groups were previously described 
in Section 2.3.1 and summarized in Table 2.1. 
 
3.3.2. Plasma ox-LDL longitudinal variations 
As described in Chapter 2, at the onset of myocardial infarction (day 0) plasma ox-LDL 
concentrations were higher than the values obtained for the reference group (Table 2.2). Log(ox-
LDL) variations progressively decrease over time (Fig. 2.1).  
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Table 3.1 – Inflammatory markers and immune cells in the two study groups. 
  AMI  
  
REF 
Day 0 Day 2 Day 40  
 Inflammatory marker      
 TNF-α (pg/ml) 0.58±0.52 1.6±1.0 a 1.8±1.0 a 2.2±1.5 a  
T lymphocytes      
CD3+ T cells (%) 19±6 7±4 a 11±5 a 14±5  
CD4+ T cells (%) 41±5 38±8 45±8 48±8 a  
CD8+ T cells (%) 23±10 16±6 a 18±6 18±7  
Values are expressed as mean±sd; a p<0.05 vs REF group. 
 
3.3.3. Serum TNF-α longitudinal variations 
Concentrations of TNF-α in AMI patients were higher than in healthy subjects (Table 3.1). Through 
the linear mixed effect model, was verified that sqrt(TNF-α) remarkably increase over time (Fig. 
3.1A). Sqrt(TNF-α) were enhanced at day 2 (p=0.036), and continue to increase until day 40 
(p<0.02). 
 
3.3.4. T Lymphocyte profile 
Low percentages of T lymphocytes (CD3+ cells) were observed in the acute phase of myocardial 
infarction in comparison to REF group (Table 3.1). Those low levels at admission significantly 
increase along time. The association between CD3+ T lymphocytes and time was significant (Fig. 
3.1B).  
The variation trend of CD4+ and CD8+ T lymphocytes was similar to CD3+. The linear mixed effect 
model showed a significant (Fig. 3.1C and D) increase in T cells sub-sets over time. 
 
3.3.5. Relationships between ox-LDL, TNF-α, immune cells and biochemical markers 
The relationship between ox-LDL and immune cells was assessed by the association of longitudinal 
variations of those parameters using linear mixed effect model. The model only reveal an 
association between serial changes of log(ox-LDL) and CD3+ T lymphocyte (+0.02, p<0.03). 
The linear mixed effect model was also tested including biochemical data, but none of these 
parameters were significantly associated to serial changes of log(ox-LDL), sqrt(TNF-α) or CD4+ T 
lymphocytes (see Table A.4). However, the CD8+ T lymphocytes longitudinal variations were 
significantly associated to NT-proBNP (p<0.01). The same association was verified for CD3+ T 
lymphocytes, which reinforce the role of CD8+ T cells. 
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Figure 3.1 – Results of the linear mixed effects models evaluating changes of inflammatory marker (sqrt(TNF-
α) – A) and T lymphocytes (CD3+ T cells – B; CD4+ T cells – C; CD8+ T cells – D) over 40 days follow-up. The 
estimated average values and the respective variances at each time point (95% confidence interval) are 
plotted. *p<0.05 vs AMI day 0. 
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3.4. DISCUSSION 
Serial changes of ox-LDL, TNF-α and percentage of T lymphocytes (CD3+, CD4+ and CD8+) in AMI 
patients, 2 days after angioplasty intervention and 40 days later, showed inverted patterns. The 
results demonstrated that serum ox-LDL levels decreased from the AMI onset until 40 days later. On 
the contrary, TNF-α and the percentage of T cells progressively increased over time, in relation to 
baseline. Furthermore, the time-variations of CD3+ T lymphocytes and ox-LDL were associated. An 
association between serial changes of CD8+ lymphocytes with NT-proBNP was also verified. 
There are few studies reporting ox-LDL and T lymphocytes measurements at the onset of AMI or a 
few days after.(68,70,86-87) In general a good agreement was found between data obtained in this work 
with similar disease conditions reported by other authors. In fact, enhanced ox-LDL levels were 
reported in patients with CAD, at different clinical conditions such as myocardial infarction, stable 
or unstable angina.(63,65,68) Low counts of T lymphocytes were also reported in AMI.(85,87) 
Two different inflammatory process could be identified in AMI patients: the coronary arterial 
inflammation that leads to the pathogenesis of AMI; and the myocardium inflammation after AMI 
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that leads to vascular remodeling.(86) And the longitudinal variations described in this study could be 
related to both these processes. 
During the acute event important feedback mechanism may be triggered to protect the organism 
from an “overshoot” of systemic pro-inflammatory cytokines and other products with tissue-damage 
potential by activated macrophages.(87) As a consequence of those feedback mechanisms no 
systemic T lymphocytes activation would happened,(88) which could partially explain the low 
percentages of T lymphocytes verified at AMI onset. After AMI, myocardial necrosis releases or 
exposes normally sequestered antigenic constituents that may cause activation and proliferation of 
T cells,(86) as observed by the CD4+ T lymphocytes increase at day 40.  
The activated T lymphocytes can target the myocardium in an autoimmune response, supporting 
the development of ventricular remodelling and congestive heart failure.(86) This hypothesis is 
reinforced by the association of longitudinal variation of CD8+ T lymphocytes with NT-proBNP, 
secreted in consequence of a rise in ventricular myocardial wall stress and myocardial ischemia.(89) 
The activation of cytokine cascade associated to myocardial necrosis and reperfusion after AMI(88) is 
also observed in this study. The enhanced serum concentrations of TNF-α in AMI patients could be 
considered part of the systemic inflammatory reaction due to local inflammation.  
The TNF-α increase after infarction, as measured in AMI patients, also suggests a continuous 
inflammatory stimulation. The sources of circulating levels of TNF-α are not fully identified, 
although heart tissue injury and T lymphocytes activation,(90) proved to contribute for TNF-α levels 
(see Chapter 4 for further discussion). 
The high levels of ox-LDL at AMI onset (day 0) were in agreement with the concept that an 
increase in ox-LDL levels can be associated with plaque instability,(65,68,70) oxidative stress 
conditions(70) and arterial wall back-diffusion mechanisms,(60,63) as previously discussed on Chapter 2. 
Abundance of ox-LDL may contribute to plaque rupture by inducing cell death of SMCs(61,63) and also 
of T lymphocytes.(91-92) The proliferation of activated T cells had also been reported to be inhibited 
by ox-LDL,(93-94) thus limiting their ability to induce immune response. These findings justified the 
association of ox-LDL and CD3+ lymphocytes serial changes. Therefore, these processes could 
somehow contribute to plaque growth and instability,(91) but could also provide a mechanism for 
fading the local inflammation reaction, evidencing the dual role of ox-LDL in atherosclerosis.(91)  
In conclusion, the results obtained in this study showed that the inflammatory response in AMI 
remains active for 40 days after acute onset, supporting the hypothesis of ongoing inflammation 
after clinical stabilization. Additionally, the immune components of the inflammatory process were 
not maximally expressed at clinical admission perhaps due to a compensation mechanism to avoid 
an inflammatory “overshoot”.  
Until now, the majority of the studies evaluating the interrelationships between ox-LDL and 
immune system, especially T lymphocytes activity, were performed in vitro, either using cell 
cultures or peripheral blood mononuclear cells. Based on the reviewed literature this seem to be 
the first study evaluating those interrelationships using blood circulation levels of ox-LDL and T 
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lymphocytes, in a time-variation manner. This sampling design allowed to contribute to a better 
understanding of the ACS and their evolution, and especially to clarify the changes in the 
interrelationship between ox-LDL and T lymphocytes activity over time in AMI patients. Thus, the 
novelty of the present study was to validate in vivo, mechanisms described for in vitro conditions. 
These results opened new perspectives to investigate the role of markers implicated in plaque 
activity together with immune response. 
 
 
 
  
 
4 INFLAMMATORY RESPONSIVENESS 
 
 
4. 1. INTRODUCTION 
Interactions between activated platelets, ECs and leukocytes, mediated by P-selectin and ICAM-1 
are associated with initiation of arterial thrombus.(20) The soluble forms of these adhesion molecules 
can be released in circulation. The main contribution to sP-selectin appears to be from activated 
platelets. Stimulated platelets and immune cells could secrete products with pro-inflammatory 
properties, such as TNF-α.  
Clinical studies relating sP-selectin, sICAM-1 and TNF-α to CAD and MI are limited and available 
data mainly derive from randomized clinical trials or retrospective studies. While, increased levels 
of sP-selectin have been consistently associated with ACS,(95-96) the measurement of sICAM-1 is not 
consensual. Persistent high levels of sICAM-1 were associated with unstable angina and AMI,(97-100) 
although a stronger predictive information for sICAM-1 could not be found.(101-102) Regarding TNF-α 
and some of its soluble receptors, increased circulating levels of these molecules were reported in 
primary cardiovascular events and associated to mortality in heart failure subsequent to MI.(103) 
sP-selectin, sICAM-1 and TNF-α assess different pathophysiological mechanisms in AMI. While P-
selectin and ICAM-1 are directly involved in atherothrombosis,(20) TNF-α is involved in ECs activation 
and in the amplification of inflammatory response.(86) Thus, their circulating levels in association 
with myocardial injury markers may help describing variation patterns along the infarct evolution 
and recovery and therefore, be useful in predicting patient’s risk. Furthermore, though a great pool 
of information concerning circulating inflammatory markers have been so far collected in different 
cardiovascular conditions, neither the onset of AMI nor its evolution have been well depicted.  
The aim of this study was to investigate, in a mechanistic perspective, the role and the 
interaction of sP-selectin, sICAM-1 and TNF-α in the AMI, by following patients at the onset of the 
thrombotic event and along the recovery period. Whether serial variations of these markers were 
independently related to coronary disease extension, physiological response of the cardiovascular 
system or risk factors was also evaluated.  
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4. 2. MATERIALS AND METHODS 
4.2.1. Study groups 
A total of 42 subjects (8 women and 34 men) were recruited at the Cardiology Service in Santa 
Marta Hospital (Lisbon). Among them, 28 patients with acute myocardial infarction constituted the 
myocardial infarction (AMI) group.  
A reference group (REF) of 14 healthy non-smokers volunteers with no previous history of coronary 
disease or chest discomfort was also established to help on inflammation baseline interpretation. 
These volunteers were not submitted to coronary angiography, and had not taken aspirin or any 
other drugs known to affect platelet function within the previous week. 
Patients’ exclusion criteria and characterization had been already described in Section 2.2. 
 
4.2.2. Sampling protocol 
As mentioned earlier, in AMI patients the circulating markers were measured at three different 
times: 1) at day 0 blood before the administration of IIb/IIIa inhibitor and PTCA (baseline measure); 
2) 2 days after intervention; and 3) 40 days after PTCA, during the recovery phase.  
Blood samples were drawn from all patients into pyrogen-free blood collection tubes without 
additives and immediately centrifuged (2500 rpm for 10 minutes). The serum was collected after 
centrifugation and placed on ice. Aliquots were stored at -80ºC until analysis (no longer than 6 
months). Samples were thawed only once.  
Soluble concentrations of ICAM-1 and P-selectin were measured by ELISA commercial kits (R&D 
Systems, USA). The concentrations of TNF-α were assessed using a commercial available high 
sensitivity ELISA (R&D Systems, USA). Each sample was measured in duplicate; the intra-assay 
variation among the duplicates for all samples was less than 10%. The concentrations of sP-selectin 
and ICAM-1 were expressed in ng/ml and those of TNF-α in pg/ml.  
 
4.2.3. Statistical analysis 
Data was summarized as mean and standard deviation (sd) for continuous variables and as 
proportions for categorical variables. Differences between healthy subjects and patients in each 
time point were tested with Bonferroni correction. 
A linear mixed effects model with random intercept and slope, was fitted to the longitudinal 
variations of each patient’s inflammatory markers (sP-selectin, sICAM-1 and TNF-α). A square root 
transformation was applied to sP-selectin and TNF-α. In addition, coronary disease extension and 
severity indexes were included to the above models to evaluate their association with the 
inflammatory markers’ variation through time. Likely, biochemical data, number of disease vessels, 
culprit vessel, number and type of stents used and ongoing therapy were also included as co-
variables.  
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Values were considered statistical significant when p<0.05. The calculations were performed using 
SPSS (version 10.0) and R (version 2.7.0) software. 
 
4. 3. RESULTS 
4.3.1. Characteristics of study groups 
The demographic characteristics and baseline clinical features of the study groups including some 
risk factors and co-morbidities are summarized in Table 4.1. REF group was constituted to obtain 
baseline characteristics for the inflammatory markers variations in AMI, not biased by medication, 
coronary disease risk factors and co-morbidities. Therefore REF subjects inevitably differed from 
patients (see Table 4.1). 
Medication intake in AMI group had into account the medication before infarct, the medication 
administered in-hospital and the medication prescribed in the follow-up. Twelve patients did not  
 
Table 4.1 – Baseline clinical characteristics of the subjects enrolled. 
 
 
REF 
(n=14) 
AMI 
(n=28) 
 
 Sex (f/m) 3/11 5/23  
 Age (y) 43±12 59±15 a  
 BMI (kg/m2) 25±3 27±3  
 Waist perimeter (cm) 88±8 95±13  
 Systolic BP (mm Hg) 130±10 122±22  
 Diastolic BP (mm Hg) 73±7 72±12  
 Ejection fraction (%) – 53±13  
 Risk factors and co-morbidity    
 Hypertension (n (%)) 0 (0) 17 (61) a  
 Smoking (n (%)) 0 (0) 13 (46) a  
 Hyperlipidemia (n (%)) 5 (33) 16 (57)  
 Diabetes (n (%)) 0 (0) 10 (36) a  
 Abdominal obesity (n (%)) 0 (0) 8 (29) ) a  
 Family history of CAD (n (%)) 0 (0) 4 (14)  
 Previous-event medication    
 Aspirin (n (%)) 0 (0) 4 (14)  
 ACE-inhibitor, (n (%)) 0 (0) 10 (36)  
 β-blockers (n (%)) 0 (0) 6 (21)  
Statins (n (%)) 0 (0) 7 (25)  
Values are expressed as mean±sd, except otherwise indicated; a p<0.05 vs REF group. 
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take any previous medication, but the remaining patients were on combinations of aspirin, β-
blockers, ACE-inhibitors and statins (Table 4.1). After admission, in-hospital medication also 
included aspirin (84%), β-blockers (12%), ACE-inhibitors (68%), statins (40%) and platelet inhibitor 
agents (76%). During follow-up the majority of patients took platelet inhibitor agents (clopidogrel, 
83%; aspirin, 88%) in addition to the previous medication referred above. 
In the 28 patients included in the AMI group, the culprit IRA was left anterior descending (LAD) in 
12, left circumflex (LCX) in 10 and right coronary in 5. Multi-vessel disease was observed in 32% of 
patients. In the course of the angioplasty, stents were implanted in 96% of the patients, being 57% 
drug-eluting stents. 
Concerning biochemical data, as listed in Table 4.2, AMI patients at admission had high levels of  
 
Table 4.2 – Biochemical data and inflammatory markers in the two study groups. 
  AMI  
  
REF 
Day 0 Day 2 Day 40  
 Lipid profile      
 TC (mg/dl) 197±30 202±52 b 164±40 b 158±34 b  
 LDL-C (mg/dl) 128±35 134±46 b 97±25 b 97±28 b  
 HDL-C (mg/dl) 55±11 41±11 b 38±13 b 39±8 b  
 TG (mg/dl) 73±11 102±58 b 106±26 b 115±73 b  
 Blood cell count      
 Total WBCs (x103/µl) 5.2±0.7 12.0±4.3 a 8.4±2.9 a 6.4±1.7  
 Neutrophils (x103/µl) 2.8±0.6 9.4±3.9 a 5.7±3.0 a 3.8±1.0  
 Lymphocytes (x103/µl) 1.9±0.3 2.1±1.5 2.0±0.7 2.2±1.4  
 Monocytes (x103/µl) 0.36±0.14 0.58±0.38 0.70±0.18 a 0.47±0.20 a  
 Platelets (x103/µl) 222±72 225±58 193±70 215±54  
 Inflammatory markers      
 sP-selectin (ng/ml) 92±19 90±39 70±28 79±26  
 sICAM-1 (ng/ml) 221±38 245±36 282±69 332±147 a  
 TNF-α (pg/ml) 0.58±0.52 1.6±1.0 a 1.8±1.0 a 2.2±1.5 a  
 hsCRP (mg/dl) 0.39±0.19 0.62±0.47 4.3±3.9 a 0.48±0.29  
Others      
Glucose (mg/dl) 93±7 179±71 b 138±53 b 122±51 b  
Albumin (g/dl) 3.9±0.3 3.5±0.4 3.2±0.4 a 3.9±0.3  
Troponin T (ng/ml) <0.01 c 2.3±4.6 a 3.6±1.7 a 0.07±0.23 a  
NT-proBNP (pg/ml) 41±28 722±990 a 2058±1754 a 762±536 a  
Values are expressed as mean±sd; a p<0.05 vs REF group; b not compared (see text); c values 
below detection limit.
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total white blood cells (WBCs) and neutrophils. Monocyte counts, hsCRP, NT-proBNP and troponin T 
reached the highest values at day 2. Contrasting, platelet counts were decreased at the same time 
point. Lipid and glucose data obtained for the two studied groups could not be directly compared as 
fasting-blood tests were only performed for REF individuals. 
 
4.3.2. Serum concentrations of inflammatory markers 
The concentrations of sP-selectin, sICAM-1 and TNF-α in the two studied groups are presented in 
Table 4.2. At infarct onset sP-selectin and sICAM-1 concentrations did not differ from REF. 
Opposite, high TNF-α concentrations (p<0.05) were observed at day 0. Furthermore, significant 
changes of these markers relative to REF values at subsequent time points were verified for TNF-α 
from day 2 and for sICAM-1 at day 40 (see Table 4.2).  
In the overall an increasing trend of the measured concentrations of sICAM-1 and TNF-α through 
time was observed. To assess the significance of these changes through time a linear mixed effects 
model was applied to appropriately transformed variables. The results of those models for the three 
inflammatory markers variations over time are represented in Fig. 4.1.   
For sqrt(sP-selectin), a decrease in concentration levels was observed at day 2 relative to the 
infarct onset time point, followed by a slight increase at day 40 (Fig. 4.1A). Although these changes 
were not significant as far as univariate statistics are concerned, the variations over time proved to 
be significant (p=0.003) as well as the decline observed at day 2 (p<0.05).  
The association of sICAM-1 with time was not significant, but the increment at day 40 relative to 
day 0, was statistically relevant (p<0.05) (Fig. 4.1B). In addition, sqrt(TNF-α) levels of AMI patients  
 
Figure 4.1 – Results of linear mixed effects models evaluating changes of inflammatory markers (sqrt(sP-
selectin) – A; sICAM-1 – B; and sqrt(TNF-α) – C) over 40 days follow-up. For each inflammatory marker the 
estimated average values at each time point and the respective variances (95% confidence interval) are 
plotted. *p<0.05 vs AMI day 0. 
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showed a progressive and significant rise over time (p=0.001). The increments to day 2 and day 40 
were both significant (Fig. 4.1C). 
 
4.3.3. Medication influence 
To assess the influence of previous-event medication on inflammatory markers concentrations at 
the acute event, AMI patients that did not take medication before AMI were compared to the 
remaining patients that had prescribed medication (see Table A.5). Only sP-selectin concentrations 
were significantly affected by the previous-event drug intake (p=0.002). AMI patients without pre-
event medication had higher levels of this molecule (113±10 ng/ml) than those with prescribed 
aspirin, ACE-inhibitors, β-blockers or statins (67±8 ng/ml). 
To further evaluate the possible influence of drug therapy in serial changes of the inflammatory 
markers studied, pre-event, in-hospital and follow-up medication data were categorized according 
to type (aspirin, platelet inhibitors, ACE-inibitors, β-blockers and statins) and added to the linear 
mixed effects models as co-variables. None of the drugs administered to the patients before or after 
admission significantly influenced the sqrt(TNF-α) or sICAM-1 (see Table A.6). However, the sP-
selectin variations over time were significantly influenced by pre-event ACE-inhibitors (p<0.001) and 
β-blockers (p=0.019) intake. Patients that received β-blockers or ACE- inhibitors showed minor serial 
changes and low levels of sP-selectin (58±5 and 57±4 ng/ml for β-blockers and ACE-inibitors 
respectively) opposite to those that were not taking those drugs (87±5 and 96±5 ng/ml, 
respectively). 
 
4.3.4. Relationship between inflammatory and biochemical markers 
The variations of sqrt(sP-selectin) and sICAM-1 through time were significantly associated with TNF-
α serial changes (Table 4.3). When TNF-α was included in the model, an additional increment of 
+0.604 was obtained for each unit increase in sqrt(sPselectin) (p=0.002) while an increment of +33.1 
for sICAM-1 (p=0.026).  
When relating biochemical data to the above models of inflammatory markers through time, 
sqrt(sP-selectin) was found to be associated with the number of total WBC’s and troponin T 
concentration, and sICAM-1 with the number of lymphocytes, monocytes and platelets (see Table 
4.3). 
 
4.3.5. Relationship between inflammatory markers and coronary disease severity and 
extension 
No interactions were verified between the sqrt(TNF-α) and sICAM-1 time-variations and the markers 
associated to coronary disease severity and extension, such as multi-vessel disease, culprit vessel  
 
Inflammatory responsiveness 35 
 
Table 4.3 – Linear mixed effects models estimates of co-variables influence, inflammatory and biochemical 
markers, demographic and clinical characteristics (increment, + signal; or decline, - signal), on the average 
changes of sqrt(sP-selectin), sICAM-1 and sqrt(TNF-α) over time. For example, in the sqrt(sP-selectin) model 
with co-variable WBCs, an increment of +0.135 was obtained for each unit increase in sqrt(sP-selectin). 
  Inflammatory Markers 
  Sqrt(sP-selectin) sICAM-1 Sqrt(TNF-α)   
 CO-VARIBLES     
 Biochemical characteristics     
 Total WBCs (x103/µl) + 0.135 a - 1.93 + 0.001  
 Neutrophils (x103/µl) + 0.114 - 4.08 - 0.002  
 Lymphocytes (x103/µl) + 0.032 + 58.9 a + 0.007  
 Monocytes (x103/µl)  + 0.717 + 215 a + 0.285  
 Platelets (x103/µl) + 0.004 + 1.15 a + 0.000  
 hsCRP (mg/dl) - 0.007 + 5.85 + 0.006  
 Troponin T (ng/ml) + 0.169 a + 1.91 + 0.000  
 NT-proBNP (pg/ml)  + 0.000 + 0.004 + 0.000  
 Democraphic and clinical characteristics     
 Age (y) - 0.053 a - 3.30 - 0.003  
 Multi-vessel disease + 1.56 a + 71.3 + 0.232  
 RCA Culprit vessel - 1.32 - 38.9 - 0.045  
 LCX Culprit vessel - 0.130 - 32.2 - 0.002  
 Stent type* + 0.385 - 52.8 - 0.188  
a significant (p<0.05) additive associations of each inflammatory marker to co-variables;  
* stent type correspond to drug-eluting stents in comparison to bare-metal stents. 
 
and TIMI flow (Table 4.3). However, the longitudinal variations of sqrt(sP-selectin) showed a 
positive association with disease extension, as given by the number of diseased vessels (p=0.031). In 
fact, AMI patients with multi-vessel disease had higher sP-selectin levels (89±6 ng/ml) than single-
vessel (75±4 ng/ml) patients. Serum sqrt(sPselectin) longitudinal variations were also negatively 
associated to age (Table 4.3). 
 
4. 4. DISCUSSION 
In the present study, longitudinal evaluation of AMI patients, 2 days after PTCA intervention and 40 
days later, showed different patterns for the variation of the measured inflammatory markers. An 
increasing trend over time in circulating levels of both sICAM-1 and TNF-α was verified. Soluble sP-
selectin levels were decreased at day 2, and 40 days after the acute event return to levels observed 
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in the healthy subjects. Medication did not prove to influence serial changes, except for sP-selectin. 
When relating biochemical data to the above models of inflammatory markers through time, sP-
selectin was found to be associated with the troponin T and WBCs, and sICAM-1 with lymphocytes, 
monocytes and platelets. Both adhesion molecules were significantly associated with TNF-α. 
Furthermore, the longitudinal variations of sP-selectin showed a positive association to number of 
diseased vessels and a negative one to age. 
After plaque disprution that leads to thrombosis, sP-selectin levels may be influenced by an 
intricate network of processes involving inflammatory stimulus of injured myocardium. The 
observed associations of troponin T and of WBCs counts with the serial changes of sP-selectin are 
indicative of the importance of this adhesion molecule linking the thrombotic and inflammatory 
responses of myocardium.(90) In fact, sP-selectin orchestrate the sequential events associated to 
ischemia/reperfusion myocardial injury(104-105) by exerting a mediator role in the interaction of 
leukocytes and platelets with ECs.(21,106) Furthermore, several studies proposed that after 
myocardial ischemia/reperfusion increases in sP-selectin could reflect activation of both ECs and 
platelets,(106) and could reveal ongoing vascular injury.(108) Therefore, increased levels of sP-selectin 
in AMI patients with multi-vessel disease may reflect CAD extension, as reported previously.(90)
The serial changes of sP-selectin shortly after MI clearly evidenced the fall of activated platelets 
in consequence of massive anti-aggregation and anti-thrombotic therapeutic measures during PTCA. 
Shimomura et al.(107) reported sP-selectin changes in AMI patients at admission and after reperfusion 
therapy similar to those presented in this study. Currently used therapies, such as ACE-inhibitors 
and β-blockers effectively counteract heightened platelet activation and aggregability(108) resulting 
in decreased circulating levels of P-selectin(109-110) as observed in this work.  
Furthermore, similar sP-selectin values between CAD patients and healthy subjects as verified in 
the present study have been also reported,(111-113) and Barbaux et al.(111) called the attention for a 
complex relation between P-selectin and CAD dependent on age. This may explain the negative 
association between sP-selectin levels and age in AMI patients and the surprisingly higher levels of 
sP-selectin found in REF subjects that were younger than AMI patients, 40% of which had more that 
65 years old. 
After ischemia/reperfusion injury, the leukocyte sequestration, including macrophages, take 
place and the release of cytokines, including TNF-α, may occur. Injured myocardium,(114) several 
extra-cardiac tissues and immune system activation,(104) proved contributing to circulating TNF-α 
levels. Increasing levels of this pro-inflammatory cytokine after infarct, as measured in AMI 
patients, has been reported previously.(108,112-113) This result suggest a continuous systemic 
inflammatory stimulation, that can trigger and/or amplify local inflammatory responses related to 
ischemia/reperfusion injury,(112) although a cytoprotective role for TNF-α have also been 
suggested.(112,115) 
The reported influence of TNF-α in the upregulation of adhesion molecules is evidenced by its 
positive association with sP-selectin and sICAM-1 serial changes. Continuous sICAM-1 increases in 
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circulation after AMI as observed in the present study to day 40, and described in literature for the 
first month after the acute event,(99,102,105) plausibly reflect ICAM-1 expression at the endothelial 
surface.(99) Consequently, sustaining the inflammatory response and favouring the adhesion of 
inflammatory cells at the injured site after infarct(99,105) as suggested by the sICAM-1 and monocytes 
increase over time, and evidenced by the association of sICAM-1 with number of lymphocytes, 
monocytes and platelets.  
Thus, temporal and sequential association of events orchestrated by both inflammatory cells, e.g. 
WBCs and platelets, and inflammatory markers, such as TNF-α, sICAM-1, and sP-selectin, seem to be 
crucial in the initiation of inflammatory responses after ischemia/reperfusion injury.  
In conclusion, reported results highlight the importance of the inflammatory response that 
remains after clinical stabilization as given by the interplay of TNF-α, sICAM-1 and sP-selectin. The 
observed serial changes reflected atherothrombosis and remodelling mechanisms that support the 
concept of a differential response of inflammatory markers in the AMI. 
Most of the current knowledge on cellular adhesion molecules and inflammatory mediators 
emerged from in vitro and experimental models. Though, there are increased evidences of 
deviating results of in vivo conditions in humans.(116) Such divergences require detailed investigation 
to firmly establish the role and the interplay of these mediators in humans. Only the simultaneous 
assessment of several markers, as innovatively done in the present study, can give a valuable 
contribution to the understanding of their importance in the acute myocardial infarction evolution.  
 
  
5 CD40L SERIAL CHANGES – RELATIONSHIP TO  
ENDOTHELIAL DYSFUNCTION AND THROMBOSIS 
 
 
5. 1. INTRODUCTION 
As described in Chapter 1, progressive development of the atherosclerotic plaque and the local 
vascular events that encircle an ACS implicate pro-inflammatory mediators, chemokines and pro-
thrombotic TF, which are expressed and released by leukocytes, platelets, macrophages, ECs and 
SMCs.(38,117-118) One molecule that could link all these cell types is CD40L, which has been gaining 
much attention for its role on immune system, inflammation and thrombosis.(38)
Recent data demonstrated that CD40L exert several roles in atherothrombosis other than simply 
supporting cell adhesion. Henn et al.(37) proposed that in vivo, once platelets were strongly 
activated in the vascular system, CD40L would be rapidly expressed, and available to interact with 
CD40 on the neighbouring ECs and monocytes trapped in the thrombus. In ECs, the CD40-induced 
CD40L expression further recruit and activate circulating monocytes,(119) triggering an inflammatory 
response.(37) Furthermore, CD40L could also have a direct participation in the thrombotic process, 
either in thrombus stabilization(120) or in its formation at the infarct-related artery.(121) Several 
studies showed high affinity of sCD40L and CD40L for CD40 when TNF-α receptors and integrins are 
expressed.(115,120) sCD40L is also a ligand of GP IIb/IIIa, and its release from activated platelets can 
be blocked by GP IIb/IIIa antagonists,(122-123) suggesting a control of sCD40L release by interrupting 
platelet CD40L/GP IIb/IIIa axis. sCD40L can induce the formation of platelet-platelet (CD40-
CD40L/CD40L-GP IIb/IIIa), platelet-leukocyte (CD40-CD40L/P-selectin-PSGL) and platelet-
endothelial (CD40L-CD40) conjugates, and therefore a role in coordination interaction between the 
cell types could be proposed to CD40L.(124)
Several studies highlight the extreme complexity of the CD40L shedding and release mechanisms. 
It was demonstrated that CD40L (33 kDa) was expressed within minutes on cell surface after 
stimulation, and the soluble form (truncated, 18 kDa) could be released through generation in an 
intracellular compartment in T lymphocytes(125) or by proteolytic cleavage of membrane-form in 
platelets.(37) The release of sCD40L from platelets is activation-dependent but does not follow the 
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regular α-granule secretion pattern by which substances, such as P-selectin, are fully released 
within 5 to 10 minutes.(122,125) CD40L release is much slower.(122)
In general, it is assumed that the CD40L solubilization represents a mean of down-regulation of 
the surface-exposed CD40L of biological importance. The regulation of CD40L in the immune system 
is thought to be required because prolonged exposure to a biologically effective form of CD40L may 
lead to a massive inflammation. Thus, some authors assume that the interaction of CD40L on 
activated platelets with co-expressed CD40 on ECs enhance inflammation of the endothelium near a 
thrombus.(37,125) Nevertheless, many of the in vivo mechanisms of the solubilization process, the 
ultimate source of sCD40L in the blood, and whether the soluble form of CD40L is capable of 
inducing an inflammatory reaction acting as a cytokine or is inactivated upon cleavage are still open 
questions.(126)  
Clinical data relating circulating levels of CD40L to coronary disease and MI are limited and 
primarily derived from randomized clinical trials, cross-sectional or retrospective studies.(127-132) 
Increased CD40L levels were used to identify patients with unstable coronary artery disease at risk 
for ACS, independently of other predictive variables.(129,133) Yet, no association of CD40L with 
subclinical atherosclerosis or atherosclerotic risk factors could be found.(134)
Although a great pool of information concerning CD40L (membrane-bound and soluble forms) have 
been so far collected in different cardiovascular conditions, the onset of MI and its evolution is not 
well depicted. Thus, the initial objective of this study was to investigate the variations of CD40L in 
the AMI and during recovery, by following patients at the onset of the thrombotic event previous to 
intervention, shortly after PTCA, and monitoring alterations along the recovery period. The CD40L 
was assessed in the soluble and membrane-bound form on platelets and T cells. The study was also 
designed to investigate the relation between the serial changes in CD40L levels and markers of 
platelet activation (P-selectin and platelet microparticles) and endothelial dysfunction (nitric oxide 
and endothelial microparticles). However, the results revealed surprisingly different patterns of 
sCD40L variations through time, allowing the identification of two sub-groups of patients, and a 
possible explanation for that differentiation in terms of drug intake and clinical conditions was 
sought. 
 
5. 2. MATERIALS AND METHODS 
5.2.1. Study groups and follow-up evaluation 
The subjects recruited at the Cardiology Service in Santa Marta Hospital (Lisbon) were divided in 
two groups, as referred previously (see Section 2.2): the AMI group with 50 ST-elevation myocardial 
infarction patients; and the reference group (REF) with 25 healthy non-smokers volunteers. 
A longitudinal evaluation of all patients in AMI group was carried out by measuring blood markers 
at three time points: at admission (day 0), before administration of IIb/IIIa inhibitor and PTCA; 2 
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days; and 40 days after the initial PTCA. Patients were additionally followed up for 10±3 months for 
death or further thrombo-embolic events. 
 
5.2.2. Blood sampling and laboratory assays 
Blood samples for soluble markers were drawn into pyrogen-free blood collection tubes without 
additives and immediately centrifuged (2500 rpm for 10 minutes). The serum was collected 
afterwards and placed on ice, and temperature controlled to 4ºC during subsequent processing.(135) 
Aliquots were stored at -80ºC until analysis (no longer than 6 months). The flow cytometry analysis 
of lymphocytes, platelet and microparticles was performed in all the healthy volunteers and in 28 
AMI patients. For those assays the blood was collected into EDTA and sodium-citrated tubes, 
respectively. Minimal tourniquet pressure was applied to avoid artefact platelet activation. 
 
Serum assays: determination of sCD40L and NO 
Concentrations of sCD40L were measured by ELISA commercial kit (R&D Systems, USA). NO 
concentrations were determined using a colorimetric commercial kit (R&D Systems, USA) which 
detect nitrite as a product of the Griess reaction. Each sample was measured in duplicate; the 
intra-assay variation among the duplicates for all samples was <10%. The concentrations of sCD40L 
and NO were expressed in ng/ml and in µmol/l, respectively.  
 
Platelet activation evaluation 
Platelet activation was assessed by flow cytometry in whole blood samples within 3 hours after 
sampling as described previously.(136) Briefly, 50 µl aliquots of whole blood were diluted 1:10 in 
modified Tyrode’s buffer (137 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 12 mM NaHCO3, 0.4 mM Na2HPO4, 
0.35% BSA, 10 mM HEPES, 5.5 mM glucose, pH 7.4) and was incubated at room temperature in the 
dark for 15 min with fluorochrome-labeled antibodies (BD, USA). Thrombin (Sigma, USA) 0.5 U/ml 
was used as platelet agonist. To assess platelet activation the expression of the adhesion molecule 
P-selectin and CD40L were labelled with APC-CD62P and PE-CD154, respectively. After incubation, 
modified Tyrode’s buffer (1 ml) was added and samples were promptly analysed by flow cytometry. 
Platelets were identified on the basis of size and of FITC-CD42a binding (see Fig. A.2). 
 
CD40L expression on T lmphocytes 
A direct immunofluorescence staining of whole blood using a lyse/wash procedure was performed to 
analyze lymphocytes sub-populations, as described in Section 3.2.3. Additionally, the expression of 
CD40L was assessed in the selected T lymphocytes populations using PE-CD154 (see Fig. A.3).  
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Microparticles assay 
Whole blood samples were centrifuged for 10 minutes at 200 g to prepare platelet-rich plasma, 
which was subsequently centrifuged at 1500 g for 7 minutes to obtain platelet-poor plasma. MPs 
were assayed within 3 hours after blood collection. For the MPs assay we have adjusted the method 
previously described by Bernal-Mizrachi et al.(137). In brief, 50 µl of platelet-poor plasma was 
incubated with 5 µl of fluorochrome-labeled antibodies (BD, USA) for 20 min with gentle (100 rpm) 
orbital shaking. Next, 1 ml of PBS buffer was added and the samples were assessed by flow 
cytometry. The CD42b-PE-Cy5 and CD31-FITC antibodies were used for MPs identification. As CD31 is 
expressed on platelets microparticles (PMPs) and on endothelial microparticles (EMPs) but CD42b 
occurs only on platelets, EMPs will be defined by CD31+/CD42- events.(138) PE-CD154 was used to 
assess the percentage of microparticles expressing CD40L. Furthermore, to assess expression of the 
adhesion molecule E-selectin in EMPs, MPs were labelled with APC-CD62E. MPs were identified on 
the basis of size using platelets size as an internal individual standard (see Fig. A.4). 
 
Flow cytometry analysis 
Flow cytometry was performed on a FACSCanto (BD, USA) and data processed with FlowJo 7.2.4 
software package. All samples were analysed using the same voltage setting. For platelet flow 
cytometry analysis, a threshold was defined for PE fluorescence, and other for APC, below which 
95% of all platelet events from unstained samples stained with PE-CD40L and APC-CD62P (see Fig 
A.2C and D). A similar threshold was also defined for PE fluorescence in lymphocyte populations 
(see Fig A.3). The expression of CD40L and CD62P were expressed in fluorescence arbitrary units 
(FAU). Other thresholds were defined for FITC, PE-Cy5, PE and APC fluorescence’s, below which 90% 
of all microparticle events from unstained samples stained with FITC-CD31, PE-Cy5-CD42b, PE-
CD40L and APC-CD62E, respectively (see Fig A.4B, C and D). Microparticle data was expressed in 
percentage of positive events.  
 
5.2.3. Statistical analysis 
Data was summarized as mean and standard deviation (sd) for continuous variables and as 
proportions for categorical variables. Non-continuous variables were analyzed using a 2x2 table and 
Fisher’s exact test. Differences between groups in each time point were tested with Bonferroni 
correction. Associations between variables were determined by Spearman’s rank correlation. 
The identification of subgroups of patients, based on sCD40L levels at day 40, was done using a 
hierarchical agglomerative cluster analysis. This is an exploratory statistical technique that places 
individuals into groups or clusters not defined a priori. The average linkage within groups method 
was used to calculate similarity between individuals. In this method, the distance between two 
clusters is defined as the distances between all possible pairs of cases in the resulting cluster. The 
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output of the cluster analysis is a dendogram (tree diagram), which illustrates the grouping: longer 
horizontal dendogram arms represent greater dissimilarities in sCD40L levels at day 40. 
The circulating markers were studied by modelling them as a response variable over time. A linear 
mixed effects model with random intercept and slope was fitted to the longitudinal variations of 
each patient’s biomarkers levels. A logarithm transformation was applied to sCD40L and NO data, 
and a square root transformation to PMPs. In addition, we were also interested in verify the possible 
association of medication and biochemical parameters on serial changes of CD40L, therefore, the 
models were also tested with those parameters and ongoing therapy as co-variables.  
Values of p<0.05 were considered statistical significant. The calculations were performed using 
SPSS (version 10.0) and R (version 2.7.0) software. 
 
5.3. RESULTS 
5.3.1. Population characterization 
The demographic characteristics, baseline clinical features and biochemical data of the study 
groups are summarized in Tables 2.1 and 2.2 (see Section 2.3.1). 
 
Table 5.1 – Soluble and expressed CD40L, markers of endothelial and platelet activation in the 
two study groups. 
  AMI  
  
REF 
Day 0 Day 2 Day 40  
 Inflammatory marker      
 sCD40L (ng/ml) 3.1±2.8 1.9±1.6 0.9±0.6 a 2.1±1.7  
 Platelet activation markers      
 Platelet CD40L (FAU) 115±18 117±24 121±21 137±31 a  
 CD62P (FAU) 296±184 322±233 340±257 334±147  
 Lymphocytes       
 CD4+ T cells CD40L (FAU) 4441±2442 4555±1669 4731±2252 5126±2500  
 CD8+ T cells CD40L (FAU) 4366±3308 4412±3454 4733±2777 5482±3362  
Micoparticles      
PMPs (%) 24±18 23±11 21±13 28±17  
EMPs (%) 16±5 20±6 18±7 20±8  
CD40L+ MPs (%) 21±5 24±11 24±14 28±13  
CD62E+ EMPs (%) 36±9 40±12 40±14 41±15  
Endothelial damage marker      
NO (µmol/l) 81±28 82±40 77±37 92±36  
Data are expressed as mean±sd; a p<0.05 vs REF group. 
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5.3.2. Serum levels of CD40L 
In general, serum sCD40L concentration values were lower in AMI patients than in healthy subjects, 
being the difference statistically significant at day 2 (Table 5.1).  
In AMI patients the variation of sCD40L over time, estimated by a linear mixed effect model for 
log(sCD40L), was significant (p=0.009). The decrease in log(sCD40L) values from day 0 to day 2 was 
significant (Fig. 5.1A). Therefore, the sCD40L values decrease after PTCA (day 2) and increased with 
patients’ stabilization, reaching values similar to REF group and to day 0. Surprisingly, the average 
increase at day 40 was not verified for all AMI patients (Fig. 5.2). 
 
Patients’ differentiation based on sCD40L levels at day 40 
In AMI patients, the sCD40L results seem to point out to different patterns of variation over time. 
Some individuals had an unambiguous increase of sCD40L at day 40, contrasting to others that had 
minor variations through time (Fig. 5.2). To identify and establish groups of individuals based on 
similarities for sCD40L at day 40 a hierarchical cluster analysis was performed.  
Clear separation of cases into three distinct groups having considerable linkage distances was 
evident when clustering analysis was performed for sCD40L levels measured at day 40 (see Fig. A.5). 
One cluster, designated as cluster A, associated a group of 18 patients having, at day 40, minimum 
sCD40L levels of 0.4 ng/ml and maximum of 1.2 ng/ml. The second cluster, cluster B, combined 12  
 
Figure 5.1 – Results of linear mixed effects model evaluating changes of CD40L (log(sCD40L) over 40 days 
follow-up – A; platelet CD40L – B; CD4+ CD40L – C; CD8+ CD40L – D). The estimated average values at each time 
point and the respective variances (95% confidence interval) are plotted.  *p<0.05 vs AMI day 0. 
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Figure 5.2 – Longitudinal variations of serum sCD40L levels in the AMI patients at the onset of MI (day 0), two 
(day 2) and 40 days (day 40) after the infarction.  
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patients with minimum sCD40L levels at day 40 of 1.9 ng/ml and 4.1 ng/ml as maximum levels. The 
most distant cluster, cluster C, had far less patients (only 6) and sCD40L concentrations measured at 
day 40 ranging from 4.8 ng/ml to 9.3 ng/ml.  
Regarding sCD40L time-variations in the three clusters, AMI patients in clusters B and C showed an 
increase trend at day 40, unlike patients of cluster A (Fig. 5.2). To evaluate possible differences a 
linear mixed effect model was applied. The results (see Fig. A.6) reveal a significant association of 
log(sCD40L) serial changes and clusters (p<0.0001), evidencing different variation patterns in the 3 
groups of AMI patients. The estimate log(sCD40L) at day 40 for cluster C was significantly higher 
(p=0.0001) than for cluster A, but it did not differ from cluster B (p=0.8676). 
Therefore, the low sCD40L concentrations over time observed in patients of cluster A, greatly 
differ from sCD40L levels in patients of clusters B and C. Furthermore, comparing cluster B and C, 
no other differences were found in biochemical parameters (see Tables A.7 and A.8) nor in clinical 
characteristics (see Table A.9). Thus, there was no differentiation between patients in clusters B 
and C in terms of any other biochemical marker (except sCD40L) and they both had similar 
increased sCD40L time-variation patterns, though the increment of sCD40L in cluster C was more 
pronounced than in cluster B. Considering this, one could assume to merge both clustered patients 
into a joined cluster BC, which improves the statistical power of the analyses by increasing the 
number of patients (18 patients) in the group. The mean levels of sCD40L measured at day 40 in 
patients joined in cluster BC is now of 3.9±1.8 ng/m (see Table A.10), with minimum concentration 
of 1.92 ng/ml and maximum of 9.3 ng/ml. 
A new linear mixed effect model was again performed to evaluate log(sCD40L) longitudinal 
variations considering two groups (cluster A and cluster BC). The results confirmed that this 
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Figure 5.3 – Results of linear mixed effects model evaluating time changes of log(sCD40L) in the two cluster 
groups (Cluster group A – circles; Cluster BC – triangles) defined for sCD40L concentrations measured at day 40. 
The estimated average values at each time point and the respective variances (95% confidence interval) are 
plotted; *p<0.05 vs Cluster group A in each time point. 
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association was statistically significant (p<0.0001; Fig. 5.3). As a direct result of rising patients’ 
number in the new cluster BC, the variability explained by the linear mixed effect model was 
higher, reinforcing the decision of merge clusters B and C. Therefore, from here forward, two 
clusters (A and BC) will be considered for AMI patients’ differentiation based on the sCD40L levels 
measured at day 40. 
 
Biochemical parameters in AMI clusters 
Comparing biochemical data between patients in both clusters there were no significant variations 
for the majority of the parameters studied including the CD40L expression both on platelets and on 
T cells (see section 5.3.3. and Tables A.10 and A.11). The only exception observed was in the 
concentrations of NT-proBNP. The levels of NT-proBNP clearly differed in the two clusters (see 
Table A.11). It is noteworthy that AMI patients in cluster BC had lower levels of NT-proBNP at days 2 
and 40, opposite to patients in cluster A. The different shift of the longitudinal pattern between 
this two clusters was also analysed by a linear mixed effect model which result in a statistical 
significant effect (+6.44, p=0.003).  
 
Drug intake in AMI clusters 
Standard management and optimization of drug therapy for ACS at the Cardiology Service in Santa 
Marta Hospital includes ACE-inhibitors, β-blockers, statins and anti-platelet therapy. These agents 
may influence the serum levels of sCD40L, although 54% patients were already taking such 
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medications at admission without detectable differences (see Table A.13). All the same, a 
comparison of the previous-event, in-hospital and follow-up medication for patients in cluster A 
with patients in cluster BC was performed (see Table A.14). AMI patients in the two clusters had 
similar prescriptions and those drugs were administered to approximately the same number of 
patients (see Table A.14). Additionally, modelling log(sCD40L) longitudinal variations in the two 
clusters A and BC with the medication intake, did not prove significant associations (see Table 
A.15). Therefore, the hypothesis of an influence of medication on the patients’ differentiation could 
be excluded. 
 
Clinical characteristics and follow-up evaluation in AMI patients’ clusters 
Patients grouped in clusters A and BC, were also compared in terms of clinical data, risk factors and 
co-morbidity. Neither sex, age, hypertension, smoking habits, diabetes, ejection fraction, BMI nor 
abdominal obesity differed in the two clusters (Table A.15), nor influenced sCD40L variations 
through time (Table A.14). 
During the 10 months follow-up, four patients died (thee before the last time point – day 40) and 
eight experienced a thrombo-embolic event. The only patient that died after day 40 was classified 
in the cluster A. Both clusters had similar number of patients with further thrombo-embolic event.  
 
5.3.3. Expression of CD40L on platelets and T lymphocytes 
At admission, platelet CD40L expression of AMI patients was similar to that of healthy volunteers 
(Table 5.1). However, through the linear mixed effect model applied, was verified that CD40L 
expression significantly increase over time (Fig. 5.1B). Platelet CD40L expression did not vary until 2 
days after PTCA but increased during recovery (day 40) relative to day 0 (Fig. 5.1B) and to REF 
group (Table 5.1).  
The variation trend of the CD40L expression on CD4+ and on CD8+ T lymphocytes was similar to the 
expression on platelets (Table 5.1). But the CD40L expression variations over time were not 
significant for both CD4+ (Fig. 5.1C) and CD8+ T cells (Fig. 5.1D) 
In addition, the serial changes of sCD40L did not associate with the expression of bound-CD40L on 
platelets (p=0.684), on CD4+ (p=0.081) or on CD8+ T cells (p=0.122). 
 
5.3.4. Platelet activation and endothelial dysfunction 
Platelet activation was assessed through P-selectin expression and microparticle production (PMPs). 
The percentage of MPs expressing CD40L was also determined. Endothelial dysfunction was inferred 
by measuring NO concentrations in serum, the percentage of EMPs and those formed by activation 
expressing E-selectin (CD62E+ EMPs). 
The expression of P-selectin (CD62P) on platelets was assessed in basal and stimulated conditions. 
No significant variations in the expression of this marker were observed in AMI patients over time 
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(F=0.21, p=0.815) or when compared to REF group (Table 5.1). However, platelet surface CD62P was 
significantly augmented by thrombin incubation, both in AMI patients and healthy volunteers, 
contrasting to CD40L, which expression did not change with agonist activation (see Fig. A.7) 
The serum concentrations of NO in AMI patients were not significantly different from healthy 
subjects values (Table 5.1). Although, in AMI group, log(NO) changes over time assessed by linear 
mixed effects model were marginally significant (p=0.057; see Fig. A.8). 
Concerning microparticles the major contribution for total MPs in each group studied was from 
platelets (Table 5.1). No differences were found in PMPs and EMPs percentage between AMI patients 
(in any time point) and healthy subjects as can be inferred in Table 5.1. Furthermore, the results of 
the linear mixed effects models showed no changes over time in PMPs (F=2.2, p=0.115), EMPs 
(F=1.06, p=0.354), CD40L+ MPs (F=0.83, p=0.444) or CD62E+ EMPs (F=0.67, p=0.518).  
 
5.3.5. Relationship of CD40L to platelet activation and to endothelium dysfunction 
In AMI patients, no associations were found between the serial changes of CD40L in its soluble or 
membrane-bound forms on platelets and T-cells, and the expression of the platelet activation 
marker CD62P or the percentage of PMPs. However, in the REF group the values of sCD40L were 
negatively correlated with basal expression of CD62P (r=-0.78, p<0.001). 
Although no significant association was verified between the longitudinal variations of sCD40L and 
CD40L+ MPs (p=0.599), the microparticle-bound form of CD40L was associated with CD40L expression 
on platelets (+0.002, p=0.002), on CD4+ (+18.82, p=0.005) and on CD8+ (+71.66, p=0.002) T-cells. 
Additionally, noteworthy associations, also evaluated through linear mixed effect model, were 
obtained for AMI patients between CD40L serial changes and endothelial activation markers. 
Positive associations were verified between the percentage of EMPs and the CD40L expression on 
platelets (+1.18, p=0.002), on CD4+ (+94.1, p=0.008) and on CD8+ T lymphocytes (+109, p=0.006). 
Additionally, the CD62E+ EMPs were also associated to time-variations of CD40L expression on 
platelets (+0.054, p<0.001), on CD4+ (+2.61, p=0.002) and on CD8+ (+3.81, p=0.010). These 
associations were not verified in the REF group, as far as correlation analyses are concerned.  
CD40L was also related to the endothelial damage marker NO. Significant associations were 
observed between NO serum levels and CD40L expression on CD4+ T cells (+0.809, p=0.013) and on 
CD8+ T cells (-15.2, p=0.012), and also to log(sCD40L) (-0.006, p=0.004). 
 
5.4. DISCUSSION 
The present study had demonstrated that patients at the MI onset before therapeutic intervention 
had no significant differences in CD40L levels when compared to healthy subjects. This was verified 
for both the soluble and the membrane-bound forms. Longitudinal evaluation of AMI patients 
showed that sCD40L levels decrease two days after PTCA and on average increase 40 days later. The 
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same increasing trend at day 40 was verified for CD40L expression on platelets. In AMI patients, no 
associations between CD40L and platelet activation (CD62P expression and PMPs) were verified. 
However, CD40L serial changes were related to endothelial damage/activation markers (NO and 
EMPs). Furthermore, two groups of patients were identified: one characterized by a remarkably 
increase in sCD40L concentrations at day 40 with levels tending to those of healthy subjects; and a 
second group of patients with low sCD40L levels at day 40 that showed minor variations with time. 
These two groups of patients also differed in NT-proBNP concentrations changes over time. 
The stratification of patients based on sCD40L levels was previously proposed in patients with 
ACS(131,133,139) and had been associated to high risk of cardiac events.(129,133,140) However, none of the 
studies had assessed only patients with ST-elevation myocardial infarction, or the variations of 
sCD40L over time, as in the current work. Besides, the existence of cardiac events had been 
evaluated after a prolonged follow-up. More recent studies not only fail to demonstrate an 
association of high level of sCD40L with increased risk of cardiovascular events,(134,141-143) but 
indicate an inverse relation of sCD40L levels with risk of recurrent ischemia.(143) 
This is the first study reporting different variation patterns of sCD40L over time in AMI patients. 
The drug-intake adds no explanation to the differentiation of patients, neither difference in clinical 
characteristics seems to exist. But, AMI patients with low sCD40L levels at day 40 had the highest 
NT-proBNP levels at day 2 and day 40, opposite to patients in the high-level sCD40L group. Since 
high levels of NT-proBNP are associated with adverse outcomes(143-148) and reflect the size or 
severity of the ischemic insult, even in the absence of myocardial necrosis,(143-145) the inverse 
association between sCD40L and NT-proBNP circulating levels in MI evolution suggests that increases 
in sCD40L levels, approximating those of healthy subjects, may reflect patient’s stabilization. 
Therefore, despite sCD40L variability at day 0 could not be used to predict bifurcation at days 2 and 
40, the observed divergence can be associated with the degree of disease severity as far as NT-
proBNP variations are concerned. 
The lack of significant variation of sCD40L concentrations between patients at the AMI onset and 
healthy volunteers could actually reflect that the eventually enhanced sCD40L levels in AMI being 
prominently used or retained by circulating cells and ECs to maintain platelet aggregates in 
thrombus. After PTCA, decreased sCD40L levels were consistent with the fall of platelet activation 
due to massive anti-platelet therapy, specially GP IIb/IIIa inhibitors,(122-123,132,149) administered during 
intervention. As the magnitude of cell activation and thrombosis is becoming controlled, sCD40L 
may be released from cell aggregates resulting in increased serum levels and in increased 
expression of CD40L on platelets. Moreover, increases of CD40L expression on thrombin-stimulated 
platelets was not observed contrasting with the boost in P-selectin (CD62P) expression, calling the 
attention for a different mechanism involved in CD40L regulation in platelets. Therefore, the similar 
sCD40L at infarct onset relative to healthy subjects, the steady levels of sCD40L and CD40L 
expression on platelets and T-cells during the first 2 days after infarction, suggest that CD40L is 
continually being used by several cell types.  
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Lack of differences in CD40L, soluble and membrane bound, had previously been described in 
cardiovascular conditions.(150-151)  
It can be assume that the action of platelets is temporary and restricted to plaque rupture and 
thrombotic events. Platelet CD40L may act immediately on neighbouring cells thus, having short 
half-life. That may be the reason for the lack of significant variation of CD40L expression on 
platelets at infarct onset, and the explanation for the higher CD40L expression on T cells than on 
platelets. These findings raise the question of which may be the major source of circulating sCD40L 
and if there will be a specific role of each cell type expressing CD40L at determined time points in 
the infarct evolution. 
Activated platelets have been considered the major contributors to the pool of sCD40L which may 
be released by proteolytic cleavage of membrane-form following a relatively slow process lasting 
approximately 45 minutes.(37,122,125) In T lymphocytes both full-length and truncated forms are 
present positioning these cells as a possible major source of sCD40L in the blood.(152) However, 
results obtained could not prove significant association between sCD40L and CD40L expression on 
platelets, CD4+ and CD8+ T lymphocytes. In theory, sCD40L could be considered as a pool of free 
soluble and microparticle-bound (mpCD40L) forms, but, the inexistence of an association between 
sCD40L and microparticles ruled out this possible interpretation, as formerly verified by Otterdal et 
al.(125). Other study suggested that a variety of cells might be the source of sCD40L,(153) hence 
explaining the lack of association of sCD40L with a specific cell type. 
In healthy subjects, P-selectin expression in stimulated platelets associate with sCD40L, what 
could not be verified in AMI patients, suggesting that in AMI, sCD40L might be in use and that the 
axis CD40L/CD40 may also be interrupted.  
In the present study no association of sCD40L with membrane-bound CD40L was found. But MPs 
expressing CD40L associated with CD40L expression levels on platelets and T cells. Also MPs 
following endothelial activation and expressing E-selectin associated with CD40L expression on 
platelets and on T lymphocytes. These results suggest that the membrane-bound CD40L, but not the 
sCD40L, could be involved in or enhance the inflammatory process, such as cell adhesion molecule 
expression (e.g. E-selectin) on ECs by interaction with CD40 expressed on circulating cells and 
ECs.(37,150,154-156) Furthermore, there are evidences that CD40L-expressing T cells can participate in 
tissue remodelling by enhancing endothelial secretion of MMPs(154,157) and by interacting with CD40 
on macrophages infiltrated in lesions, and therefore assisting the secretion of inflammatory 
cytokines and chemokines.(155)  
Interestingly the associations of CD40L (soluble and T-lymphocyte-bound) to NO circulating levels 
in AMI reinforce the hypothesis of the involvement of membrane-bound CD40L in endothelial 
inflammation. 
Under endothelial dysfunction condition that may compromise regular production of NO, its levels 
may be maintained in blood by inducible form of nitric oxide synthase expressed in circulating cells 
and platelets.(158-159) NO can inhibit platelet aggregation(160) by suppressing the expression of P-
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selectin, and inducing conformational change in GP IIb/IIIa, which is involved in fibrinogen(161) and 
sCD40L binding.(120) Several studies also reported that CD40L/CD40 interactions on ECs, on T 
lymphocytes(162) and on platelets(163) could be critical for the NO production. The steady levels of NO 
observed in AMI patients comparable to healthy volunteers may then reflect a compensatory 
mechanism related to inducible nitric oxide synthase in order to maintain the control over 
endothelial inflammation and cell-cell interaction through CD40L. 
The reported results highlight the complex interactions of CD40L in thrombosis, inflammation and 
endothelial damage/dysfunction. At AMI onset, the great magnitude of the thrombotic process 
associated to plaque disruption, conceal possible CD40L variations since this molecule is used by 
different cell types involved in those processes. As patients’ stabilize and the thrombosis is being 
controlled, the CD40L is no longer retained in the multiple cell interactions, and the CD40L-
mediated inflammation in endothelium may become a major route of its action.  
It is also important to highlight that none of the association between CD40L and endothelial 
dysfunction and activation (NO and EMPs) were verified for the REF group, suggesting an enhanced 
systemic pro-thrombotic and inflammatory response and/or regulation of CD40L in ACS. 
In conclusion, a new differentiation of AMI patients based on the variation patterns of sCD40L over 
time was proposed. Although NT-proBNP may reflect evidence of ventricular failure and indirectly 
of myocardial necrosis, it provides no information about the pathophysiologic state within the 
coronary artery. On the contrary, circulating sCD40L may reflect platelet activation caused by 
intracoronary plaque disruption, fissuring or erosion, and intracoronary dynamics of thrombosis and 
inflammation. Therefore, combining NT-proBNP and sCD40L levels may have a prognostic value in 
AMI evolution. Moreover, the differential response of sCD40L levels observed, could be important in 
the future in terms of personalized therapies.  
Despite no changes can be associated to the acute event in terms of bound or soluble CD40L, 
patient differentiation at day 40 based on sCD40L, its clear association with NT-proBNP, and the 
relationship of bound CD40L through time with markers of ECs activation call the attention for a 
complex behaviour of this molecule in the AMI and its evolution. 
Most of the knowledge on CD40L interactions and solubilization mechanisms results from 
experimental studies, both in vitro and in vivo, using animal models or human primary cultured 
cells. However reported results are not consensual, what strengthens the requirement of their 
clarification. Further research about the forms of CD40L in the circulating cells in humans and their 
possible interactions, would be helpful, extending what was done in the present study in AMI. 
However, due to the intricate mechanism of CD40L this task is not straightforward. Undoubtedly 
this study contributed to clarify the changes in the interrelationship between the soluble and 
membrane-bound form of CD40L and also the associations of those forms and endothelial damage 
and platelet activations markers over time in AMI patients. 
 
 
  
 
6 CONCLUSIONS AND IMPLICATIONS 
 
 
6. 1. CONCLUSIONS 
It is now widely recognized that inflammation play a critical role in plaque destabilization and 
vulnerability and that is, together with thrombosis and endothelial dysfunction, a key-event in 
AMI.(164) In the last decades, important information about the pathophysiology and mechanism of 
AMI had been extensively studied.(8,24,30-31,40,42,46-47,164-168) However, the understanding of the 
interactions between inflammation, thrombosis and endothelial dysfunction and between the 
different cell types involved in those process remain relatively unexplored, especially in human 
populations. 
This is the first study evaluating the inter-relationships between markers of inflammation, 
thrombosis, immune response and endothelial damage in AMI progression/evolution. Some of the 
previous studies that had evaluated interrelationships between ox-LDL and immune system and 
between some inflammatory mediators were performed in vitro, either using cell cultures or 
peripheral blood mononuclear cells. Thus, part of the novelty of the results here presented is the in 
vivo validation of mechanism so far only described using in vitro assays. 
Furthermore, an innovative multi-parameter longitudinal approach was used in the present study. 
This design allowed a better understanding of the complex relationships between the studied 
markers that meant to capture processes of inflammation, thrombosis, immune response and 
endothelial dysfunction involved in the different phases of AMI evolution. The results presented in 
the previous chapters reflect atherothrombosis and myocardial remodelling mechanisms that 
support the concept of a differential response over time in AMI. 
Therefore, the present thesis allowed unveiling the interplay between inflammatory, thrombotic, 
immune and endothelial damage mechanisms and their relative importance in each phase. The 
achievement of this objective decisively contributes to better understanding of the pathology and 
mechanisms of AMI. 
Two different and subsequent processes could be identified in AMI patients: the plaque disruption 
and subsequent thrombotic process that leads to the pathogenesis of AMI at onset of the event (day 
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0); and the myocardial inflammation post-AMI, resulting of ischemia/reperfusion, which leads to 
vascular remodeling, during the recovery phase (day 40). It is important to emphasize that the 
results presented in this study could be related to both those processes (Fig. 6.1).  
High levels of ox-LDL and TNF-α, and low percentage of T cells were observed at the acute phase. 
The higher concentrations of ox-LDL at AMI onset were suggested to be related to plaque instability 
(Chapter 2). This destabilizing effect associated to ox-LDL could enhance the inflammatory and 
thrombotic processes(65) and stimulate the immune response,(169-170) as verify by ox-LDL and CD3+ T 
cells association in AMI patients. The activation of the immune system by ox-LDL could result in T 
cells-increased production of TNF-α, as confirmed by the higher concentrations of TNF-α in AMI 
patients at admission in comparison to the REF group. Additionally, the ox-LDL could also initiate 
activation of inflammatory-related genes, and augmenting the production of pro-inflammatory 
cytokines, including TNF-α,(169) initiating the inflammatory response. That inflammatory process in 
the lesion could contribute to plaque rupture, since this cytokine is capable of regulate MMP activity 
and of augmenting the TF synthesis, (169) leading to plaque disruption and thrombosis. 
On the other hand, the immune suppression observed at the AMI onset, characterized by the 
lower levels of T cells compared to the ones found in REF group, was related to the existence of a 
feedback mechanism to protect the organism from a inflammatory “overshoot”(87) at the onset of 
the event (Chapter 3). 
In AMI patients at day 0, when the thrombotic process is expected to be maximally expressed, no 
major differences were observed in sCD40L, expression of CD40L and CD62P on platelets and PMPs, 
which are well established markers of platelet activation and thrombosis.(125,133,150,171) The retention 
in the thrombus could be the main factor responsible for those results. It was proposed that CD40L 
could be prominently used by circulating cells and activated platelets, perpetuating the 
inflammatory stimulus and eventually maintaining the thrombotic process (Chapter 5). As patients 
stabilize and the magnitude of cell activation and thrombosis is controlled, the CD40L is no longer 
retained in the multiple cell interactions of the thrombotic process, and the vascular wall may 
become the major target of their actions, as verified by the significant associations of CD40L serial 
changes to endothelial damage markers NO and EMPs (Chapter 5).  
The inflammatory response of the myocardium to the ischemia/reperfusion injury could be seem 
in this study through the progressively increased levels of TNF-α, sICAM-1 and T cells percentages. 
These results are reinforced by the significant associations found of serial changes of CD8+ T cells to 
NT-proBNP, sICAM-1 to lymphocytes, monocytes and platelets, and also of sP-selectin with troponin 
T. Thus, temporal and sequential association of events orchestrated by both inflammatory cells, 
e.g. T lymphocytes, monocytes and platelets, and inflammatory markers, such as TNF-α, sICAM-1, 
sP-selectin and CD40L (soluble and membrane-bound forms), seem to be crucial in the initiation of 
inflammatory responses after ischemia/reperfusion injury. These results suggest the existence of an 
enhanced systemic inflammatory response in AMI that remains active for 40 days after acute onset,  
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Figure 6.1 – Schematic representation of the principal results and conclusions. 
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supporting the hypothesis of ongoing inflammation after clinical stabilization. The lack of the above 
described associations between the inflammatory markers and immune cells, and the endothelial 
and myocardium damage markers for the REF group further confirmed this hypothesis. 
Therefore, based on circulating levels of ox-LDL, inflammatory markers and immune cells in AMI 
patients, it is possible to suggest that an oxidative stress situation, which stets the conditions to the 
ox-LDL formation, precedes the activation of inflammatory and immune response associated to AMI.  
In conclusion, the reported results highlight the great magnitude of the thrombotic process 
associated to plaque disruption at AMI onset that conceals possible variations of platelet-related 
thrombosis markers, mainly expressed by CD40L. Additionally, the results emphasize the importance 
of the inflammatory response that remains after clinical stabilization as given by the interplay of 
TNF-α, sICAM-1, sP-selectin, CD40L, leukocytes, NO and EMPs.  
 
 
56 Chapter 6 
 
6. 2. STUDY LIMITATIONS 
Some difficulties concerning flow cytometry had to be overcome during the execution of the 
present thesis. The major one regards the MPs determination and comparison of results between 
laboratories. In fact, the lack of standardization for MPs measurement and characterization may 
account for some confusion regarding their role in AMI. The majority of the authors that measure 
MPs by flow cytometry did not accurately display the results of the population characterization, 
which could raise doubts if authors are measuring and characterizing the same particles. 
Furthermore, another important limitation concerns the detection of small MPs (e.g., < 300 nm in 
diameter), which could be smaller than the detection limit of the instrument. Conventional FACS 
instruments are designed to measure cells which are 10- to 100-fold greater in diameter than MPs. 
In spite of these limitations, MPs measurement by flow cytometry is an innovative technique that 
justifies further improvements. The introduction of an internal standard (microspheres of 1 µm) to 
size(172-173) and flow rate calibration will allow the estimation of the count of MPs per analyzed 
volume.(174) Moreover, some improvements could also be performed in the MPs characterization, 
especially regarding EMPs. In the present study, EMPs were defined as CD31+/CD42- events,(138) and 
the CD62E+ EMPs events were also established to assess endothelial activation. However, it is 
important to notice that EMPs exist as heterogeneous species in proportions varying with the nature 
of the ECs injury, and therefore, is unlikely that any single marker will efficiently label total EMPs. 
For that reason, in future studies a pool of several endothelial markers should be used to 
characterize EMPs, such as CD144 (VE-Cadherin, specific marker of EC dysfunction)(175-176) and CD54 
(ICAM-1),(177) in addition to CD31. In addition, measurement of lymphocyte-derived MPs (CD3)(175) 
and of monocyte-derived MP (CD11b)(170-179) should also be performed. 
 
6. 3. IMPLICATIONS AND FUTURE RESEARCH 
An important implication of the present thesis is the proposed differentiation of AMI patients based 
on the variation patterns of sCD40L over time and their combination with NT-proBNP levels. Apart 
from a possible prognostic value in AMI evolution using the combination of the above mentioned 
markers, the patients’ differentiation could also have a considerable impact in terms of clinical 
management, especially in individualized treatment.  
Considering the importance of this proposed stratification of AMI patients, the continuity of the 
study is mandatory. Prolonged follow-up should be included to better estimate the survival and the 
differentiations. New markers should also be evaluated, including some markers to evaluate the 
thrombotic process, such as fibrinogen, TF and monocyte-platelet aggregates. Furthermore, the role 
of transcription factors as NF-κB in activation of inflammatory genes in response to oxidative stress 
and in enhancing thrombosis(164) could also be assessed.  
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The existence of genetic differences in CD40L genes among the two groups of patients was 
considered, and in fact, within the project supporting the present thesis that hypothesis was 
explored using single nucleotide polymorphisms. However, the work carry out so far did not allow 
any considerable conclusions, since few of the 50 AMI patients were analysed. Considering the 
advances in genetic technologies, including gene expression microarray technology,(169,182) further 
studies evaluating the polymorphisms and the expression profiles of other inflammatory/immunity-
associated genes should be performed. 
The association of ox-LDL with CAD severity and eventually to lesion characteristics depending on 
the infarct-related artery involved was another important finding of this work. Further studies are 
necessary to verify this hypothesis. The use of new and advanced imaging techniques for lesion 
assessment, such as intravascular ultrasound (IVUS) based spectral analysis methodology (or virtual 
histology – IVUS-VH), which allows the differentiation and identification of morphology and 
composition of coronary lesions,(180-183) could bring some clarification to the results. The combined 
use of these invasive bioimaging technique with biomarkers detection could increase the and overall 
predictive value of each potential diagnostic biomarker and technique.(53,184) This will be of the 
utmost importance to identify the degree of dependence of circulating ox-LDL levels on culprit 
vessel and lesion type and therefore validate its goodness as a marker of plaque instability. 
Additionally, further investigations are necessary to understand the relations between CD40L 
variations and the infarct size and abnormal ventricular function. This could ultimately contribute 
to reveal the complexes interactions of CD40L in AMI and eventually to clarify the patients’ 
differentiation. 
Finally this work provided valuable data for possible applications in the development of new 
therapeutical approaches. In the previous chapters was shown that the common used therapies such 
as statins, aspirin, ACE-inhibitors and β-blockers did not shown any influence in the levels of TNF-α, 
T lymphocytes nor in CD40L. These results seem to point out for the need of an alternative or 
additional therapeutic strategy consisting in modulate the immune and inflammatory responses, like 
has been recently proposed.(164,170) Therefore, supplementary studies should explore those pathways 
for the development of new therapies for AMI. 
 
 
 
  
 
REFERENCES 
 
 
1. World Health Organization (WHO). Cardiovascular diseases. Fact sheet 2007; 317. Accessed in 
4 December 2008, at: http://www.who.int/mediacentre/factsheets/fs317/en/index.html. 
2. Mallat Z, Tedgui A. Current perspective on the role of apoptosis in atherothrombotic disease. 
Circ Res 2001; 88:998-1003. 
3. Gensini GF, Dilaghi B. The unstable plaque. Eur Hart J Supp 2002; 4:B22-B27. 
4. Shah PK. Mechanism of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41:15S-22S. 
5. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque. J 
Am Coll Cardiol 2005; 46:937-954. 
6. Mauriello A, Sangiorgi G, Fratoni F et al. Diffuse and active inflammation occurs in both 
vulnerable and stable plaques of the entire coronary tree. J Am Coll Cardiol 2005; 45:1585-
93. 
7. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis, implications for 
vaccine development. Arterioscler Thromb Vasc Biol 2005; 25:18-28. 
8. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes 
-Part IV: matrix metalloproteinases and biomarkers of platelet activation. Circulation 2006; 
113:e382-e385. 
9. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Asp Med 2005; 26: 33-65. 
10. Andreassi MG. Coronary atherosclerosis and somatic mutations: an overview of the 
contributive factors for the oxidative DNA damage. Mut Res 2003; 543:67-86. 
11. Halliwell B, Guttteridge JMC. Free radicals in biology and medicine. United States of America: 
Oxford Science Publications, 1999:936. 
12. Libby P, Aikawa M, Schönbeck U. Cholesterol and atherosclerosis. Bioch Bioph Acta 2000; 
1529:299-309. 
13. Harvey EJ, Ramji DP. Interferon-γ and atherosclerosis: pro- or anti-atherogenic? Cardio Res 
2005; 67:11-20. 
60 References 
 
14. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human 
atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 
2002; 105:2107-2111. 
15. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241. 
16. Martins e Silva J, Saldanha C. Arterial endothelium and atherothrombogenesis: I – Intact 
endothelium in vascular blood homeostasis. Rev Port Cardiol 2006; 25:1061-1083. 
17. Channon KM, Qian H, George SE. Nitric oxide synthase in atherosclerosis and vascular injury. 
Arterioscler Thromb Vasc Biol 2000; 20:1873-1881. 
18. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. FRBM 1996; 
20:707-727. 
19. Ross R. Atherosclerosis – an inflammatory disease. In: Epstein FH, ed. Mechanisms of disease. 
N Engl J Med 1999; 340:115-126. 
20. Price DT, Loscalzo J. Cellular Adhesion molecules and atherogenesis. Am J Med 1999; 107:85-
97. 
21. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 
103:1718-2170. 
22. Lowenstein C, Matsushita K. The acute phase response and atherosclerosis. Drug Discov 
Today: Dis Mech 2004; I:17-22. 
23. Andrews RK, Bernt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114:447-453. 
24. Scott J. Pathophysiology and biochemistry of cardiovascular disease. Curr Opin Genet Dev 
2004; 14:271-279. 
25. Skoog T, Dichtl W, Boquist S et al. Plasma tumour necrosis factor-α and early carotid 
atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23:376-383. 
26. Furman MI, Benoit SE, Barnard MR et al. Increased platelet reactivity and circulating 
monocytes-platelet aggregates in patients with stable coronary artery disease. J Am Coll 
Cardiol 1998; 31:352-358. 
27. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 
352:1685-1695. 
28. Plutzky J. The vascular biology of atherosclerosis. Am J Med 2003; 115:55S-61S. 
29. Heistad DD. Unstable coronary-artery plaques. N Engl J Med 2003; 349:2285-2287. 
30. Davies MJ. Coronary disease: the pathophysiology of acute coronary syndromes. Heart 2000; 
83:361-366. 
31. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J 
Intern Med 2008; 263:517-527. 
32. Graf D, Korthauer U, Mages HW, Senger G, Kroczek RA. Cloning of TRAP, a ligand for CD40 on 
human T cells. Eur J Immunol 1992; 22:3191-3194. 
References 61 
 
33. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface 
protein on activated CD4  T cells that induces contact-dependent B cell differentiation (help). 
J Exp Med
+
 1992; 175:1091-1101. 
34. Gauchat JF, Henchoz S, Mazzei G et al. Induction of human IgE synthesis in B cells by mast 
cells and basophils. Nature 1993; 365:340-343. 
35. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory 
reaction of endothelial cells. Nature 1998; 391:591-594. 
36. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58:4-43. 
37. Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 
ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed 
CD40. Blood 2001; 98:1047-1054. 
38. Santilli F, Basili S, Ferroni P, Davì G. CD40/CD40L system and vascular disease. Intern Emerg 
Med 2007; 2:256-268. 
39. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and 
coagulation. Circulation 2004; 109:2698-2704. 
40. Fichtlscherer S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. 
Curr Opin Pharmacol 2004; 4:124-131. 
41. Mallat Z, Benamer H, Hugel B et al. Elevated levels of shed membrane microparticles with 
procoagulant potential in the peripheral circulating blood of patients with acute coronary 
syndromes. Circulation 2000; 101:841-843. 
42. VanWijik MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. 
Cardiovac Res 2003; 59:277-287. 
43. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and 
thrombosis. Scand J Immunol 2007; 66:159-165. 
44. Martínez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from 
circulating and vascular cells in regulating vascular function. Am J Physiol Heart Cir Physiol 
2005; 288:H1004-H1009. 
45. Collinson PO, Gaze DC. Biomarkers of cardiovascular damage and dysfunction – an overview. 
Heart Lung Circ 2007; 16:S71-S82. 
46. Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic basis of disease. China: Elsevier 
Saunders, 2004:1525. 
47. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. 
Cardiovasc Res 2002; 53:31-47. 
48. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 
2001; 104:365-372. 
49. Kapoun AM, Liang F, O’Young G et al. B-type natriuretuc peptide exerts broad functional 
opposition to transforming growth factor-β in primary human cardiac fibroblasts: firbosis, 
myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94:453-461. 
62 References 
 
50. Mehta PK, Griendling KK. Angiotensin II cell signalling: physiological and pathological effects 
in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97. 
51. Prahash A, Lynch T. B-type natriuretic peptide: a diagnostic, prognostic, and therapeutic tool 
in heart failure. Am J Critical Care 2004; 13:46-55. 
52. Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship 
to outcome. Curr Atheroscler Rep 2004; 6:243–250. 
53. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J 
Nucl Med 2007; 48:1800–1815. 
54. Petterson KS, Witting PK, Stocker R. Antioxidant intervention studies in animals. In: Dean RT, 
Kelly DT, ed. Atherosclerosis – Gene expression, cell interactions and oxidation. Great 
Britain: Oxford University Press, 2000:1-23. 
55. Halliwel B. Oxidative stress in cell culture: an under-appreciated problem? FEBS Letters 2003; 
540:3-6. 
56. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes 
- Part III: biomarkers of oxidative stress and angiogenic growth factors. Circulation 2006; 
113:e289-e292. 
57. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler 
Thromb Vasc Biol 2005; 25:29-38. 
58. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 
84:1381–1478.  
59. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FSEB J 2001; 
15:2073-2084. 
60. Toshima S, Hasegawa A, Kurabayashi M et al. Circulating oxidized low density lipoprotein 
levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 
2000; 20:2243-2247. 
61. Holvoet P, Stassen JM, Cleemput JV, Collen D, Vanhaecke J. Oxidized low density lipoproteins 
in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 
1998; 18:100-107. 
62. Wen Y, Leake DS. Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ 
Res 2007; 100:1337-1343. 
63. Holvoet P, Vanhaecke J, Janssens S, Werf FV, Collen D. Oxidized LDL and malondialdehyde-
modified LDL in patients with acute coronary syndromes and stable coronary artery disease 
oxidized. Circulation 1998; 98:1487-1494. 
64. Holvoet P, Mertens A, Verhamme P et al. Circulating oxidized LDL is a useful marker for 
identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21:844-
848. 
References 63 
 
65. Ehara S, Ueda M, Naruko T et al. Elevate levels of oxidized low density lipoprotein show a 
positive relationship with severity of acute coronary syndromes. Circulation 2001; 103:1955-
1960. 
66. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of 
the antibody against oxidized low-density lipoprotein in patients with atherosclerotic coronary 
artery disease. J Am Coll Cardiol 2001; 37:775-779. 
67. Vasankari T, Ahotupa M, Toikka J et al. Oxidized LDL and thickness of carotid intima-media 
are associated with coronary atherosclerosis in middle aged men: lower levels of oxidized LDL 
with statin therapy. Atherosclerosis 2001; 155:403-412. 
68. Inoue T, YaguchiI, Uchida T et al. Clinical significance of the antibody against oxidized low-
density lipoprotein in acute myocardial infarction. Cardiology 2002; 98:13-17. 
69. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Oxidized low-density 
lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J 
Cardiol 2006; 113:167-173. 
70. Naruko T, Ueda M, Ehara S et al. Persistent high levels of plasma oxidized low-density 
lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb 
Vasc Biol 2006; 26:877-883. 
71. Tsimikas S, Bergmark C, Beyer RW et al. Temporal increases in plasma markers of oxidized 
low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll 
Cardiol 2003; 41:360-370. 
72. Nordin Fredrikson G, Hedblad B, Berglund, Nilsson J. Plasma oxidized LDL: a predictor for 
acute myocardial infarction? J Internal Med 2003; 253:425-429. 
73. Ehara S, Ueda M, Naruko T et al. Pathophysiological role of oxidized low-density lipoprotein in 
plaque instability in coronary artery diseases. J Diabetes Complications 2002; 16:60-64. 
74. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) 
effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 
46:1425-1433. 
75. Crisby M, Bordin-Fredrikson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment 
increases collagen content and decreases lipid content, inflammation, metalloproteinases, 
and cell death in human carotid plaques: implications for plaque stabilization. Circulation 
2001; 103:926-933. 
76. Inami S, Okamatsu K, Takano M et al. Effects of statins on circulating oxidized low-density 
lipoprotein in patients with hypercholesterolemia. Jpn Heart J 2004; 45:969-975. 
77. Hofnagel O, Luechtenborg B, Weissen-Plenz G, Robenek H. Statins and foam cell formation: 
impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim 
Biophys Acta 2007; 1771:1117-1124. 
78. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H oxidase by 
oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of 
64 References 
 
hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation. 2001; 104:1767–
1772. 
79. Keidar S. Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998; 63:1-11. 
80. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and 
atherogenesis: part I - oxidative stress and atherogenesis. Circulation 2002;105:393-396. 
81. Moshfegh K, Redondo M, Julmy F et al. Antiplatelet effects of clopidogrel compared with 
aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am 
Coll Cardiol 2000; 36:699-670. 
82. Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006; 186:240-
259. 
83. Ashidate K, Kawamura M, Mimura D. Gentisic acid, an aspirin metabolite, inhibits oxidation of 
low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human 
plasma. Eur J Pharmacol 2005; 513:173-179. 
84. Leon M, Klauss V, Stone G et al. The right coronary artery has a different plaque component 
profile when compared to the other two epicardial arteries: VH-IVUS Report from the Global 
VH-IVUS Registry. Am J Cardiol 2006; Abstract TCT246. 
85. Blum A, Yeganeh S. The role of T-lymphocyte subpopulation in acute myocardial infarction. 
Eur J Int Med 2003; 14:407-410. 
86. Cheng X, Liao YH, Ge H et al. Th1/Th2 functional imbalance after acute myocardial 
infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol 2005; 
25:246-253. 
87. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP. Cytokine dysregulation, inflammation 
and well-being. Neuroimmunomodulation 2005; 12:255-269. 
88. Steppich BA, Moog P, Matissek C et al. Cytokine profiles and T cell function in acute coronary 
syndromes. Atherosclerosis 2007; 190:443-451. 
89. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. 
Heart 2006; 92:843-849. 
90. Fang L, Wei H, Mak KH et al. Markers of low-grade inflammation and soluble cell adhesion 
molecules in Chinese patients with coronary artery disease. Can J Cardiol 2004; 20:1433-1438. 
91. Larbi A, Khalil A, Douziech N, Guérard KP, Fülöp JrT. Oxidized low-density lipoproteins 
induced inflammatory process during atherogenesis with aging. Rad Physic Chem 2005; 
72:387-397. 
92. Harlan LM, Chan MA, Benedict SH. Two different modes of costimulation predispose human T 
lymphocytes to differential responses in the presence of HDL or oxidized LDL. Atherosclerosis 
2007; 193:309-320. 
93. Caspar-Bauguil S, Benooist H, Alcouffe J et al. Oxidized LDL, T lymphocytes, and graf 
atherosclerosis. Transplant Proceed 1997; 29:2328-2329. 
References 65 
 
94. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4+ CD25+ regulatory T 
cells in patients with acute coronary syndromes. Eur Heart J 2006; 27:2530-2537. 
95. Hollander JE, Muttreja MR, Dalesandro MR, Shofer FS. Risk stratification of emergency 
department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol 1999; 
34:95-105. 
96. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. 
Circulation 2001; 103:491-495. 
97. Shyu KG, Chang H, Lin CC, Kuan P. Circulating intercellular adhesion molecule-1 and E-
selectin in patients with acute coronary syndrome. Chest 1996; 109:1627-1630. 
98. Mulvihill N, Foley JB, Ghaisas N, Murphy R, Crean P, Walsh M. Early temporal expression of 
soluble cellular adhesion molecules in patients with unstable angina and subendocardial 
myocardial infarction. Am J Cardiol 1999; 83:1265-1267. 
99. Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in 
unstable angina and non–Q wave myocardial infarction. J Am Coll Cardiol 2000; 36:1210-1216. 
100. Ray KK, Morrow DA, Shui A, Rifai N, Cannon CP. Relation between soluble intercellular 
adhesion molecule–1, statin therapy, and long-term risk of clinical cardiovascular events in 
patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol 2006; 
98:861-865. 
101. Haim M, Tanne D, Boyko V et al. Soluble intercellular adhesion molecule-1 and long-term risk 
of acute coronary events in patients with chronic coronary heart disease data from the 
bezafibrate infarction prevention (BIP) study. J Am Coll Cardiol 2002; 39:1133-1138. 
102. Hartford M, Wiklund O, Hulten KM et al. CRP, interleukin-6, secretory phospholipase A2 group 
IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes 
and long-term follow-up. Int J Cardiol 2006; 108:55-62. 
103. Valgimigli M, Ceconi C, Malagutti P et al. Tumor necrosis factor-α receptor 1 is a major 
predictor of mortality and new-onset heart failure in patients with acute myocardial 
infarction.  Circulation 2005; 111:863-870. 
104. Chiu CA, Wu CJ, Yang CY et al. Levels and value of soluble P-selectin following acute 
myocardial infarction: evaluating the link between soluble P-selectin levels and recruitment 
of circulating white blood cells and the marker for the rapid diagnosis of chest pain. Chan 
Gung Med J 2005; 28:699-707. 
105. O’Malley T, Ludlam CA, Riemermsa RA, Fox KAA. Early increase in levels of soluble inter-
cellular adhesion molecule-1 (sICAM-1). Eur Heart J 2001; 22:1226-1234. 
106. Xu Y, Huo Y, Toufektsian MC et al. Activated platelets contribute importantly to myocardial 
reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290:H692-H699. 
107. Shimomura H, Ogawa H, Arai H et al. Serial changes in plasma levels of soluble P-selectin in 
patients with acute myocardial infarction. Am J Cardiol 1998; 81:397-400. 
66 References 
 
108. Bauriedel G, Skowasch D, Schneider M, Andrié R, Jabs A, Lüderitz B. Antiplatelet effects of 
angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: A pilot study 
with whole-blood aggregometry. Am Heart J 2003; 145:343-348. 
109. Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor 
agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J 
Am Coll Cardiol 2004; 43:1982-1988. 
110. Cha JK, Jo WS, Shin HC, Bae HR, Ho JM, Kim JW. Increased platelet CD63 and P-selectin 
expression persist in atherosclerotic ischemic stroke. Platelets 2004; 15:3-7. 
111. Barbaux SC, Blankenberg S, Rupprecht HJ et al. A between P-selectin gene polymorphisms and 
soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb 
Vasc Biol 2001; 21:1668-1673. 
112. Blancke F, Claeys MJ, Jorens P et al. Systemic inflammation and reperfusion injury in patients 
with acute myocardial infarction. Mediators Inflamm 2005; 6:385-389. 
113. Khare A, Shetty S, Ghosh K, Mohanty D, Chatterjee S. Evaluation of markers of endothelial 
damage in cases of young myocardial infraction. Atherosclerosis 2005;180:375–380. 
114. Dawn B, Guo Y, Rezazadeh A et al. Tumor necrosis factor-α does not modulate 
ischemia/reperfusion injury in naïve myocardium but is essencial for the development of late 
preconditioning. J Mol Cell Cardiol 2004; 37:51-61. 
115. Zirlik A, Bavendiek U, Libby P et al. TRAF-1, -2, -3, -5, and -6 are Induced in atherosclerotic 
plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. 
Arterioscler Thromb Vasc Biol 2007; 27:1101-1107. 
116. Jaakkola K, Jalkanen S, Kaunismäki K et al. Vascular adhesion protein-1, intercellular 
adhesion molecule-1 and P-selectin mediate leukocyte binding to ischemic heart in humans. J 
Am Coll Cardiol 2000; 36:122-129. 
117. von Hundelshausen P, Weber C. Platelets as immune cells bridging inflammation and  
cardiovascular disease. Circ Res 2007; 100:27-40. 
118. Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. 
Trends Cardiovasc Med 2007; 17:118-123. 
119. Wagner AH, Güldenzoph B, Lienenlüke, Hecker M. CD154/CD40-mediated expression of CD154 
in endothelial cells: consequences for endothelial cell–monocyte interaction. Arterioscler 
Thromb Vasc Biol 2004; 24:715-720. 
120. André P, Prasad KS, Denis CV et al. CD40L stabilizes arterial thrombi by a beta3 integrin-
dependent mechanism. Nat Med 2002; 8:247-252. 
121. Youssef AA, Chang LT, Sheu JJ et al. Association between circulating level of CD40 ligand and 
angiographic morphologic features indicating high-burden thrombus formation in patients with 
acute myocardial infarction undergoing primary coronary intervention. Circ J 2007; 71:1857-
1861. 
References 67 
 
122. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger III AL, Michelson AD. Release of 
soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J 
Am Coll Cardiol 2004; 43:2319-2325. 
123. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists 
and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 
2003; 107:1123-1128. 
124. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences 
platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 2005; 
25:2428-2434. 
125. Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation: 
studies on the solubilization phase. Thomb Res 2004; 114:167-177. 
126. Hammöhner M, Ittenson A, Dierkes J et al. Platelet expression of CD40/CD40 ligand and its 
relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. 
Exp Biol Med 2007; 232:581-589. 
127. Aukrust P, Müller F, Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 
ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet 
involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100:614-620. 
128. Garlichs CD, Eskafi S, Raaz D et al. Patients with acute coronary syndromes express enhanced 
CD40 ligand/CD154 on platelets. Heart 2001; 86:649-655. 
129. Varo N, Lemos JA, Libby P et al. Soluble CD40L: risk prediction after acute coronary 
syndromes. Circulation 2003; 108:1049-1052. 
130. Brueckmann M, Bertsch T, Lang S et al. Time course of systemic markers of inflammation in 
patients presenting with acute coronary syndromes. Clin Chem Lab Med 2004; 42:1132-1139. 
131. Kinlay S, Schwartz G, Olsson A et al. Effect of atorvastatin on risk of recurrent cardiovascular 
events after an acute coronary syndrome associated with high soluble CD40 ligand in the 
myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. 
Circulation 2004; 110:386-391. 
132. Ohashi Y, Kawashima S, Mori T et al. Soluble CD40 ligand and interleukin-6 in the coronary 
circulation after acute myocardial infarction. Int J Cardiol 2006; 112:52-58. 
133. Heeschen C, Dimmeler S, Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. N 
Engl J Med 2003; 348:1104-11. 
134. De Lemos JA, Zirlik A, Schönbeck U et al. Associations between soluble CD40 ligand, 
atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart 
Study. Arterioscler Thromb Vasc Biol 2005; 25:2192-2196. 
135. Ahn ER, Lande G, Jy W et al. Differences of soluble CD40L in sera and plasma: implications on 
CD40L assay as marker of thrombotik risk. Thrombosis Res 2004; 114:143-148. 
68 References 
 
136. Monteiro MC, Sansonetty F, Gonçalces MJ, O’Connor JE. Flow cytometric kinetic assay of 
calcium mobilization in whole blood platelets using Fluo-3 and CD41. Flow Cytometry 1999; 
35:302-310. 
137. Bernal-Mizrachi  L, Jy W, Jimenez JJ et al. High levels of circulating endothelial 
microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145:962-970. 
138. Chirinos JA, Zambrano JP, Virani SS et al. Correlation between apoptotic endothelial 
microparticles and serum interleukin-6 and C-reactive protein in healthy men. Am J Cardiol 
2005; 95:1258-1260. 
139. Yan JC, Zhu J, Gao L et al. The effect of elevated serum soluble CD40 ligand on the 
prognostic value in patients with acute coronary syndromes. Clin Chim Acta 2004; 343:155-
159. 
140. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in 
women. Circulation 2001; 104:2266-2268. 
141. Tanne D, Haim M, Goldbourt U et al. CD40 ligand and risk of ischemic stroke or coronary 
events in patients with chronic coronary heart disease. Int J Cardiol 2006; 107:322-326. 
142. Lip GYH, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 
ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular 
atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and 
prognosis. Stroke 2007; 38:1229-1237. 
143. Olenchock BA, Wiviott SD, Murphy SA et al. Lack of association between soluble CD40L and 
risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb 
Thrombolysis 2008; 26:79-84. 
144. Sadanandan S, Cannon CP, Chekuri K et al. Association of elevated B-type natriuretic peptide 
levels with angiographic findings among patients with unstable angina and non–ST-segment 
elevation myocardial infarction. J Am Coll Cardiol 2004; 44:564-568. 
145. Blankenberg S, McQueen MJ, Smieja M et al. Comparative impact of multiple biomarkers and 
N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the 
prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation 
(HOPE) study. Circulation 2006; 114:201-208. 
146. Estrada JL, Rubinstein F, Bahit MC et al. Nt-probrain natriuretic peptide predicts complexity 
and severity of the coronary lesions in patients with non-ST-elevation acute coronary 
syndromes. Am Heart J 2006; 151:1093.e1-1093.e7. 
147. Almeida R, Mariano L, Gavina C et al. The value of NT-proBNP in early risk stratification of 
acute coronary syndromes. Rev Port Cardiol 2006; 25:71-75. 
148. Morrow DA, Cannon CP, Jesse RL et al. National academy of clinical biochemistry laboratory 
medicine practice guidelines: clinical characteristics and utilization of biochemical markers in 
acute coronary syndromes. Circulation 2007; 115:e356-e375. 
References 69 
 
149. Welt FGP, Rogers SD, Zhang X et al. GP IIb/IIa inhibition with eptifibative lowers levels of 
soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc 
Interv 2004; 61:185-189. 
150. Stumpf C, Lehner C, Eskafi S et al. Enhanced levels of CD154 (CD40 ligand) on platelets in 
patients with chronic heart failure. Eur J Heart Fail 2003; 5:629-637. 
151. Chung I, Choudhury A, Patel J, Lip GYH. Soluble CD40L, platelet surface CD40L and total 
platelet CD40L in congestive heart failure: relationship to platelet volume, mass and 
granularity. J Intern Med 2008; 263:313-321. 
152. Weber A-A, Hermann A, Rauch BH, Schrör K. Molecular identity of platelet CD40L ligand 
(CD40L). Thromb Haemost 2001; 86:718. 
153. Blann AD, Choudhury A, Freestone J, Patel J, Lip GYH. Soluble CD40 ligand and atrial 
fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J 
Cardiol 2008; 127:135-137. 
154. May AE, Kälsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein 
IIb/IIIa (αIIbβ3) on platelets upregulates CD40L and triggers CD40L-dependent matrix 
degradation by endothelial cells. Circulation 2002; 106:2111-2117. 
155. Büchner K, Henn V, Gräfe M, Boer OJ, Becker AE, Kroczer RA. CD40 ligand is selectively 
expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in 
atherosclerosis. J Pathol 2003; 201:288-295. 
156. Chai H, Yan S, Wang H et al. CD40 ligand increases expression of its receptor in human 
coronary artery endothelial cells. Surgery 2006; 140:236-242. 
157. Schönbeck U, Mach F, Sukhova GK et al. Regulation of matriz metalloproteinase expression in 
human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque 
rupture? Circ Res 1997; 81:448-454. 
158. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide 
released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100:350-
356. 
159. Ouvinã SM, La Greca RD, Zanaro NL, Palmer L, Sassetti B. Endothelial dysfunction, nitric oxide 
and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001; 
102:107-114. 
160. Schäfer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid 
regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109:1819-1822. 
161. Ekmekçi H, Isler I, Sonmez H et al. Comparison of platelet fibronectin, ADP-induced platelet 
aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary 
artery disease. Thromb Res 2006; 117:249-254. 
162. Bingaman AW, Pearson TC, Larsen CP. The role of CD40L in T cell-dependent nitric oxide 
production by murine macrophages. Transpl Immunol 2000; 8:195-202. 
70 References 
 
163. Pignatelli P, Sanguigni V, Lenti I et al. Oxidative stress-mediated platelet CD40 ligand 
upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost 
2007; 5:1170-1178. 
164. Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF. Cytokine imbalance in acute coronary 
syndrome. Curr Opin Pharmacol 2004; 4:166-170. 
165. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003; 
91;3A-6A. 
166. Wiviott SD, de Lemos JA, Morrow DA. Pathophysiology, prognostic significance and clinical 
utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta 2004; 346: 
119–128. 
167. Jefferson BK, Topol EJ. Molecular mechanisms of myocardial infarction. Curr Probl Cardiol 
2005; 30:333-74. 
168. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by 
ischemic pre- and postconditioning. Herz 2008; 33:88-100. 
169. Mehra VC, Ramgolam VS, Bender JR. Inflammatory mechanisms in vascular disease. Drug 
Discov Today: Dis Mech 2005; 2:77-84. 
170. Hasson GK. Atherosclerosis – an immune disease. The Anitschkov lecture 2007. Atherosclerosis 
2009; 202:2-10. 
171. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GYH. Platelet microparticles and soluble P 
selectin in peripheral artery disease: Relationship to extent of disease and platelet activation 
markers. Annals Med 2005; 37: 61-66. 
172. Dignat-George F, Sabatier F, Camoin-Jau L, Sampol J. Measuring circulating cell-derived 
microparticles. J Thomb Haemost 2004; 2:1844-1845. 
173. Shet AS, Key NS, Hebbel RP. Measuring circulating cell-derived microparticles. J Thomb 
Haemost 2004; 2:1848-1850. 
174. Simak J, Gelderman MP. Cell membrane microparticles in blood products: potentially 
pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20:1-26. 
175. Ambile N, Guérin AP, Leroyer A et al. Circulating endothelial microparticles are associated 
with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 
16:3381-3388. 
176. Koga H, Sugiyama S, Kugiyama K et al. Elevated levels of VE-Cadherin-positive endothelial 
microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll 
Cardiol 2005; 45:1622-1630. 
177. Combes V, Simon AC, Grau GE et al. In vitro generation of endothelial microparticles and 
possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 
104:93-102. 
178. Diehl P, Nagy F, Sossong V et al. Increased levels of circulating microparticles in patients with 
severe aortic valve stenosis. Thromb Haemost 2008; 99:711-719. 
References 71 
 
179. Myers DD, Hawley AE, Farris DM et al. P-selectin and leukocyte microparticles are associated 
with venous thrombogenesis. J Vasc Surg 2003; 38:1075-1089. 
180. Miller DT, Ridker PM, Libby P, Kwiatkowski DJ. Atherosclerosis: the path from genomics to 
therapeutics. J Am Coll Cardiol 2007; 49:1589-1599. 
181. Rodriguez-Granillo GA, García-García HM, Fadden EPM et al. In vivo intravascular ultrasound-
derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am 
Coll Cardiol 2005; 26:2038-2042. 
182. García-García HM, Goedhart D, Schuurbiers JCH et al. Virtual histology and remodelling index 
in vivo identification of allegedly high-risk coronary plaques in patients with acute coronary 
syndromes: a three vessel intravascular ultrasound radiofrequency data analysis. Euro Interv 
2006; 2:338-344. 
183. Nair A, Margolis MP, Kuban BD, Vince DG. Automated coronary plaque characterization with 
intravascular ultrasound backscatter: ex vivo validation. Euro Interv 2007; 3:113-120. 
184. Marcovina SM, Crea F, Davignon J et al. Biochemical and bioimaging markers for risk 
assessment and diagnosis in major cardiovascular diseases: a road to integration of 
complementary diagnostic tools. J Intern Med 2007; 261:214-234. 
185. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: 
importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery 
disease Risk. J Clin Endocrinol Metab 2004; 89:2601–2607. 
186. Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity 
and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288:H2031–H2041. 
187. Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes, and 
vascular diseases. Eur Heart J 2008; 29:2959-2971. 
188. Viles-Gonzalez JF, Badimon JJ, Fuster V. Definition and pathogenesis of acute coronary 
syndromes. In: O’Rourke RA, Fuster V, Alexander RW et al, ed. Hurst’s the heart: manual of 
cardiology. United States of America: McGraw-Hills, 2004:237-249. 
189. Monaco C, Mathur A, Martin JF. What causes acute coronary syndromes? Applying Koch’s 
postulates. Atherosclerosis 2005; 179:1-15. 
190. Janeway CA, Travers P, Walport M, Sclomchik M. Immunobiology. USA: Garland, 2001:732. 
191. Alexander RW, Ryan TJ, Pratt CM, Roberts R. Diagnosis and management of patients with ST-
segment-elevation myocardial infarction. In: O’Rourke RA, Fuster V, Alexander RW et al, ed. 
Hurst’s the heart: manual of cardiology. United States of America: McGraw-Hills, 2004:251-
285. 
192. Yuan XM, Brunk UT, Hazell. The morphology and natural history of atherosclerosis. In: Dean 
RT, Kelly DT, ed. Atherosclerosis – Gene expression, cell interactions and oxidation. Great 
Britain: Oxford University Press, 2000:1-23. 
193. Junqueira LC, Carneiro J, Kelley RO. Basic histology. United States of America: McGraw-Hills, 
1998:494. 
72 References 
 
194. Ibelgaufts H. COPE: cytokines & cells online pathfinder encyclopedia. 2008. Accessed in 18 
January 2009, at: http://www.copewithcytokines.de/cope.cgi?key=Cell%20activation. 
195. Masharani U, Karam JH, German MS. Pancreatic hormones & diabetes mellitus. In: Greenspan 
FS, Gardner DG, ed. Basic & clinical endocrinology. United States of America: McGraw-Hills, 
2004:658-746. 
196. Lullman H, Mohr K, Ziegler A, Bieger D. Color athas of pharmacology. Germany: Thieme, 
2000:366. 
197. Antezano ES, O’Rourke RA. Diagnosis and management of patients with unstable angina and 
non-ST-segment-elevation myocardial infarction. In: O’Rourke RA, Fuster V, Alexander RW et 
al, ed. Hurst’s the heart: manual of cardiology. United States of America: McGraw-Hills, 
2004:251-285. 
198. Ruberg FL, Leopold JA, Loscalzo J. Atherothrombosis: plaque instability and thrombogenesis. 
Prog Cardiovasc Dis 2002; 44:381-394. 
199. O’Keefe JH, Wetzel M, Moe RR, Brosnahan K, Lavie CJ. Should an angiotensin-converting 
enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll 
Cardiol 2001; 37:1-8. 
200. Hoffman B. Adrenoreceptor-activating & other sympathomimetic drugs. In: Katzum BG, ed. 
Basic & clinical pharmacology. United States of America: McGraw-Hills, 2001:120-137. 
201. Hoffman B. Adrenoreceptor antagonist receptors. In: Katzum BG, ed. Basic & clinical 
pharmacology. United States of America: McGraw-Hills, 2001:138-153. 
202. Ormerod MG. Flow cytometry. United Kingdom: BIOS Scientific Publishers Limited, 1999:109. 
203. Carter NP, Ormerod MG. Introduction to the principles of flow cytometry. In: Ormerod MG, 
ed. Flow cytometry. United States of America: Oxford University Press, 2000:1-22. 
204. Riley RS. Principles and applications of flow cytometry. Accessed in 19 March 2006, at: 
http://www.pathology.vcu.edu/education/lymph/documents/Flow.pdf. 
205. Maloy MJ, Kane JP. Disorders of lipoprotein metabolism. In: Greenspan FS, Gardner DG, ed. 
Basic & clinical endocrinology. United States of America: McGraw-Hills, 2004:658-746. 
206. Guyton AC, Hall JE. Textbook of medical physiology. Chile: Saunders, 2000:1064. 
  
GLOSSARY 
 
Abdominal obesity – accumulation of adipose tissue in the trunk and abdominal cavity.(46) Abdominal 
obesity could be defined through waist perimeter: higher than in 102 cm in men and than 88 cm 
in women.(185) The total amount of body fat (that could be estimated by the body mass index – 
BMI) remains an important indicator of weight-related illness, however, the location of body fat 
has gained much attention recently because of this role in lipid and glucose metabolism and in the 
production of several cytokines. The increased prevalence of excessive visceral obesity is related 
with risk of cardiovascular events.(186-187)
Acute coronary syndromes (ACS) – heterogeneous spectrum of clinical conditions united by the 
common feature of coronary artery occlusion, whether permanent or intermittent, as a result of 
thrombosis due to plaque disruption.(188-189) The conditions include unstable angina (UA), non-ST-
elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) and 
sudden death, which are differentiated and determined by whether there is sufficient blood flow 
through the culprit vessel or via collaterals. UA correspond to a relatively small disruption of an 
atherosclerotic plaque with transient episodes of thrombosis, resulting in a temporary vascular 
occlusion, perhaps lasting only 10 to 20 minutes. In NSTEMI, the occurrence of more severe 
plaque damage could result in more persistent thrombotic occlusion, perhaps lasting up to 1 hour. 
Finally, in STEMI, the plaque disruption leads to a persistent thrombus and subsequently to an 
abrupt cessation of myocardium perfusion for more than 1 hour, resulting in necrosis of the 
involved myocardium.(188)
Acute phase response – systemic response of the innate immune system to infection or trauma, 
characterized by the secretion into the blood of hundreds of soluble proteins that stimulate tissue 
inflammation, limit infection and repair damaged tissue.(22,190)
Angina pectoris (AP) – complex symptoms of ischemic heart disease characterized by convulsive and 
usually recurrent attacks of chest discomfort (variously described as constricting, squeezing, 
choking or knifelike) caused by transient (15 second to 15 minutes) myocardial ischemia that falls 
short of inducing the cellular necrosis that defines an infarction.(46) The most common form of AP 
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is stable angina (SA), that appears to be caused by the reduction of coronary perfusion to a 
critical level by chronic stenosing coronary atherosclerosis.(46)
Angiography – invasive X-ray diagnostic technique of the blood vessels or chambers of the heart. A very 
small tube (catheter) is inserted into the blood vessel, and a special fluid (called contrast medium 
or dye) is injected, which is visible by X-ray, and allowed the visualization of pictures of the 
heart, called angiograms.(191)
Angioplasty – intervention for the dilatation of a stenosis of an artery, by an inserted catheter. Is 
extensively used especially for coronary artery dilatation (percutaneous transluminal coronary 
angioplasty – PTCA or percutaneous coronary intervention - PCI).(46,193)  Most of PCIs now involve 
balloon dilatation followed by coronary stenting.(191)
Apoptosis – pathway of cell death induced by a tightly regulated program in which cells destined to die 
activate enzymes that degrade the cell own DNA, and nuclear and cytoplasmatic proteins. It is a 
programmed form of cell death designed to eliminate unwanted cells during several normal 
physiologic processes. However, it can also occur under certain pathologic conditions when cells 
are damaged beyond repair.(46,190)
Arteriosclerosis – generic term that refers to all lesions in which there is an increase in the thickness 
and loss of elasticity of arterial walls.(46,192)
Atherosclerosis – the most common type of arteriosclerosis and is characterized by intimal lesions 
called atheromas or fibrofatty plaques, which protube into the vascular lumens obstructing them, 
and weaken the underlying media.(46,192)
Atherothrombosis – identifies the coexistence of atherosclerosis in several vascular arteries and the 
formation of a superimposed thrombus, which lead to clinical pictures of CAD.(3)  
Blood vessels – part of the circulatory system. Their function is to transport blood throughout the body. 
The basic constituents of the wall of blood vessels are ECs, SMCs and extracellular matrix 
(including elastin, collagen and glycosaminoglycans). The vessels are composed by three layers: 
intima, media and adventitia.(46,193) 
Cell activation – stimulation of cellular processes initiated as a response to external stimuli. Thus, the 
terms activated cells refer to any cell type that undergone stimulation. The term was developed 
from observations of cells cultured in vitro which reacted to a variety of substances by altering 
their biochemical and functional activities.(194)
Cell death – ultimate result of cell injury (which could be considered the sequence of events that are 
activated when the limit of adaptative response to a stimulus is exceeded) and one of the most 
crucial events in the disease evolution of any tissue or organ.(46)
Coagulation cascade – proteolytic  sequence of plasma enzymes that triggers blood clotting when blood 
vessels are damaged.(46,190)
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Coronary arteries – arteries, with 5 to 10 cm long and 2 to 4 mm diameter, disposed along the external 
surface of the heart. The tree major coronary arteries are the left anterior descending (LAD) 
and the left circumflex (LCX) arteries, both arising from bifurcation branches of the left (main) 
coronary artery, and the right coronary artery (RCA).(46)
Coronary artery disease (CAD) or coronary heart disease (CHD) – generic designation for a group of 
closely related syndromes that correspond to the end result of the accumulation of 
atherosclerotic plaques within the vascular walls of coronary arteries that supply blood to the 
myocardium.(46) Could also be termed ischemic heart disease. 
Culprit vessel – lesion in a coronary artery considered, on the basis of angiographic, autopsy, or other 
findings, to be responsible for the clinical event.(5) In the case of AMI, the knowledge of the areas 
of supply (perfusion) of the three major coronary arteries helps correlate the site of vascular 
obstruction with the regions of the myocardium affected by the infarction (see Fig. 1.3). 
Typically, the LAD supplies most of the apex of the heart, the wall of the left ventricle, and the 
anterior two thirds of the ventricular septum. The LCX generally perfuse only the lateral wall of 
the left ventricle, and the RCA supplies the entire right ventricular free wall and the posterior-
basal wall of the left ventricle and the posterior third of the ventricular septum. Thus, occlusions 
of the RCA as well as in the LAD can cause left ventricular damage,(46) but the last affect a larger 
area of the myocardium in that region, being therefore responsible for more severe damages. 
Diabetes mellitus – group of metabolic disorders sharing the common underlying feature of 
inappropriate hyperglycemia, that results from defects in insulin secretion, insulin action or both. 
There are two types: type 1 diabetes, characterized by an absolute deficiency of insulin caused 
by pancreatic β-cell destruction; and type 2 diabetes that is a heterogeneous disorder 
encompassing a spectrum of defects consisting in some cases of defects in β-cells function alone 
but most commonly associated with insulin resistance in the presence of an associated 
impairment in compensatory insulin secretion.(46,195)
Drugs – are designated to exert a selective influence on a vital processes in order to alleviate or 
eliminate symptoms of disease.(196-197) The therapeutic interventions in AMI aim to restore blood 
flow in the occluded vessel in order to reduce infarct size or to restore ischemic myocardial 
tissue. Standard drug therapy for AMI includes anti-platelet therapy (such as aspirin, GP IIb/IIIa 
receptor antagonists, abcximab and clopidogrel), ACE-inhibitors, β-blokers and statins. 
Aspirin (acetylsalicylic acid) is widely used in the secondary prevention of thrombotic occlusive 
events as it counteracts platelet aggregation and vasoconstriction.(82,197-198) In low doses, aspirin 
irreversibly inhibits the enzyme cyclooxygenase, thereby blocking the synthesis of prostaglandins 
and thromboxane A2  in platelets producing an inhibitory effect on platelet aggregation. Recently, 
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an antioxidant effect has been proposed to aspirin relating to the scavenging activity of gentisic 
acid, which is one product of aspirin metabolism.(83)  
Clopidogrel irreversible inactivates the platelet ADP receptor P2Y12, which is necessary for full 
platelet activation and aggregation response.(82,197-198)
Glycoprotein IIb/IIIa receptor antagonists inhibit platelet aggregation by blocking fibrinogen 
binding to the integrin domain.(198) 
Abcximab is a monoclonal antibody fragment that binds irreversibly to GP IIb/IIIa, therefore 
strongly inhibiting platelet aggregation.(198)
Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A redutase, which is central in 
cholesterol metabolism, but also plays a key role in cell signalling in many vascular cells.(74) This 
drugs are able to block late-limiting step in cholesterol synthesis leading to an upregulation of the 
LDL receptors in the liver, thus limiting circulating LDL levels).(198) Besides this well know lipid-
lowering effects a recent work pointed out other lipid-independent effects of statins.(74) Among 
those effects were those related to endothelial activation/function, coagulation and 
inflammation, which, in a simplistic view, assign statins to inhibition of signalling pathways 
capacity.(74) Furthermore, statins could also modulate the immune system activity linked to the T 
lymphocytes.(74)
ACE-inhibitors improve endothelial dysfunction, by the reduction of angiotensin II levels and 
increase NO production,(82,199) and may also modulate thrombosis. This effect could be 
accomplished by the effect of these agents on reducing fibrinolysis (through the decrease of 
plasminogen activator inhibitor-1 expression) and fibrinogen levels.(82,198)
β-blokers are drugs that bind to β-adrenergic receptors, blocking the ligation of norepinephrine 
and epinephrine (hormones secreted by adrenal medulla that are released into the bloodstream 
and stimulate heart and metabolic rate and blood pressure) to those receptors, inhibiting the 
normal sympathetic nervous system action. Consequently heart rate lowers and blood pressure 
drops due to vasodilation, among other benefits.(200-201)
Endothelium – extremely thin tissue constituted by a monolayer of ECs that continuously lining the 
entire cardiovascular system.(46) This tissue is a selectively permeable barrier between blood and 
tissues and has both sensory and executive functions, having the capacity to generate effector 
molecules that regulate thrombosis, inflammation, vascular tone and vascular remodelling.(15)
Endothelial activation – response of structurally intact ECs to various pathophysiologic stimuli by 
adjusting their usual (constitutive) functions and by expressing newly acquired (inducible) 
properties.(46)
Endothelial dysfunction – defined by an altered endothelial phenotype that impairs vasoreactivity or 
induces a surface that is thrombogenic or abnormally adhesive to inflammatory cells.(46,189)
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Enzyme-linked immunosorbent assay (ELISA) – assay in which bound antigen or antibody is detected 
by a linked enzyme that converts a colorless substrate into a colored product.(190)
Flow cytometry – multiparametric technique that simultaneously analyze physical and chemical 
properties of live cells or other biological particles as they pass in a fluid, single-cell stream 
through an apparatus.(202-203) A flow cytometer is made up of three main systems: fluidics (system 
of fluid that transports particles in a stream to the laser beam for interrogation), optics (consists 
of lasers to illuminate the particles in the sample stream and optical filters to direct the resulting 
light signals to the appropriate detectors), and electronics (converts the detected light signals 
into electronic signals that can be processed by the computer).(202-203) When particles pass through 
the laser intercept, they scatter laser light. Absorbed light of the appropriate wavelength may be 
re-emitted as fluorescence if the cell contains a naturally fluorescent substance or one or more 
fluorochrome-labeled antibodies are attached to surface or internal cell structures. Light scatter 
is dependent on the internal structure of the cell and its size and shape. Fluorescent substances 
absorb light of an appropriate wavelength and reemit light of a different wavelength. Fluorescein 
isothiocyanate (FITC), Texas red, and phycoerythrin (PE) are the most common fluorescent dyes 
used in the biomedical sciences. Light and/or fluorescence scatter signals are detected by a 
series of photodiodes and amplified. Optical filters are essential to block unwanted light and 
permit light of the desired wavelength to reach the photodetector. The resulting electrical pulses 
are digitized, and the data is stored, analyzed, and displayed through a computer system. The 
end result is quantitative information about every cell analyzed. This data can be analyzed to 
provide information about subpopulations within the sample.(204)
Hyperlipidemia – lipoprotein metabolism disorder that is characterized by the elevation of plasma total 
cholesterol and/or triglyceride concentrations or a low HDL level that contributes to the 
development of atherosclerosis. Causes may be genetic or dietary.(46,205) Hyperlipidemia is defined 
when plasma concentrations of total cholesterol and triglycerides are above 190 mg/dl and 180 
mg/dl, respectively. 
Hypertension – or high blood pressure is characterized by greater mean arterial pressure than the 
upper range of accepted normal measure. It commonly accepted that hypertension occurs when 
the diastolic blood pressure is greater that 90 mmHg and the systolic blood pressure greater than 
140 mmHg. Hypertension could be lethal or harmful by excess workload on the heart, could 
induce rupture of blood vessels and could also cause multiple hemorraheges in organs like the 
kidneys.(206)
Immune response – response made by the organism to defend itself against a pathogen.(190)
Infarction – ischemic necrosis in a tissue area caused by occlusion of either the arterial supply or the 
venous drainage.(46)
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Inflammation – protective complex reaction to injurious agents that consists of vascular responses, 
migration and activation of leukocytes and systemic reactions. The inflammatory response is 
closely intertwined with the process of repair.(46)
Ischemia – loss of blood supply that comprises not only insufficient oxygen, but also reduced availability 
of nutrient substrates and inadequate removal of metabolites.(46)
Myocardial infarction – or “heart attack” is the death of cardiac muscle resulting from ischemia.(46,188)
Necrosis – spectrum of morphologic changes that follow cell deaths after abnormal stresses due to 
chemical or physical injury and resulting from the progressive degradative action of enzymes on 
the lethally injured cell. The necrosis is always pathologic and leaves extensive cellular debris 
that needs to be removed by phagocytes.(46,190)
Oxidative stress – disturbance in the prooxidant-antioxidant balance in favour of the former, leading to 
potential damage.(11)
Reperfusion – restoration of coronary flow.(46)
Restenosis – narrowing of the vessel lumen due to vascular remodelling following angioplasty.(15)  
Stenosis – abnormal narrowing in a blood vessel.(46)
Stent – a tube of metallic mesh that is inserted percutaneously in the arteries to reduce restenosis and 
to solve acute vessel closure after angioplasty.(46,191) The stents could be bare-metal (BMS), which 
are mesh-like tubes of thin wire without a coating, or drug-eluting (DES), when it slowly releases 
a drug to block cell proliferation and prevent endothelization and thrombus formation in the 
stented artery.(191)
Thrombosis – could be considered an inappropriate activation of normal hemostatic process, such as 
the formation of blood cloth (thrombus) in injured vasculature or thrombotic occlusion of vessel 
after relatively minor injury.(46)
Vascular homeostasis – ability of the vascular system to maintain normal hemorheological 
conditions.(46)
Vascular remodelling – active process of altering structure and arrangement in blood vessels through 
growth, death and migration of cells, and production or degradation of the extracellular 
matrix.(46)
Vulnerable or unstable plaque – atherosclerotic plaque that is prone to rupture or undergo an episode 
of thrombosis. In spite of many uncertainty, there is a widespread unanimity in the belief that the 
features that make a plaque vulnerable are: a large lipid core occupying at least 50% of the 
overall plaque volume; a high density of macrophages; a low density of smooth muscle cells in the 
cap; a high tissue factor content; a thin fibrous cap in which the collagen structure is 
disorganized.(30,189) Synonyms terms are also high-risk and thombosis-prone plaque.(5)
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Table A.1 – Comparison of demographic and clinical characteristics between AMI patients 
who died or were lost to follow-up and the remaining patients. 
  AMI Patients  
 
 
Died or Lost to Follow-up 
(n=14) 
Remaining 
(n=36) 
 
 Sex (f/m) 3/11 6/30  
 Age (y) 62±18 60±13  
 BMI (kg/m2) 26±4 28±4  
 Waist perimeter (cm) 96±12 97±12  
 Systolic BP (mm Hg) 119±24 123±19  
 Diastolic BP (mm Hg) 68±11 74±12  
 Ejection fraction (%) 43±13 53±11  
Risk factors and co-morbidity    
Hypertension, (n (%)) 5 (36) 24 (67) a  
Smoking (n (%)) 8 (57) 17 (47)  
Hyperlipidemia (n (%)) 5 (36) 23 (64) a  
Diabetes (n (%)) 3 (21) 10 (28)  
Abdominal obesity (n (%)) 3 (21) 11 (31)  
Family history of CAD (n (%)) 2 (14) 6 (17)  
Multivessel disease (n (%)) 6 (43) 17 (47)  
Culprit vessel    
LAD (n (%)) 8 (57) 16 (44)  
RCA (n (%)) 4 (29) 13 (36)  
LCX (n (%)) 2 (14) 6 (17)  
Values are expressed as mean±sd, except otherwise indicated; a p<0.05. 
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Table A.2 – Comparison of baseline (day 0) biochemical parameters between AMI 
patients who died or were lost to follow-up and the remaining patients. 
  AMI Patients  
  Died or Lost to Follow-up Remaining  
 Lipid profile    
 TC (mg/dl) 197±44 200±50  
 LDL-C (mg/dl) 137±44 131±41  
 HDL-C (mg/dl) 42±11 40±13  
 TG (mg/dl) 97±61 118±59  
 ox-LDL (U/l) 86±46 90±39  
 Blood cell count    
Total WBCs (x103/µl) 12±5 13±4  
Neutrophils (x103/µl) 9.3±5.0 9.8±3.5  
Lymphocytes (x103/µl) 1.5±0.8 2.1±1.4  
Monocytes (x103/µl) 0.58±0.42 0.66±0.37  
Platelets (x103/µl) 213±50 230±44  
CD3+ T cells (%) 6.7±4.0 7.8±4.7  
CD4+ T cells (%) 35±9 39±8  
CD8+ T cells (%) 19±7 14±6  
Inflammatory markers    
sP-selectin (ng/ml) 92±36 90±41  
sICAM-1 (ng/ml) 247±28 245±39  
sCD40L (ng/ml) 2.1±1.3 1.9±1.7  
TNF-α (pg/ml) 1.7±0.8 1.5±1.1  
hsCRP (mg/dl) 0.79±0.54 0.68±0.49  
Platelet activation markers    
CD154 platelet (FAU) 126±24 112±24  
CD62P (FAU) 285±117 342±279  
Endothelial damage marker    
NO (µmol/l) 65±27 90±43 a  
Microparticles    
PMPs (%) 23±12 23±11  
EMPs (%) 18±7 21±6  
Other physiological markers    
Glucose (mg/dl) 191±85 172±62  
Albumin (g/dl) 3.3±0.4 3.5±0.4  
Troponin T (ng/ml) 1.59±2.24 2.56±5.80  
NT-proBNP (pg/ml) 809±1105 606±727  
Values are expressed as mean±sd. 
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Table A.3 – Linear mixed effects models results examining the changes 
of log(ox-LDL) with biochemical, demographic, clinical characteristics 
and drug-intake. The influence of co-variables could be of increment 
(+ signal) or decline (- signal). For example, the log(ox-LDL)model with 
co-variable LCX culprit vessel, a decline of -0.33 was obtained for 
each unit increase in log(ox-LDL).
  Log(ox-LDL)  
 CO-VARIBLES 
 
 
 Biochemical characteristics   
 hsCRP (mg/dl) - 0.01  
 Troponin T (ng/ml) - 0.01  
 NT-proBNP (pg/ml) - 0.00  
 Democraphic and clinical characteristics   
 Age (y) - 0.006  
 Multi-vessel disease - 0.004  
 LCX culprit vessel  - 0.33 a  
Stents type * + 0.15  
Medication   
Previous-event medication   
Aspirin - 0.38 a  
ACE-inhibitor - 0.22  
β-blockers - 0.27  
Statins - 0.13  
 In-hospital medication   
Aspirin - 0.49  
ACE-inhibitor - 0.39 a  
β-blockers + 0.22  
Statins + 0.06  
Follow-up medication   
Aspirin - 0.43  
ACE-inhibitor - 0.10  
β-blockers - 0.44 a  
Statins - 0.68 a  
a significant (p<0.05) additive associations to co-variables; * correspond 
to drug-eluting stents in comparison to bare-metal stents. 
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Figure A.1 – Identification of lymphocytes sub-populations. (A) Representative flow cytometry dot-plot 
showing the region within elliptic area Lymphocyte, defined based on forward scatter (FSC) and side scatter 
(SSC) light property that identifies the lymphocytes population. (B) Representative flow cytometry dot-plot 
illustrating the presence of CD45 positive cells gated in lymphocytes region. (C) Representative flow 
cytometry fluorescence histogram showing the expression of CD3 T lymphocytes. The open histogram 
corresponds to unstained control and the black histogram to CD3-fluorescein (FITC) positive lymphocytes. 
(D) Representative flow cytometry fluorescence scattergram recognizing the T lymphocytes sub-populations 
using specific antibodies CD4-APC-Cy7 and CD8-APC, gated on CD3+ region. The CD3+, CD4+ and CD8+ gates 
were defined for FITC, APC and APC-Cy7 fluorescence’s and corresponds to a threshold below which 95% of 
all lymphocyte events from unstained control stained with FITC-CD3, APC-CD8 and APC-Cy7-CD4. 
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Table A.4 – Linear mixed effects models results examining the changes of parameters (CD3+, CD4+ and CD8+ 
T cells, sqrt(TNF-α) and log(ox-LDL)) with co-variables (immune cells and biochemical parameters).   
  Parameters  
  CD3+ CD4+ CD8+ Sqrt(TNF-α) Log(ox-LDL)  
 CO-VARIBLES       
 Immune cells       
 CD3+ T cells (%) – – – + 0.0125 + 0.0203 a  
 CD4+ T cells (%) – – – + 0.0218 - 0.0031  
 CD8+ T cells (%) – – – - 0.0102 + 0.0062  
 Biochemical characteristics      
 hsCRP (mg/dl) - 0.51 a - 0.14 - 0.29 + 0.0062 - 0.0133  
 Troponin T (ng/ml) - 0.28 a - 0.24 - 0.27 + 0.0003 - 0.0128  
NT-proBNP (pg/ml) - 0.0008 a - 0.0007 - 0.0007 a - 0.0000 - 0.0000  
a significant (p<0.05) additive associations of each parameter to co-variables. 
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Table A.5 – Baseline (day 0) levels of inflammatory markers and biochemical data of 28* 
AMI patients with and without previous-event medication. 
  AMI Patients   
 
Previous-event Medication
Without Medication
(n=12) 
With Medication
(n=16) 
 
 Inflammatory markers    
 sP-selectin (ng/ml) 113±35 67±30 a  
 sICAM-1 (ng/ml) 241±36 250±39  
 TNF-α (pg/ml) 1.5±0.9 1.5±1.2  
 hsCRP (mg/dl) 0.57±0.37 1.63±1.70  
Biochemical characteristics    
Total WBCs (x103/µl) 15±5 9±3  
Neutrophils (x103/µl) 12±4 7±3  
Lymphocytes (x103/µl) 2.3±1.0 1.8±0.7  
Monocytes (x103/µl) 0.73±0.53 0.63±0.25  
Platelets (x103/µl) 229±63 209±75  
Troponin T (ng/ml) 4.1±6.3 1.9±1.8  
NT-proBNP (pg/ml) 886±942 864±889  
Values are expressed as mean±sd; a p<0.05.  
* Data presented in this table correspond to Chapter 4, in which only 28 AMI patients were 
included.  
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Table A.6 – Linear mixed effects models results examining the changes of inflammatory 
markers (sqrt(sP-selectin), sICAM-1 and sqrt(TNF-α)) with medication. The influence of 
medication could be of increment (+ signal) or decline (- signal). For example, in the 
sqrt(sP-selectin) model with pre-event ACE-inhibitor intake, a decline of -2.64 was 
obtained for each unit increase in sqrt(sP-selectin).
  Inflammatory Markers 
 CO-VARIABLES Sqrt(sP-selectin) sICAM-1 Sqrt(TNF-α)   
 Medication     
 Previous-event medication     
 Aspirin - 1.5121 - 80.0 + 0.2529  
 ACE-inhibitor - 2.63745 a - 38.3 - 0.2158  
 β-blockers - 1.9524 a + 5.5 + 0.1109  
 Statins - 1.2072 - 29.1 - 0.0973  
 In-hospital medication     
 Aspirin - 0.2219 + 66.7 + 0.3139  
 ACE-inhibitor - 0.5813 + 58.3 + 0.2617  
 Antiplatelet inhibitors + 0.0637 + 57.9 + 0.3761  
 β-blockers + 0.4327 + 15.1 + 0.6855  
 Statins + 1.7767 + 14.1 + 0.3154  
 Follow-up medication     
 Aspirin - 1.4050 + 40.7 + 0.0741  
 ACE-inhibitor - 1.6383 + 22.6 - 0.1486  
 Antiplatelet inhibitors - 1.5018 + 40.7 - 0.2189  
 β-blockers - 0.0717 + 60.5 + 0.3800  
Statins - 1.1177 + 55.2 + 0.2781  
a significant (p<0.05) additive associations of each inflammatory marker to co-variables. 
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Figure A.2 – Identification of platelet population. (A) Representative flow cytometry dot-plot showing the 
region within elliptic area Platelet, defined based on light scatter property that identifies the platelets 
population. (B) Representative flow cytometry dot-plot illustrating the presence of CD42a positive cells 
gated in platelets region. (C and D) Representative flow cytometry fluorescence histograms showing the 
expression of surface CD40L (C) and CD62P (D) immunostained with antibody specific for CD40L conjugated 
with PE and for CD62P conjugated with APC, gated on CD42+ Platelets region. The open histograms 
corresponds to unstained control, the grey histograms to basal (no agonist), and the black histograms to 
stimulated condition (using thrombin 0.5 U/ml as agonist). The CD40L+ and CD62P+ gates were defined for PE 
and APC fluorescence’s and corresponds to a threshold below which 95% of all platelets events from 
unstained control stained with PE-CD40L and APC-CD62P. 
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Figure A.3 – Representative flow cytometry fluorescence histogram showing the surface expression of CD40L 
gated on CD4+ (grey histogram) and CD8+ (black histogram) T lymphocytes region (see Fig. A.1). The CD40L+ 
gate was defined for PE fluorescence, and correspond to a threshold below which 95% of all T lymphocyte 
events from unstained control stained with PE-CD40L. 
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Figure A.4 – Identification of microparticles. (A) Representative flow cytometry zebra-plot (contour and 
density) showing the region within elliptic area Micropaticles defined based on light property, and localized 
below Platelets. (B) Representative flow cytometry fluorescence scattergram recognizing the PMPs (right 
upper quarter) and EMPs (right lower quarter) subsets using specific antibodies CD31-FITC and CD42b-PE-
Cy7, gated on Microparticles region. (C and D) Representative flow cytometry fluorescence histograms 
showing the surface CD40L-positive-MPs (C) and CD62E-positive-EMPs (D), gated on MPs and EMPs region, 
respectively. The open histogram corresponds to unstained control and the black histogram to CD40L-PE 
positive MPs in C and to CD63E-APC positive EMPs in D. The CD40L+ and CD62E+ gates were defined for PE 
and APC fluorescence’s and corresponds to a threshold below which 90% of all microparticles events from 
unstained control stained with PE-CD40L and APC-CD62E. 
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Figure A.5 – Dendogram of hierarchical cluster analysis based on sCD40L levels measured at day 40. 
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Figure A.6 – Results of linear mixed effects model evaluating time changes of log(sCD40L) in the three 
clusters (Cluster A – circles; Cluster B – triangles; Cluster C – lozenges) defined based on sCD40L 
concentrations measured at day 40. The estimated average values at each time point and the respective 
variances (95% confidence interval) are plotted; *p<0.05 vs Cluster A in each time point. 
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Table A.7 – Comparison of CD40L levels and markers of endothelial and platelet activation between the three clusters defined based on sCD40L concentrations 
measured at day 40. 
  AMI Patients  
 
 
Cluster A 
(n=18) 
      Cluster B
(n=12) 
Cluster C
(n=6) 
 
  Day 0 Day 2 Day 40  Day 0 Day 2 Day 40  Day 0 Day 2 Day 40  
  Inflammatory marker             
sCD40L (ng/ml) 2.4±2.5 0.9±0.7 0.7±0.2  1.7±2.0 2.4±3.3 2.8±0.6 a    
             
             
             
            
            
             
             
             
             
             
             
        
2.4±2.0 1.7±1.3 5.9±1.6 a,b  
Platelet activation markers
Platelet CD40L (FAU) 124±27 125±18 139±38  106±26 115±20 130±21  103±16 101±19 139±32  
CD62P (FAU) 456±381 372±275 351±191 242±120 321±339 272±68 280±202 363±241 377±123
T lymphocytes 
CD4+ CD40L (FAU) 4760±1128 4783±2425 5694±2827 3378±697 3696±657 2987±1006 6546±2754 b 7182±3989 6041±2124
CD8+ CD40L (FAU) 4592±1514 4920±2962 6013±3641 2566±757 3260±655 2796±1860 6688±4872 b 7521±6150 6888±3117
Micoparticles
MPs CD40L+ (%) 31±16 27±18 27±16 18±7 21±9 25±12 20±2 18±3 32±9
PMPs (%) 26±13 29±15 23±13 27±13 23±12 37±25 16±6 19±11 27±9
EMPs (%) 22±6 18±7 22±8 19±5 18±8 17±9 23±9 22±5 21±6
EMPs CD62E+ (%) 46±14 44±18 40±16 35±6 38±10 35±14 42±10 30±13 50±8
Endothelial damage marker
NO (µmol/l) 94±45 88±38 99±34 113±71 75±28 87±40 56±28 51±22 84±34  
Values are expressed as mean±sd; a p<0.05 vs Cluster A in each time-point; b p<0.05 vs Cluster B in each time-point. 
 
Table A.8 – Comparison of several biochemical parameters between the three clusters defined based on sCD40L concentrations measured at day 40. 
  AMI Patients  
  Cluster A  Cluster B  Cluster C  
  Day 0 Day 2 Day 40  Day 0 Day 2 Day 40  Day 0 Day 2 Day 40  
 Lipid profile             
TC (mg/dl)             
           
   
             
            
             
    
    
    
            
     
     
    
       
            
             
        
      
    
189±52 176±108 156±56 207±48 194±23 145±29 222±36 196±28 186±30
LDL-C (mg/dl) 127±46 89±27 100±53 125±25 118±17 80±20 155±40 115±14 108±39
HDL-C (mg/dl) 42±12 35±8 38±9  36±12 33±11 31±8  43±19 62±13 41±12
TG (mg/dl) 106±67 91±28 93±44 237±252 233±172 166±72 119±27 93±0.7 181±128
ox-LDL (U/l) 93±37 84±36 67±35 83±35 67±39 57±37 89±45 72±30 81±50
Blood cell count
Total WBCs (x103/µl) 13±5 7.7±1.3 6.7±1.9 12±3 10±3 6.8±1.8  12±3 7.4±2.0 6.5±1.0  
Neutrophils (x103/µl) 10±4 4.8±1.1 4.1±1.5 8.4±2.7 6.1±1.9 4.0±1.4  9.5±2.7 5.4±1.9 4.0±0.7  
Monocytes (x103/µl) 0.70±0.44 0.64±0.28 0.50±0.22 0.63±0.28 0.86±0.17 0.53±0.69  0.60±0.29 0.78±0.15 0.38±0.03  
Inflammatory markers 
sP-selectin (ng/ml) 91±38 77±32 75±23  98±57 76±26 94±28 68±30 48±17 70±34
sICAM-1 (ng/ml) 267±108 282±89 336±178  311±89 388±154 348±77 251 254 231
TNF-α (pg/ml) 1.4±1.0 1.6±0.8 2.1±1.3 1.9±1.4 2.4±1.6 3.2±2.2  1.0±0.4 1.2±1.1 1.4±0.9  
CRP (mg/dl) 0.53±0.32 3.2±2.1 0.44±0.29  1.0±0.7 4.7±4.5 0.44±0.35 0.62±0.47 1.6±0.8 0.39±0.15
Other physiological markers
Glucose (mg/dl) 159±59 143±67 116±47 202±73 166±57 138±59 140±21 129±32 105±23
Albumin (g/dl) 3.4±0.3 3.1±0.3 3.9±0.3  3.5±0.4 3.4±0.3 4.0±0.4 3.4±0.4 3.4±0.6 3.9±0.3
Troponin T (ng/ml) 2.1±5.4 3.4±1.6 0.08±0.23  3.9±7.5 3.2±2.3 0.01±0.01 0.9±1.3 2.6±2.1 0.01±0.01 
NT-proBNP (pg/ml) 1047±1963 2146±1551 1595±1449  751±873 838±604 582±286 a 103±84 887±659 380±204 a  
Values are expressed as mean±sd; a p<0.05 vs Cluster A in each time-point. 
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Table A.9 – Comparison of demographic and clinical characteristics between the clusters B and C, based 
on sCD40L concentrations measured at day 40. 
  AMI Patients  
  Cluster A (n=18) 
Cluster B 
(n=12) 
Cluster C 
(n=6) 
 
 Sex (f/m) 5/13 0/12 1/5  
 Age (y) 61±13 57±12 63±13  
 BMI (kg/m2) 27±4 28±4 28±2  
 Waist perimeter (cm) 95±15 99±10 100±5  
 Systolic BP (mm Hg) 123±19 125±24 127±10  
 Diastolic BP (mm Hg) 70±9 81±21 81±13  
 Ejection fraction (%) 53±12 53±7 53±11  
 Risk factors and co-morbidity     
Hypertension (n (%)) 11 (67) 9 (75) 4 (67)  
Smoking (n (%)) 7 (39) 8 (67) 2 (33)  
Hyperlipidemia (n (%)) 11 (62) 8 (67) 4 (67)  
Diabetes (n (%)) 5 (28) 2 (17) 3 (50)  
Abdominal obesity (n (%)) 6 (32) 4 (33) 1 (17)  
Family history of CAD (n (%)) 2 (11) 2 (17) 2 (33)  
Multivessel disease (n (%)) 8 (44) 6 (50) 3 (50)  
Culprit vessel     
LAD (n (%)) 7 (39) 6 (50) 3 (50)  
RCA (n (%)) 9 (50) 2 (17) 2 (33)  
LCX (n (%)) 2 (11) 3 (25) 1 (17)  
Stents     
Bare metal stents (n (%)) 9 (50) 2 (17) 2 (33)  
Drug-eluting stents (n (%)) 9 (50) 9 (75) 4 (67)  
Values are expressed as mean±sd, except otherwise indicated. 
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Table A.10 – Comparison of CD40L levels and markers of endothelial and platelet activation between the two clusters based on sCD40L measurement at day 40. 
  AMI Patients  
 
 
Cluster A 
(n=18) 
   Cluster BC
(n=18) 
 
  Day 0 Day 2 Day 40  Day 0 Day 2 Day 40  
  Inflammatory marker         
sCD40L (ng/ml) 2.4±2.5 0.9±0.7 0.7±0.2  1.9±2.0 2.1±2.8 3.9±1.8 a  
Platelet activation markers      
        
     
      
    
   
Platelet CD40L (FAU) 124±27 126±19 139±38  106±23 112±19 135±26  
CD62P (FAU) 458±381 373±275 351±191  256±110 336±295 320±107  
T lymphocytes  
CD4+ CD40L (FAU) 4760±1128 4783±2425 5694±2827  4171±1892 4568±2277 4684±2286  
CD8+ CD40L (FAU) 4593±1514 4920±2963 6013±3641  3597±2728 4326±3098 5069±3287  
Micoparticles     
MPs CD40L+ (%) 31±16 27±18 27±16  19±6 20±8 29±11  
PMPs (%) 26±13 29±15 23±13  23±12 21±11 33±19  
EMPs (%) 22±6 18±7 22±8  21±6 20±7 18±8  
EMPs CD62E+ (%) 46±14 44±18 40±16  37±8 39±10 42±14  
Endothelial damage marker    
NO (µmol/l) 95±45 88±38 99±34 93±65 67±29 86±37  
Values are expressed as mean±sd; a p<0.05 vs Cluster A in each time point. 
 
 
 
 
 
 
 
Table A.11 – Comparison of several biochemical parameters between the two clusters based on sCD40L measurement at day 40. 
  AMI Patients  
  Cluster A  Cluster BC  
  Day 0 Day 2 Day 40  Day 0 Day 2 Day 40  
 Lipid profile         
TC (mg/dl) 189±52 176±108 156±57  212±44 194±22 158±35  
LDL-C (mg/dl) 127±46 89±27 101±53  136±33 118±15 89±29  
        
         
    
   
    
         
      
      
      
HDL-C (mg/dl) 42±12 35±8 38±10  38±14 39±17 35±10  
TG (mg/dl) 106±67 91±28 93±44  200±214 202±161 171±89  
ox-LDL (U/l) 93±37 88±38 67±36 85±37 69±36 65±43
Blood cell count
Total WBCs (x103/µl) 13±5 7.7±1.3 6.7±1.9 12±3 9.1±2.7 6.7±1.6  
Neutrophils (x103/µl) 10±4 4.8±1.1 4.1±1.6  8.8±2.6 5.9±1.8 4.1±1.2  
Monocytes (x103/µl) 0.70±0.44 0.64±0.28 0.50±0.22 0.63±0.28 0.83±0.16 0.49±0.20  
Other physiological markers
Glucose (mg/dl) 159±59 143±67 116±47  180±66 155±53 127±52  
Albumin (g/dl) 3.4±0.3 3.1±0.4 3.8±0.3 3.5±0.4 3.5±0.4 4.0±0.4
CRP (mg/dl) 0.53±0.32 3.3±2.1 0.45±0.29 0.83±0.60 3.8±4.0 0.42±0.28
Troponin T (ng/ml) 2.1±5.4 3.4±1.6 0.08±0.24 2.8±6.2 2.9±2.1 0.01±0.01
NT-proBNP (pg/ml) 1047±1963 2146±1551 1595±1450  578±797 854±594 a 514±274 a  
Values are expressed as mean±sd; a p<0.05 vs Cluster A in each time point. 
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Table A.12 – Comparison of baseline (day 0) biochemical parameters between AMI 
patients with and without previous-event medication. 
  AMI Patients  
 
Previous-event Medication
Without Medication
(n=17) 
With Medication
(n=33) 
 
 Lipid profile    
 TC (mg/dl) 205±54 197±43  
 LDL-C (mg/dl) 135±53 132±35  
 HDL-C (mg/dl) 39±11 42±14  
 TG (mg/dl) 127±64 99±54  
 ox-LDL (U/l) 103±46 84±37  
 Blood cell count    
Total WBCs (x103/µl) 13±4 11±5  
Neutrophils (x103/µl) 10±4 9.0±4.6  
Lymphocytes (x103/µl) 2.3±1.9 1.7±0.7  
Monocytes (x103/µl) 0.64±0.42 0.57±0.30  
Platelets (x103/µl) 229±62 217±72  
CD3+ T cells (%) 6.0±3.6 8.0±4.9  
CD4+ T cells (%) 41±7 38±8  
CD8+ T cells (%) 15±3 15±8  
Inflammatory markers    
sCD40L (ng/ml) 1.8±1.5 1.9±1.6  
hsCRP (mg/dl) 0.61±0.33 0.78±0.61  
Platelet activation markers    
CD154 platelet (FAU) 112±37 116±22  
CD62P (FAU) 211±89 343±285  
Endothelial damage marker    
NO (µmol/l) 94±51 79±34  
Microparticles    
PMPs (%) 29±12 23±10  
EMPs (%) 21±7 19±6  
CD40L+ MPs (%) 29±14 24±12  
CD62E+ EMPs (%) 9.5±6.1 8.0±4.8  
Other physiological markers    
Glucose (mg/dl) 169±71 174±60  
Albumin (g/dl) 3.5±0.4 3.4±0.4  
Troponin T (ng/ml) 2.8±5.6 1.7±4.9  
NT-proBNP (pg/ml) 644±775 610±823  
Values are expressed as mean±sd. 
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Table A.13 – Comparison of drug intake between the two cluster groups based on 
sCD40L concentrations measured at day 40. 
  AMI Patients  
  Cluster Group A (n=18) 
Cluster Group BC 
(n=18) 
 
 Medication    
 Previous-event medication    
 Aspirin (n (%)) 5 (28) 3 (18)  
 ACE-inhibitor (n (%)) 10 (56) 7 (41)  
 β-blockers (n (%)) 3 (17) 5 (29)  
 Statins (n (%)) 4 (22) 7 (41)  
  In-hospital medication    
 Aspirin (n (%)) 15 (83) 16 (94)  
 ACE-inhibitor (n (%)) 15 (83) 13 (76)  
 Platelet inhibitor (n (%)) 15 (83) 15 (88)  
 β-blockers (n (%)) 2 (11) 3 (18)  
 Statins (n (%)) 7 (39) 2 (12)  
 Follow-up medication    
 Aspirin (n (%)) 16 (89) 15 (88)  
 ACE-inhibitor (n (%)) 12 (67) 12 (71)  
 Platelet inhibitor (n (%)) 15 (83) 16 (94)  
 β-blockers (n (%)) 14 (78) 14 (82)  
Statins (n (%)) 15 (83) 16 (94)  
Values are expressed as number (n) and percentage (%). 
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Table A.14 – Linear mixed effects models results examining the 
changes of log(scd40L) associating to cluster groups with 
biochemical, demographic, clinical characteristics and drug-intake. 
  Log(sCD40L) Clusters  
 CO-VARIBLES 
 
 
 Biochemical characteristics   
 CRP - 0.035  
 Troponin T + 0.039  
 NT-proBNP  + 0.0003 a  
 Clinical characteristics   
 Multi-vessel disease + 0.37  
 Culprit vessel  - 0.0724  
Stents type * - 0.58  
Medication   
Previous-event medication   
Aspirin + 0.36  
ACE-inhibitor + 0.49  
β-blockers - 0.068  
Statins - 0.30  
 In-hospital medication   
Aspirin + 0.015  
ACE-inhibitor + 0.34  
Antiplatelet inhibitors + 0.39  
β-blockers - 0.012  
Statins - 0.33  
Follow-up medication   
Aspirin + 0.27  
ACE-inhibitor + 0.24  
Antiplatelet inhibitors - 0.37  
β-blockers - 0.024  
Statins - 0.51  
a significant (p<0.05) additive associations to co-variables; * correspond to 
drug-eluting stents in comparison to bare-metal stents. 
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Table A.15 – Comparison of demographic and clinical characteristics between the 
two cluster groups based on sCD40L concentrations measured at day 40. 
  AMI Patients  
  Cluster A (n=18) 
Cluster BC 
(n=18) 
 
 Sex (f/m) 5/13 1/17  
 Age (y) 61±13 59±12  
 BMI (kg/m2) 27±4 28±3  
 Waist perimeter (cm) 95±15 100±9  
 Systolic BP (mm Hg) 123±19 126±19  
 Diastolic BP (mm Hg) 70±9 81±18  
 Ejection fraction (%) 53±12 53±9  
 Risk factors and co-morbidity    
Hypertension (n (%)) 11 (67) 13 (72)  
Smoking (n (%)) 7 (39) 10 (56)  
Hyperlipidemia (n (%)) 11 (62) 12 (67)  
Diabetes (n (%)) 5 (28) 5 (28)  
Abdominal obesity (n (%)) 6 (32) 5 (28)  
Family history of CAD (n (%)) 2 (11) 4 (22)  
Multivessel disease (n (%)) 8 (44) 10 (56)  
Culprit vessel    
LAD (n (%)) 7 (39) 9 (53)  
RCA (n (%)) 9 (50) 4 (24)  
LCX (n (%)) 2 (11) 4 (24)  
Stents    
Bare metal stents (n (%)) 9 (50) 5 (28)  
Drug-eluting stents (n (%)) 9 (50) 13 (76)  
Values are expressed as mean±sd, except otherwise indicated. 
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Figure A.7 – Platelet surface expression of CD40L (A) and CD62P (B) in subjects from the REF (open 
bars) and AMI (black bars) groups, at admission. The platelet activation was assessed in basal (no 
agonist) and induced (thrombin 0.5 U/ml as agonist) conditions. Values are expressed as mean±sd; 
*p<0.05 vs basal expression (no agonist). 
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Figure A.8 – Results of linear mixed effects model evaluating changes of log(NO) over 40 days follow-up. 
The estimated average values at each time point and the respective variances (95% confidence interval) 
are plotted.
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Figure A.9 – Variations (mean±sd) in the expression of CD40L on MPs (A) and of CD62E on EMPs (B) in 
REF subjects (circles) and in AMI patients (squares) at the onset of MI (day 0), two (day 2) and 40 days 
(day 40) after the initial PTCA. 
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